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Summary	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  doctoral	  research	  
	  In	  my	  doctoral	  studies,	  I	  was	  studying	  cross-­‐reactive	  adaptive	  immune	  responses	  in	  the	  context	  of	  autoimmunity	  and	  vaccination.	  The	  main	  focus	  was	  initially	  set	  on	  elucidating	  the	  mechanisms	  underlying	  the	  pathogenesis	  of	  giant	  cell	  arteritis.	  This	  work	  resulted	  in	  a	   publication	   challenging	   the	   usefulness	   of	   anti-­‐14-­‐3-­‐3	   antibodies	   as	   biomarkers	   for	  diagnosing	  GCA:	  A	  part	  of	  these	  autoantibodies	  seem	  to	  target	  epitopes	  revealed	  during	  immunopathology	  while	  others	  may	  be	  directed	  against	  a	  secreted	  protein	  of	  T.	  gondii	  (Kistner	  A	  &	  Bigler	  MB	  et	  al.,	  Rheumatology	  2017).	  In	  a	  second	  publication,	  we	  showed	  that	   T	   cells	   recognizing	   Varicella	   zoster	   virus	   antigens	   are	   not	   more	   frequent	   in	   GCA	  patients.	  Moreover,	  we	  found	  no	  evidence	  for	  an	  increased	  self-­‐reactivity	  of	  peripheral	  blood	  T	  cells	  from	  GCA	  patients	  (Bigler	  MB	  &	  Hirsiger	  J	  et	  al.,	  Arthritis	  &	  Rheumatology	  2017).	   These	   data	   challenge	   a	   disease-­‐triggering	   role	   of	   this	   virus	   as	   suggested	   by	  others.	   Finally,	   the	  molecular	   analysis	   of	   the	  T	   cell	   repertoire	   in	   the	   inflamed	   arteries	  yielded	   so	   far	   promising	   preliminary	   results,	   suggesting	   that	   indeed	   dominantly	  expanded	  clones	  can	  be	  found	  in	  the	  artery.	  The	  completion	  of	  this	  project	  will	  provide	  more	  information	  about	  disease-­‐relevant	  antigens	  recognized	  by	  these	  expanded	  T	  cell	  receptors.	  	  	  The	  main	  focus	  for	  the	  second	  part	  of	  my	  PhD-­‐studies	  shifted	  to	  studying	  the	  influenza	  vaccine-­‐induced	  cross-­‐reactivity	  of	  B	  cell	  responses.	  I	  established	  a	  workflow	  for	  sorting	  of	   influenza-­‐specific	   B	   cells,	   analyzing	   escape	   variants,	   and	   establishing	   a	   BCR	  sequencing	   pipeline.	   The	   data	   from	   this	   study	   suggests	   that	   a	   skewed	   B	   cell	   receptor	  repertoire	   aggravates	   escape	   from	   the	   vaccine	   response	   upon	   viral	   antigenic	   drift	  (Bigler	   MB	   &	   Egli	   SE	   et	   al.,	   in	   preparation).	   In	   an	   international	   collaboration,	   I	   also	  established	  a	  protocol	  for	  site-­‐directed	  mutagenesis	  and	  production	  of	  influenza	  escape	  variants	   that	   will	   be	   applied	   in	   a	   prospective	   vaccination	   cohort	   that	   we	   started	   in	  2017/18.	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Finally,	   in	   a	   side	   project,	   I	   analyzed	   samples	   of	   a	   clinical	   trial	   on	   psychoactive	   drugs	  reflecting	   different	   types	   of	   stress.	   We	   found	   that	   pharmacological	   stress	   hormone	  release	   led	   to	   an	   increase	   of	   cytotoxic	  NK	   cells	   in	   the	   periphery.	   These	  NK	   cells	  were	  characterized	   by	   a	   typical	   surface	   receptor	   expression	   pattern,	   e.g.	   high	   expression	   of	  stress-­‐relevant	  hormone	   receptors	   (Bigler	  MB	  et	  al.,	   PLoS	  One	  2015).	  This	  paper	   (and	  some	  co-­‐authorships	  for	  which	  I	  contributed	  experimental	  data)	  was	  not	  included	  in	  the	  cumulative	  thesis	  but	  is	  attached	  in	  the	  appendix.	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  Innate	   immune	  mechanisms	  are	  very	  efficient	  at	  mounting	  rapid	  immune	  responses	  at	  the	   site	   of	   infection.	   Complete	   clearance	   of	   a	   pathogen	   and	   long-­‐lasting	   protection	  through	  memory	   formation	   requires	   the	   adaptive	   immune	   system.	  To	  be	   able	   to	   cope	  with	   the	   large	   variety	   of	   pathogens	   we	   encounter,	   T	   and	   B	   cells	   acquire	   an	   almost	  infinite	   number	   of	   specificities	   by	   VDJ-­‐recombination	   and	   somatic	   hypermutation.	  However,	   not	   all	   recombinations	   are	   equally	   likely	   to	   occur	   and	   the	   majority	   of	  lymphocyte	   clones	   will	   never	   be	   released	   from	   the	   thymus	   or	   bone	   marrow	   due	   to	  negative	   selection.	   T	   cells	   also	   need	   to	   recognize	   host	   HLA-­‐proteins,	   adding	   further	  constraints.	   Therefore,	   immune	   cell	   diversity	   is	   more	   restricted	   than	   theoretically	  possible.	   A	   certain	   redundancy	   is	   induced	   by	   the	   fact	   that	   a	   T	   or	   B	   cell	   clone	   may	  recognize	   multiple	   epitopes,	   albeit	   with	   different	   affinities,	   a	   feature	   termed	   cross-­‐reactivity.	  	  In	  a	  vaccine	  against	  a	  genetically	  diverse	  pathogen,	  cross-­‐reactivity	  of	  vaccine-­‐induced	  immune	   cells	   is	   desirable.	   An	   ideal	   vaccine	   enables	   the	   host	   to	   mount	   an	   immune	  response	  not	  only	  against	  the	  vaccine	  strain	  but	  also	  against	  naturally	  occurring	  variants	  that	  may	  be	  antigenically	  different.	  Influenza	   virus	   is	   one	   of	   the	  most	   prevalent	   human	   pathogens	   and	   of	   high	   economic	  relevance.	  The	  ‘success’	  of	  influenza	  virus	  is	  tightly	  linked	  to	  its	  extraordinary	  ability	  to	  evolve	  –	  that	  is,	  evading	  the	  host’s	  immune	  system	  –	  while	  still	  maintaining	  its	  integrity	  and	   virulence.	   Annually	   updated	   influenza	   vaccines	   provide	   some	   protection	   against	  infection.	   However,	   vaccine	   efficacy	   is	   strongly	   reduced	   when	   there	   is	   an	   antigenic	  mismatch	  between	  vaccine	  strain	  and	  predominant	  circulating	  virus.	  	  	  We	  hypothesized	  that	   the	  cross-­‐reactivity	  of	   the	   influenza	  vaccine	  response	   is	  affected	  by	   the	   individual	   B	   cell	   repertoire	   and	   wanted	   to	   test	   whether	   low	   cross-­‐reactivity	  associates	  with	  a	  narrow	  repertoire.	  A	  narrow	  antibody	  repertoire	  could	  be	  related	   to	  the	   previous	   infection	   history	   or	   to	   repetitive	   vaccination	  with	   very	   similar	   influenza	  vaccine	   strains.	   Consequently,	   this	  may	   lead	   to	   higher	   susceptibility	   to	   emerging	   viral	  variants.	   The	   breadth	   and	   degree	   of	   antigen-­‐specificity	   of	   the	   B	   cell	   receptor	   (BCR)	  repertoire	  can	  be	  assessed	  by	  sequencing	  the	  immunoglobulin	  heavy	  chains	  before	  and	  after	   vaccination.	   We	   tested	   this	   hypothesis	   by	   analyzing	   samples	   from	   a	   previous	  cohort	   of	   influenza-­‐vaccinated	   healthy	   subjects	   and	   aimed	   to	   extend	   our	   findings	   by	  conducting	  a	  prospective	  clinical	  influenza	  vaccination	  study	  in	  individuals	  with	  known	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General	  introduction	  
	  
Immunity	   and	   autoimmunity	   –	   infections	   as	   potential	   triggers	   of	  
autoimmune	  diseases	  Somatic	   recombination	   in	   adaptive	   immune	   cells	   provides	   us	   with	   an	   immense	  repertoire	  of	  antigen-­‐specificities	  to	  be	  able	  to	  recognize	  the	  enormous	  range	  of	  foreign	  antigens.	  This	  goes	  along	  with	  an	  increased	  risk	  for	  recognition	  of	  antigens	  derived	  from	  self-­‐proteins,	   thereby	  enabling	  autoimmunity.	  To	  reduce	  this	  risk,	  mechanisms	  termed	  central	   tolerance	   have	   evolved	   to	   delete	   T	   and	   B	   cells	   that	   bind	   too	   strong	   to	   self-­‐antigens.	  In	  the	  medulla	  of	  the	  thymus,	  T	  cells	  are	  negatively	  selected	  by	  exposing	  them	  to	   self-­‐protein-­‐derived	   antigens	   on	   APCs	   and	   specialized	   mTECs	   (medullary	   thymic	  epithelial	  cells)	  1.	  Central	  tolerance	  of	  B	  cells	  is	  taking	  place	  in	  the	  bone	  marrow	  and	  can	  induce	   apoptosis	   in	   developing	   B	   cells	   or	   make	   them	   tolerant	   (non-­‐reactive)	   to	   self	  antigen	   2.	   However,	   since	   these	   central	   selection	   or	   suppression	   mechanisms	   are	  imperfect,	   every	   individual	   harbors	   some	   functional	   autoreactive	   lymphocytes.	   The	  mechanisms	   that	   prevent	   T	   and	   B	   cells	   from	   reacting	   to	   self-­‐antigens	   after	   their	  maturation	   are	   summarized	   as	   peripheral	   tolerance.	   These	   include	   regulatory	   T	   cells	  that	   can	   prevent	   the	   action	   of	   autoreactive	   T	   cells	   through	   inhibitory	   cytokines	   or	  surface	  receptors	  or	  by	  modulating	  APC-­‐activation	  3.	  Peripheral	  B	  cell	  tolerance	  can	  be	  induced	   in	   the	   germinal	   center	   (GC)	   reaction	   in	   lymph	   nodes	   or	   the	   spleen	   4.	   Also,	  lymphocytes	   are	   physically	   hindered	   from	   entering	   certain	   zones	   of	   potential	   self-­‐antigen	  encounter,	  e.g.	  through	  the	  blood-­‐brain	  barrier	  5.	  Importantly,	  in	  the	  absence	  of	  an	   inflammatory	  response,	  dendritic	  cells	   (DC)	  are	   immature,	  present	  self-­‐antigen	  and	  induce	  inhibitory	  signals	  to	  binding	  T	  cells	  eventually	  leading	  to	  cell	  death	  6.	  	  	  Owing	  to	  all	  these	  immunological	  checkpoints,	  the	  mere	  presence	  of	  autoreactive	  cells	  is	  usually	   not	   sufficient	   to	   induce	   an	   autoimmune	   disease;	   additional	   hereditary	   and	  environmental	   factors	   are	   necessary	   to	   break	   tolerance.	   A	   frequently	   reported	  hereditary	   factor	   predisposing	   to	   autoimmune	   disease	   such	   as	   rheumatoid	   arthritis,	  psoriasis	   and	   GCA	   is	   the	   HLA-­‐locus	   7,8.	   Some	  HLA	  molecules	   thus	  might	   be	   especially	  efficient	  in	  presenting	  certain	  antigens	  to	  autoreactive	  T	  cells.	  Further	  evidence	  for	  the	  importance	   of	   the	   genetic	   background	   is	   coming	   from	   monozygotic	   twin	   studies.	  Exemplified,	  a	  Danish	  study	  reporting	  disease	  concordance	  for	  type	  I	  diabetes	  mellitus	  of	  53%	  in	  monozygotic	  twins,	  but	  only	  11%	  in	  dizygotic	  twins	  9.	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Concerning	  environmental	   factors,	   infections	   frequently	  precede	  onset	  of	   autoimmune	  disease.	   In	   some	   cases	   of	   molecular	   mimicry,	   that	   is,	   a	   shared	   epitope	   between	   a	  pathogen	   protein	   and	   a	   host	   protein,	   the	   immunological	   targets	   could	   be	   defined.	   For	  example,	   rabbits	   immunized	   with	   a	   peptide	   derived	   from	   the	   hepatitis	   B	   virus	  polymerase	   (HBVP)	   were	   shown	   to	   generate	   antibodies	   against	   both	   HBVP	   and	   host	  myelin	  basic	  protein	   (MBP),	   thereby	   inducing	  encephalitis	   10.	  Before	  onset	  of	   systemic	  lupus	  erythematosus	  (SLE),	  disease-­‐relevant	  antibody	  reactivity	  against	  both	  the	  RNA-­‐binding	  protein	  60	  kDa	  Ro	  and	  the	  Epstein-­‐Barr	  virus	  (EBV)	  protein	  EBNA-­‐1	  has	  been	  reported	  in	  some	  patients	  11.	  	  Besides	   molecular	   mimicry,	   other	   mechanisms	   of	   infection-­‐mediated	   autoimmunity	  have	  been	  proposed.	  Bystander	  activation	  is	  the	  accidental	  triggering	  of	  an	  autoreactive	  T	   cell	   by	   activated	  APCs	  or	   cytokines	  during	   an	   immune	   response	   targeted	  against	   an	  infection	  12.	  The	  release	  of	  endogenous	  epitopes	  through	  immune-­‐mediated	  damage	  can	  lead	  to	  immune	  responses	  against	  these.	  This	  process	  is	  termed	  ‘epitope	  spreading’	  and	  has	  been	  described	  in	  a	  multitude	  of	  diseases	  12,13.	  Intriguingly,	  allelic	  exclusion	  seems	  to	  work	   incompletely	   and	   human	   T	   cells	   have	   been	   found	   that	   co-­‐express	   two	   different	  TCR	   alpha	   chains	   or	   beta	   chains	   14,15.	   These	   dual	   TCRs	   can	   theoretically	   possess	  pathogen-­‐reactivity	  and	  autoreactivity.	  However,	  this	  has	  so	  far	  only	  been	  addressed	  in	  transgenic	  models	  16.	  	  Despite	  the	  numerous	  reports	  about	  the	  presence	  of	  autoreactive	  T	  and	  B	  cells	  in	  organs	  affected	   by	   autoimmune	   diseases,	   a	   clear	   causal	   link	   between	   a	   pathogen	   and	  autoimmunity	  has	  rarely	  been	  proved.	  This	  might	  be	  due	  to	  the	  reason	  that	  B	  cells	  react	  to	   antigens	   released	   by	   epitope	   spreading	   at	   the	   site	   of	   infection	   rather	   than	   through	  molecular	   mimicry.	   This	   would	   render	   testing	   of	   host-­‐pathogen	   cross-­‐reactivity	  impossible.	   In	   T	   cells,	   cross-­‐reactivity	   between	   host	   and	   pathogen	   structures	   may	  simply	  have	  been	  missed.	  An	  elegant	  study	  showed	  that	  T	  cell	  clones	  reactive	  towards	  an	   HLA-­‐DR2-­‐restricted	   MBP-­‐peptide	   proliferated	   also	   upon	   recognition	   of	   some	   viral	  peptides	   predicted	   to	   bind	   to	  HLA-­‐DR2	   17.	  Of	   note,	   the	   amino	   acid	   sequences	   of	   these	  peptides	  were	  often	  very	  different	   from	   the	  original	   peptide	   (degenerate),	   revealing	   a	  certain	   ambiguity	   in	   TCR-­‐antigen	   binding.	   Thus,	   autoreactivity	   cannot	   be	   simply	  predicted	   by	   aligning	   pathogen-­‐derived	   peptides	   with	   host	   peptides.	   This	   T	   cell	  degeneracy	  may	  on	  one	  hand	  increase	  the	  risk	  for	  infection-­‐induced	  autoimmunity,	  but	  on	  the	  other	  hand	  may	  also	  increase	  cross-­‐reactivity	  against	  related	  pathogens.	  	  
Focus	  I:	  Breadth	  and	  limitations	  of	  the	  influenza	  vaccine-­‐induced	  immune	  response	  	  
	   	  7	  
Generation	  of	  immune	  repertoire	  diversity:	  VDJ-­‐recombination	  Analyzing	  immune	  cell	  receptor	  repertoires	  in	  the	  context	  of	  B	  cell	  cross-­‐reactivity	  and	  T	   cell	   antigen-­‐recognition	   is	   a	   central	   part	   of	   this	   thesis.	   Given	   that	   B	   cell	   receptors	  (BCR)	  have	  properties	  beyond	  antigen-­‐recognition,	  can	  undergo	  affinity	  maturation	  but	  share	  some	  basic	  features	  with	  T	  cell	  receptors	  (TCR),	  this	   introduction	  focuses	  on	  the	  generation	   of	   mature	   B	   cells	   and	   their	   BCR	   repertoire	   only.	   The	   concept	   of	   somatic	  rearrangement	  is	  translatable	  to	  the	  TCR.	  	  	  
	  
	  
Figure	   1:	   Genomic	   rearrangements	   at	   the	   IgH	   locus.	   The	   IgH	   locus	   is	   located	   towards	   the	  telomeric	   end	   of	   the	   long	   arm	   of	   chromosome	   14.	   It	   harbors	   multiple	   variable	   (VH,	   green),	  diversity	   (DH,	   red)	   and	   joining	   regions	   (JH,	   blue),	   many	   of	   them	   being	   non-­‐functional	  pseudogenes.	   The	   D-­‐J	   and	   afterwards	   V-­‐DJ	   recombination	   requires	   the	   VDJ-­‐recombinase	  complex,	   which	   includes	   the	   enzymes	   RAG-­‐1	   and	   RAG-­‐2.	   The	   recombination	   signal	   sequences	  (RSS)	  include	  a	  12-­‐bp	  or	  a	  23-­‐bp	  spacer.	  A	  12-­‐bp	  RSS	  (green	  arrow)	  can	  only	  pair	  with	  a	  23-­‐bp	  RSS	   (orange	   arrow),	   thereby	   ensuring	   proper	   recombination.	   In	   naïve	   B	   cells,	   only	   two	   of	   the	  constant	  regions	  (CH,	  yellow)	  are	  attached	  to	  VDJ	  by	  alternative	  splicing:	  Cμ	  (M)	  and/or	  Cδ	  (D)	  leading	   to	   an	   IgM	   and/or	   IgD	   isotype.	   Enhancers	   (E,	   pink	   diamonds)	   located	   upstream	   of	   the	  different	  C	  regions	  enable	  distant	  “donor”	  and	  “acceptor”	  chromosomal	  regions	  to	  come	  in	  close	  contact	   and	   initiate	   the	   genomic	   recombinations	   resulting	   in	   class	   switch	   to	   another	   isotype	  (more	  detailed	  in	  main	  text).	  Figure	  adapted	  from	  Dyer	  et	  al.,	  Blood	  2010	  18.	  	  	  A	  complete	  BCR	  consists	  of	  two	  pairs	  of	  an	  immunoglobulin	  heavy	  and	  light	  chain.	  The	  heavy	  chain	  has	  a	  V	  (variable),	  D	  (diversity),	  J	  (junction)	  and	  a	  C	  (constant)	  region,	  the	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light	  chain	  only	  has	  a	  V	  and	  J	  region.	  Each	  region	  is	  encoded	  by	  multiple	  genes	  that	  arose	  from	  gene	  duplication	  and	  underwent	  substantial	  differentiation.	  The	  rearrangement	  of	  V,	   D	   and	   J	   genes	   requires	   recombination	   of	   genomic	  DNA.	   This	   is,	   among	  many	   other	  proteins,	   initiated	   by	   RAG-­‐1	   (recombination	   activating	   gene)	   and	   RAG-­‐2	   resulting	   in	  recombination	   by	   non-­‐homologous	   end	   joining	   (NHEJ).	   The	   importance	   of	   this	   step	   is	  clearly	  illustrated	  by	  the	  severe	  complications	  that	  arise	  when	  RAG-­‐genes	  are	  mutated:	  The	  spectrum	  encompasses	  severe	  combined	  immunodeficiency	  (SCID)	  without	  T	  and	  B	  cells,	   immune	   dysregulation	   and	   T	   cell-­‐mediated	   autoimmunity.	   VDJ	   recombination	  already	  induces	  considerable	  combinatorial	  diversity,	  which	  is	  further	  enhanced	  by	  the	  addition	  of	  random	  nucleotides	  at	  the	  recombination	  sites	  (junctional	  diversity).	  The	  C	  gene	  (Cμ,	  leading	  to	  an	  IgM-­‐BCR)	  is	  spliced	  to	  VDJ	  on	  mRNA	  level	  19.	  (Figure	  1:	  Overview	  of	  VDJ-­‐recombination)	  	  The	  generation	  of	  immature	  B	  cells	  takes	  place	  in	  the	  bone	  marrow.	  In	  order	  to	  enter	  the	  pre-­‐B	   cell	   stage,	   a	   complete	   heavy	   chain	   in	   combination	   with	   a	   surrogate	   light	   chain	  needs	   to	   be	   expressed.	   This	   triggers	   the	   VJ-­‐recombination	   of	   the	   light	   chain	   and	  eventually	   leads	   to	   the	   expression	  of	   a	   complete	   IgM-­‐BCR.	   If	   a	  B	   cell	   is	  not	  deleted	  or	  rendered	  anergic	  (non-­‐responsive)	  due	  to	  self-­‐reactivity,	   it	  can	  enter	  the	  circulation	  as	  an	   immature	   B	   cell.	   These	   immature	   B	   cells	   become	   long-­‐lived	   naïve	   B	   cells	   once	  passaged	  through	  the	  spleen	  where	  they	  receive	  BCR-­‐mediated	  survival	  signals	  20–22.	  	  	  	  
B	  cell	  affinity	  maturation	  and	  class-­‐switch	  Eventually,	  a	  naïve	  B	  cell	  may	  enter	  the	  B	  cell	  follicle	  of	  the	  spleen	  or	  a	  lymph	  node	  and	  encounter	   its	   cognate	   antigen	   presented	   on	   specialized	   APCs	   such	   as	   the	   follicular	  dendritic	  cells	  (FDC).	  If	  the	  B	  cell	  receives	  help	  from	  follicular	  T-­‐helper	  cells	  recognizing	  the	  same	  antigen,	  a	  germinal	  center	  (GC)	  can	  form	  inside	  the	  follicle.	  Within	  the	  GC,	  the	  B	  cell	  is	  cycling	  between	  the	  dark	  zone	  (DZ)	  and	  the	  light	  zone	  (LZ).	  During	  this	  time,	  the	  activity	   of	   the	   enzyme	   AID	   (activation-­‐induced	   cytidine	   deaminase)	   is	   elevated.	   AID-­‐mediated	  deamination	  of	  cytosine	  to	  uracil	  takes	  place	  in	  the	  VDJ-­‐region,	  increasing	  the	  likelihood	   of	   inducing	   mutations	   during	   the	   next	   round	   of	   replication	   (somatic	  hypermutation,	   SHM).	   The	   B	   cells	   mainly	   replicate	   in	   the	   DZ;	   afterwards,	   they	   are	  exposed	   again	   to	   their	   antigen	   in	   the	   LZ.	   Clones	  with	  mutations	   increasing	   their	  BCR-­‐affinity	  proliferate	  faster,	  have	  therefore	  a	  selective	  advantage	  and	  may	  undergo	  further	  DZ-­‐LZ	  iterations	  (and	  mutations).	  Finally,	  they	  are	  released	  and	  either	  become	  memory	  B	  cells	  or	  antibody-­‐secreting	  plasma	  cells	  4,21.	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B	  cell	  class	  switch,	   i.e.	  the	  replacement	  of	  the	  Cμ	  or	  Cδ	  region	  by	  another	  C	  region,	   is	  a	  second	  AID-­‐mediated	  mechanism	  promoting	  B	  cell	  diversity.	  The	  result	  is	  antibodies	  of	  other	   isotypes	   such	   as	   IgG1,	   IgA1	   or	   IgE	   that	   are	   adapted	   to	   different	   tissue	  compartments.	  These	  can	  bind	  with	  varying	  avidity	   to	  components	  of	   the	  complement	  system	   23	   and	   can	   attach	   to	   Fc-­‐receptors	   initiating	   cellular	   responses	   such	   as	  phagocytosis	  (ADCP)	  or	  antibody-­‐dependent	  cellular	  cytotoxicity	  (ADCC)	  24,25.	  	  Class	   switch	   can	   be	   induced	   before	   GC-­‐formation.	   Depending	   on	   the	   signals	   received,	  transcription	  is	   initiated	  upstream	  of	  Cμ	  /	  Cδ	  and	  other	  C-­‐regions	  (e.g.	  Cα1	  for	  IgA1	  or	  Cγ1	  for	  IgG1).	  A	  DNA-­‐RNA-­‐hybrid	  is	  formed	  which	  facilitates	  the	  recruitment	  of	  AID.	  As	  in	   SHM,	   subsequent	   action	   of	   uracil	   DNA	   glycosylase	   (UNG)	   results	   in	   an	   abasic	   site	  repaired	   by	   an	   error-­‐prone	   form	  of	   the	   base	   excision	   repair	   (BER)	   pathway	   that	  may	  induce	  double-­‐strand	  breaks	  (DSB).	  Alternatively,	  the	  MMR	  (mismatch	  repair)	  pathway	  recognizes	  the	  U:G	  base	  mismatches	  and	  creates	  DSBs	  during	  repair.	  The	  new	  C-­‐region	  is	   then	  relocated	  downstream	  of	  VDJ	  by	   the	  NHEJ	  pathway	  24.	  Summing	  up,	  after	   their	  release	  from	  the	  bone	  marrow,	  B	  cells	  are	  selected	  for	  the	  best	  possible	  affinity	  towards	  their	  cognate	  antigen	  while	  also	  induced	  to	  produce	  the	  type	  of	  antibodies	  that	  may	  be	  most	   suitable	   to	   a	   particular	   type	   and	   site	   of	   infection.	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FOCUS	   I:	   BREADTH	   AND	   LIMITATIONS	   OF	   THE	   INFLUENZA	  




Clinical,	  epidemiological	  and	  economic	  features	  of	  influenza	  Influenza	   is	   a	  viral	   infectious	  disease	  of	   the	   respiratory	   tract	   that	  occurs	   seasonally	   in	  temperate	   zones,	   i.e.	   from	   late	   fall	   until	   early	   spring	   in	   the	   northern	   hemisphere.	   The	  characteristic	   flu	   symptoms	   are	   fever,	   cough,	   muscle	   and	   joint	   pain,	   sore	   throat	   and	  running	  nose.	  While	  most	   people	   recover	  within	   one	  week,	   the	   disease	   course	   can	   be	  very	   severe	   and	   an	   estimated	   number	   of	   290’000	   to	   650’000	   people	   succumb	   to	  complications	  from	  respiratory	  disease	  annually	  26.	  	  	  Risk	  groups	  more	  prone	  to	  develop	  severe	  disease	  or	  complications	  include	  the	  elderly,	  children	  younger	   than	   five	  years,	  pregnant	  women,	  patients	  with	  chronic	  diseases	  and	  immunosuppressed	   individuals.	   Of	   note,	   case	   fatalities	   due	   to	   influenza	   is	   highest	   in	  those	   above	   65	   years	   in	   industrialized	   countries,	   whereas	   infant	   death	   is	  much	  more	  common	  in	  developing	  countries	  27,28.	  	  Additional	  to	  the	  high	  disease	  burden,	  the	  economic	  impact	  due	  to	  healthcare	  costs,	  loss	  of	  workforce	  and	  lower	  workforce	  productivity	   is	  considerable.	  A	  model	  to	  predict	  the	  economic	   impact	   in	   case	   of	   an	   influenza	   pandemic	   included	   the	   population	   structure,	  epidemiology	   and	   current	   vaccine	   coverage.	   The	   estimate	   ranged	   from	   71.3	   billion	   to	  166.5	  billion	  US	  dollars	  for	  the	  US	  only	  29.	  Thus,	  the	  socioeconomic	  impact	  of	  the	  virus	  is	  vast	  and	  worldwide.	  	  
	  
	  
Influenza	  virus	  structure	  and	  life	  cycle	  Influenza	   viruses	   are	   enveloped	   spherical	   viruses	   belonging	   to	   the	   Orthomyxoviridae	  family.	  They	  contain	  8	  segments	  of	  single-­‐stranded,	  negative-­‐sense	  RNA	  that	  encode	  up	  to	  16	  proteins.	  The	  segments	  PA,	  PB1	  and	  PB2	  encode	  parts	  of	  the	  viral	  RNA-­‐dependent	  RNA	   polymerase	   (RdRp).	   HA	   is	   coding	   for	   hemagglutinin,	   the	   predominant	   surface	  protein	  of	  influenza	  virus,	  important	  for	  binding	  to	  the	  host	  cell	  and	  therefore	  infection.	  Neuraminidase	  (NA)	  is	  a	  second	  transmembrane	  protein	  especially	  important	  in	  release	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of	   the	   virus.	   The	   viral	   ribonucleoproteins	   (vRNP)	   consist	   of	   vRNA-­‐segments	  wrapped	  around	   NP	   (nucleoprotein)	   with	   the	   polymerase	   complex	   attached	   to	   the	   ends.	   M	  encodes	  the	  matrix	  protein	  M1	  and	  the	  viral	  pore	  protein	  M2.	  The	  NS	  (non-­‐structural)	  segment	  encodes	  proteins	  hijacking	  the	  host’s	  spliceosome	  30	  and	  helping	  vRNP	  export	  31,32.	  Influenza	  virus	  structure	  is	  displayed	  in	  Figure	  2A.	  	  Influenza	   virus	   can	   attach	   to	   epithelial	   cells	   of	   the	   respiratory	   tract	   by	   binding	   of	  hemagglutinin	   to	   sialic	   acids	   (SA),	   the	   outermost	   structures	   on	   surface	   glycoproteins.	  The	  SA-­‐galactose	  (Gal)	  bond	  on	  glycoproteins	  is	  different	  between	  mammals	  and	  birds	  and	   confers	   specificity	   for	   certain	   influenza	   viruses	   33.	   Following	   endocytosis,	   the	  endosome	   gets	   more	   acidic	   which	   enables	   the	   fusion	   peptide,	   a	   part	   of	   the	   HA,	   to	  mediate	  the	  fusion	  of	  viral	  envelope	  with	  the	  bilayer	  of	  the	  endosome	  34.	  Acidification	  of	  the	  virus	  lumen	  results	  in	  vRNP	  release	  31,35.	  	  	  
	  	  
Figure	   2:	   Influenza	   virus	   structure	   and	   life	   cycle.	   A)	   A	   schematic	   representation	   of	   an	  influenza	  virion.	  All	  eight	  viral	  RNA	  (vRNA)	  segments	  and	  all	  transmembrane	  proteins	  present	  on	  the	   virus	   surface	   are	   depicted.	  B)	   A	   simplified	   display	   of	   the	   viral	   replication	   cycle.	   Influenza	  virus	  extensively	  uses	  the	  host	  cellular	  machinery:	  Among	  other,	  RNA	  polymerase	  II	  synthesizes	  vRNA,	   ribosomes	   in	   the	  cytoplasm	  and	   the	  ER	   translate	  viral	  RNA	  and	  host	  proteases	  generate	  functional	  HA	  in	  released	  virions	  by	  cleaving	  it	  into	  HA1	  and	  HA2	  subunits.	  Figure	  adapted	  from	  Shi	  et	  al.,	  Nat.	  Rev.	  Microbiology	  2014	  36.	  	  	  The	  vRNP	  contains	  nuclear	   localization	  signals	   that	  enable	  the	   import	   into	  the	  nucleus	  37.	   Complementary	   RNA	   (cRNA)	   is	   generated	   by	   RdRp	   and	   vRNA	   is	   synthesized	   by	  cellular	   RNA	   polymerase	   II	   38,39.	   5’-­‐capping	   and	   splicing	   is	   carried	   out	   by	   the	   host’s	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machinery,	  whereas	  polyadenylation	   is	   performed	  by	  RdRp	   40,41.	   The	   viral	  mRNAs	   are	  exported,	   translated,	   return	   as	   vRNPs	   to	   the	   nucleus	   and	   are	   re-­‐exported	   by	   CRM1-­‐dependent	   export	   37.	   The	  mRNAs	   of	   the	  membrane	   proteins	   HA,	   NA,	   M1	   and	  M2	   are	  shuttled	  through	  the	  ER	  –	  Golgi	  route	  and	  vRNPs	  and	  membrane	  proteins	  form	  mature	  virions	  at	  the	  plasma	  membrane	  32,42.	  	  	  The	  release	  of	  the	  virions	  by	  budding	  requires	  the	  action	  of	  NA:	  The	  sialic	  acids	  on	  the	  surface	  of	  the	  host	  cells	  need	  to	  be	  cleaved	  in	  order	  to	  disrupt	  the	  binding	  of	  HA	  to	  the	  glycoproteins	  43.	  HA-­‐cleavage	  by	  host	  proteases	  into	  HA1	  and	  HA2	  subunits	  renders	  the	  virus	   infective	   44	   (Life	   cycle	   summary:	  Figure	   2B).	   The	   humoral	   immune	   system	   can	  interfere	   with	   the	   viral	   life	   cycle	   by	   inhibiting	   viral	   entry	   and	   release,	   and	   also	   by	  disrupting	  membrane	  fusion	  and	  HA-­‐cleavage	  45.	  	  	  	  
Taxonomy,	  serotypes,	  hosts	  and	  strains	  The	  Orthomyxoviruses	   include,	   among	   other	   genera,	   the	   influenza	   viruses	  A,	   B	   and	  C.	  The	  family	   is	  characterized	  by	  containing	  segmented	  negative-­‐strand	  ssRNA	  as	  genetic	  material,	   expressing	  HA,	  NP	   and	  RdRP	   and	  possessing	   a	   lipid	   envelope	   46.	   Influenza	  A	  virus	  is	  able	  to	  infect	  a	  broad	  range	  of	  birds	  and	  mammals,	  including	  humans.	  Influenza	  B	  virus	  has	  only	  been	  isolated	  from	  humans	  and	  seals	  47.	  Influenza	  C	  virus	  is	  the	  rarest	  form;	  its	  hosts	  are	  humans	  and	  pigs	  48.	  	  Influenza	   A	   virus	   is	   the	   most	   abundant	   species	   causing	   influenza	   in	   humans.	   It	   is	  categorized	  into	  so-­‐called	  serotypes	  of	  which	  only	  two	  are	  currently	  present	  in	  humans,	  H1N1	  and	  H3N2.	  These	  serotypes	  are	  defined	  by	   the	   type	  of	  HA	  and	  NA	  expressed	  by	  the	   virus.	   All	   influenza	   A	   serotypes	   have	   their	   origin	   in	   avian	   influenza	   viruses	   49.	  Waterfowl	   are	   the	   main	   reservoir	   of	   Influenza	   A	   viruses	   and	   harbor	   mostly	   low	  pathogenic	  avian	  influenza	  viruses	  (LPAIV).	  Brigde	  species	  such	  as	  domestic	  poultry	  are	  usually	   necessary	   to	   enable	   occasional	   zoonotic	   spread	   of	   LPAIV	   to	   swine	   or	   humans	  50,51.	   Crossing	   of	   the	   species	   barrier	   happens	   quite	   frequently	   between	   swine	   and	  humans.	   This	   can	   lead	   to	   pandemics	   in	   case	   viruses	   reassort	   vRNA	   segments	   from	  different	   species,	   as	   it	   happened	   in	   the	   2009	   H1N1	   pandemic	   52.	   While	   some	   viral	  mutations	   (e.g.	   in	   the	   HA	   receptor	   binding	   site	   or	   in	   PB2)	   have	   been	   associated	  with	  adaptation	   to	   another	   host	   species,	   the	   mechanisms	   required	   for	   bird-­‐to-­‐mammal	   or	  mammal-­‐to-­‐mammal	   host	   switch	   and	   stable	   transmission	   within	   the	   new	   host	   are	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Figure	   3:	   Zoonotic	   spread	   of	  
influenza	  A	  virus.	  Waterfowl	  such	  as	  ducks	   and	   gulls	   harbor	   the	   broadest	  range	  of	   serotypes	  and	  constitute	   the	  main	   virus	   reservoir.	   Viruses	  originating	  from	  wild	  birds	  have	  been	  able	   to	   switch	   to	   and	   being	  transmitted	   within	   other	   wild	   and	  domestic	  mammals	   and	  birds.	  Within	  humans,	   only	   the	   H1N1	   and	   H3N2	  serotypes	   are	   currently	   circulating.	  Zoonotic	   spread	   to	   humans	   has	   been	  reported	   for	   H1N1	   and	   H3N2	   strains	  (from	  pigs),	  as	  well	  as	  for	  H5N1,	  H9N2	  and	   different	   H7	   serotypes	   (from	  poultry,	   rare).	   The	   latter	   is	   especially	  feared	  due	  to	  the	  occurrence	  of	  highly	  pathogenic	  influenza	  viruses	  (HPAIV).	  Figure	  adapted	  from	  Wahlgren,	   Infect	  Ecol,	  Epidemiol	  2011	  54.	  	  	  	  	  A	   standardized	   nomenclature	   is	   used	   to	   unambiguously	   name	   different	   influenza	  strains.	  It	  includes	  the	  genus,	  the	  host	  of	  origin	  (if	  not	  of	  human	  origin),	  the	  geographical	  origin,	  strain	  number,	  year	  of	  isolation	  and	  optionally	  the	  serotype	  in	  case	  of	  influenza	  A	  55.	  Examples	  below	  are	  obtained	  from	  the	  influenza	  database	  GISAID	  56.	  	  GISAID	  EPI_ISL_166859:	  	   A/Switzerland/9715293/2013(H3N2)	  GISAID	  EPI_ISL_1463:	  	   	   B/Seal/Netherlands/1/99	  	  For	  better	  readability,	  the	  strains	  mentioned	  in	  manuscript	  1	  are	  sometimes	  referred	  to	  as	  e.g.	  “Switzerland”	  instead	  of	  A/Switzerland/9715293/2013(H3N2).	  	  	  	  
The	  immune	  response	  against	  influenza	  virus	  Influenza	   virus	   is	   directly	   transmitted	   from	   person	   to	   person	   through	   aerosols	   and	  droplets,	  which	  are	   formed	  e.g.	   through	  coughing	  or	   sneezing.	  Touching	  contaminated	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Influenza	  vaccine	  composition	  Vaccination	   is	   an	   efficient	  way	   to	   reduce	   the	   risk	   for	   influenza.	   Currently,	  most	   of	   the	  marketed	   vaccines	   are	   produced	   as	   split	   vaccines	   (detergent-­‐inactivated)	   containing	  either	  all	  viral	  proteins	  or	  only	  HA	  with	  or	  without	  neuraminidase	  74.	  The	  vaccines	  are	  annually	  updated	  in	  order	  to	  contain	  virus	  strains	  that	  were	  dominating	  in	  the	  previous	  season.	  Over	  the	  past	  decades,	  the	  vaccine	  always	  included	  a	  representative	  of	  the	  H1N1	  and	  the	  H3N2	  serotype	  and	  at	   least	  one	   influenza	  B	   lineage	  (Yamagata	  or	  Victoria),	  or	  more	  recently	  both	  of	  them	  in	  the	  quadrivalent	  vaccine	  available	  since	  2014.	  Stabilizing	  agents	   and	   buffer	   salts	   in	   varying	   concentrations	   are	   included.	   Traces	   of	   detergents,	  sucrose	   and	   chicken	   egg	   proteins	   such	   as	   ovalbumin,	   all	   related	   to	   the	   vaccine	  production,	  may	  be	  found.	  	  Compared	   to	   other	   virus	   or	   bacteria	   vaccines,	   the	   efficacy	   of	   the	   influenza	   vaccine	   is	  rather	  low.	  Estimates	  range	  between	  20	  and	  60%,	  depending	  on	  the	  season	  and	  type	  of	  the	  vaccine	  but	  the	  range	  is	  even	  broader	  when	  separated	  by	  genus	  and	  serotype	  75.	  The	  low	   efficacy	   has	   been	   attributed	   to	   the	   high	   capability	   of	   the	   virus	   to	   evolve	   through	  antigenic	   drift	   and	   thereby	   evading	   the	   host’s	   immune	   system	   76.	   Moreover,	   most	  current	   influenza	   vaccines	   are	   produced	   in	   fertilized	   chicken	   eggs.	   This	   can	   result	   in	  viral	   variants	   adapted	   to	   binding	   to	   avian-­‐type	   sialic	   acids	   77.	   It	   has	   been	   shown	   that	  these	   variants	   can	   induce	   antibodies	   that	   are	   poorly	   binding	   to	   naturally	   occurring	  viruses	  78–80.	  The	  concept	  of	  original	  antigenic	  sin	  states	  that	   the	  antigens	  encountered	  earliest	   in	   life	  (“senior”	  antigens)	  will	  be	  preferentially	   targeted	  throughout	   life	  due	  to	  immunological	  memory	  81,82.	  Reduced	  vaccine	  efficacy	  in	  years	  where,	  compared	  to	  the	  previous	  season,	   identical	  or	  very	  similar	  strains	  were	   included	  in	  the	  preparation	  has	  been	  reported	  83–85.	  	  	  	  
Hemagglutinin:	  Main	  antibody-­‐target	  Hemagglutinin	  (HA)	  is	  the	  most	  abundant	  protein	  on	  the	  viral	  surface	  usually	  present	  as	  a	  homotrimer.	  It	  is	  a	  transmembrane	  protein,	  has	  a	  molecular	  weight	  of	  around	  60	  kDa	  (monomer)	  and	  consists	  of	  the	  HA1	  subunit	  (roughly	  defined	  as	  the	  “head”)	  and	  the	  HA2	  subunit	  (partly	  constituting	  the	  “stalk”	  or	  “stem”)	  that	  are	  covalently	  attached	  through	  a	  disulfide	   bond.	   The	   receptor-­‐binding	   site	   (RBS)	   on	  HA1	  makes	   contact	  with	   the	   sialic	  acids	  present	  on	  the	  host	  cell	  and	  hence	  mediates	  endocytosis	  of	  the	  virus	  86.	  The	  HA2	  subunit	   harbors	   the	   fusion	   peptide,	   a	   structure	   activated	   upon	   acidification	   of	   the	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endosome,	  which	  enables	   the	  release	  of	   the	  virus	   into	   the	  cytosol	   34.	  Characteristics	  of	  Influenza	  A	  HA	  are	  shown	  on	  a	  surface	  representation	  of	  the	  protein	  (Figure	  4).	  	  Due	  to	  its	  exposed	  position,	  HA	  is	  the	  influenza	  structure	  that	  is	  preferentially	  targeted	  by	  antibodies,	  the	  head	  region	  much	  more	  frequently	  than	  the	  stalk	  region.	  Five	  regions	  on	  the	  head,	  designated	  A	  to	  E,	  are	  especially	  antigenic	  87–89.	  Consequently,	  the	  selection	  pressure	   is	   higher	   on	   the	   head	   region	   resulting	   in	   higher	   sequence	   variability	   in	   this	  area.	   From	   the	   virus	   perspective,	   a	   successful	   mutation	   leads	   to	   immune	   evasion	  through	  antigenic	  drift,	  while	  maintaining	  the	  fitness	  of	  the	  virus.	  It	  has	  been	  suggested	  that	  major	  changes	  in	  antigenicity	  (for	  influenza	  A	  H3N2)	  can	  be	  attributed	  to	  mutations	  in	   only	   seven	   amino	   acids	   adjacent	   to	   the	   RBS	   90.	   Due	   to	   its	   importance	   in	   viral-­‐endosomal	  membrane	   fusion,	   large	  parts	  of	  HA2	  are	  relatively	   intolerant	   to	  mutations	  and	  thus	  show	  a	  high	  degree	  of	  conservation	  91.	  This	  is	  also	  partly	  true	  for	  the	  RBS;	  but	  given	   its	   proximity	   to	   antigenic	   sites,	   the	   RBS	   is	   a	   primary	   target	   for	   antibodies	   and	  mutations	  requiring	  compensatory	  mutations	  have	  been	  described	  91,92.	  	  	  	  
Figure	  4:	  Surface	  representation	  of	  HA	  
monomer	   from	   A/Victoria/361/2011	  
(H3N2).	   The	   HA1	   subunit	   is	   shown	   in	  grey,	   HA2	   subunit	   in	   white	   with	   the	  fusion	   peptide	   highlighted	   in	   black.	   The	  major	   antigenic	   sites	   (A	   –	   E,	   partly	  hidden)	   are	   depicted	   in	   shades	   of	   cyan	  and	  blue	  87–89.	  The	  receptor	  binding	  site	  93	  (yellow)	   is	   lined	   by	   seven	   amino	   acids	  causing	   major	   antigenic	   changes	   when	  mutated	   (red)	   90.	   HA	   is	   a	   glycoprotein	  with	   many	   N(Asparagin)-­‐linked	  glycosylations	   that	   may	   alter	   antigenic	  properties.	   The	   innermost	   sugars	  (GlcNAc,	   N-­‐Acetylglucosamine)	   are	  represented	   as	   green	   spheres.	   Figure	  created	   with	   Mac	   PyMol	   molecular	  graphics	  system,	  version	  1.7,	  Schrödinger	  LLC.	  PDB	  ID:	  4O5N	  	  	  
Assays	  to	  characterize	  the	  antibody	  response	  against	  influenza	  virus	  Neutralizing	   antibodies	  mostly	   target	  HA	   and	  may	   interfere	  with	   any	   step	  of	   the	   viral	  replication	  cycle.	  They	  consist	  of	  antibodies	  (i)	  abrogating	  the	  association	  of	  the	  RBS	  of	  HA	   with	   sialic	   acids,	   (ii)	   inhibiting	   virus-­‐endosome	   fusion,	   iii)	   block	   proteolytic	   HA-­‐cleavage	  or	  (iv)	  interfering	  with	  viral	  release	  through	  virion	  cross-­‐linking	  or	  interfering	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with	  Neuraminidase	  function	  45.	  Non-­‐neutralizing	  antibodies	  do	  not	  interfere	  with	  viral	  replication	  but	  can	  exert	  complement-­‐	  or	  Fc-­‐mediated	  effects	   to	  remove	   infected	  cells.	  Broadly	   neutralizing	   (bnAbs)	   or	   non-­‐neutralizing	   antibodies	   in	   addition	   are	   able	   to	  target	  a	  very	  wide	  spectrum	  of	  related	  strains.	  
	  The	   hemagglutination	   assay	   and	   the	   hemagglutination	   inhibition	   assay	   (HAI)	   are	  standard	  techniques	  to	  measure	  the	  amount	  of	  virus	  or	  influenza-­‐specific	  antibodies	  in	  the	  serum.	  When	  influenza	  virions	  are	  mixed	  in	  a	  microtiter	  plate	  with	  erythrocytes,	  the	  HA	   on	   the	   viral	   surface	   binds	   to	   the	   sialic	   acids	   on	   the	   erythrocytes’	   surface,	   thereby	  forming	   a	   lattice.	   This	   process	   is	   called	   hemagglutination.	   By	   keeping	   the	   amount	   of	  erythrocyte	  fixed	  and	  serially	  diluting	  the	  virus,	  the	  virus	  titer	  can	  be	  deduced.	  The	  virus	  titer	  is	  defined	  as	  the	  highest	  dilution,	  where	  the	  amount	  of	  virus	  is	  sufficient	  to	  induce	  hemagglutination.	   In	  higher	  dilutions,	   the	   erythrocytes	   form	  a	  pellet	   on	   the	  bottom	  of	  the	  plate.	  	  	  HAI	  is	  an	  extension	  of	  the	  hemagglutination	  assay	  described	  above.	  Here,	  the	  amount	  of	  erythrocytes	   and	   virus	   are	   fixed	   and	   serum	   is	   serially	   diluted	   into	   the	   plate.	   The	  HAI	  titer	   is	   defined	   as	   the	   highest	   serum	   dilution	  where	   hemagglutination	   is	   prevented	   94	  (Figure	  5).	  The	  higher	  the	  HAI	  titer,	  the	  higher	  is	  the	  amount	  and	  avidity	  of	  HA-­‐specific	  antibodies.	  The	  HAI	   titer	  does	  not	   give	   information	   about	   all	  HA-­‐specific	   and	  possibly	  neutralizing	  antibodies,	  but	   is	  restricted	  to	  neutralizing	  antibodies	   interfering	  with	  the	  RBS.	  Nevertheless,	   since	  HAI	   titers	   above	  40	   (that	   is,	   40-­‐fold	   serum	  dilution	  or	  more)	  were	   shown	   to	   confer	   protection	   in	   more	   than	   50%	   of	   experimentally	   infected	  individuals,	  HAI	  is	  a	  very	  frequently	  used	  technique	  95.	  	  	  Since	   it	  measures	   the	   ability	  of	   the	  virus	   to	   infect	   target	   cells,	   the	  microneutralization	  assay	   is	   a	   powerful	   tool	   to	   detect	   all	   neutralizing	   antibodies	   against	   influenza.	   Brief,	  serum	   is	   serially	   diluted	   in	   a	  microplate	   and	   fixed	   amounts	   of	   virus	   are	   added	   to	   the	  wells.	  After	   two	  hours	  of	   incubation,	  virus-­‐antibody	  mixtures	  are	  added	  to	  MDCK	  cells	  for	  over	  night	  incubation.	  Following	  fixation,	  the	  degree	  of	  infection	  is	  then	  assessed	  by	  ELISA,	  e.g.	  by	  staining	  for	  influenza	  NP.	  Similar	  to	  HAI,	  titers	  are	  calculated	  based	  on	  the	  highest	  serum	  dilution	  without	  apparent	  viral	  infection	  96.	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Figure	   5:	   Hemagglutination	   inhibition	   assay.	   Serum	   stems	   from	   a	   newborn	   infected	   with	  pandemic	  H1N1	  2009	  virus	  10,	  24	  and	  42	  days	  after	  birth.	  First,	  serial	  dilutions	  of	  HA-­‐depleted	  serum	  are	  given	  to	  the	  microtiter	  plate,	  followed	  by	  addition	  of	  a	  fixed	  amount	  of	  virus.	  After	  30	  minutes	   of	   incubation	   at	   room	   temperature,	   samples	   are	  mixed	  with	   turkey	   erythrocytes	   and	  incubated	  for	  another	  30	  minutes	  at	  room	  temperature.	  HAI	  titers	  (here:	  HI	  titers)	  are	  defined	  as	  the	  highest	   serum	  dilution	   (or	   the	   reciprocal	   thereof)	  where	  hemagglutination	   is	   inhibited.	  On	  the	  plate	  above,	  titers	  are	  10	  at	  day	  10,	  160	  at	  day	  24	  and	  320	  at	  day	  42.	  	  	  	  	  	  In	   order	   to	   characterize	   breadth	   of	   influenza-­‐specific	   antibodies,	   the	   response	   against	  multiple	   viruses	   has	   to	   be	   tested.	   This	   is	   not	   feasible	   with	   the	   abovementioned	  techniques.	  A	  multiplexed	  assay	  allows	  to	  analyze	  binding	  of	  broadly	  cross-­‐recognizing	  antibodies.	   Multiple	   microspheres	   (beads)	   with	   different	   fluorescence	   properties	   are	  covalently	   linked	   with	   HA	   from	   different	   strains.	   These	   beads	   are	   simultaneously	  exposed	   to	   serum	   antibodies,	   which	   are	   then	   detected	   with	   a	   fluorescent	   secondary	  antibody.	   The	   antibody	   signal	   per	   bead	   type	   enables	   the	   analysis	   of	   cross-­‐reactive	  antibodies	   against	   a	   set	   of	   HA	   97.	   These	   bead-­‐based	   assays	   have	   been	  widely	   used	   in	  assessing	   vaccine-­‐induced	   antibody	   cross-­‐reactivity,	   including	   the	   flu	   vaccine	   98–100.	  While	   informing	   about	   the	   breadth	   of	   the	   vaccine-­‐induced	   antibody	   response,	   such	  multiplexed	  assays	  do	  not	  measure	  neutralization	  capacity	  of	  these	  antibodies.	  	  	  
Influenza	  virus	  evolution	  The	   relatedness	   between	   two	   viruses	   (or	   any	   organisms)	   can	   be	   measured	   by	   the	  genetic	   distance,	   that	   is,	   the	   amount	   of	   mutations	   or	   polymorphisms	   that	   separate	   a	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specific	  virus	  from	  another	  one.	  In	  the	  case	  of	  influenza	  virus,	  it	  is	  the	  HA	  segment	  that	  diverges	   most	   between	   viral	   isolates.	   These	   differences	   can	   be	   represented	   in	  phylogenetic	   trees	   where	   each	   node	   usually	   corresponds	   to	   a	   non-­‐synonymous	  mutation.	   Isolates	   of	   influenza	   viruses	   bearing	   the	   same	   amino	   acid	   change	   or	   set	   of	  amino	  acid	  changes	  are	  clustered	  into	  specific	  clades	  or	  subclades	  (see	  Figure	  6).	  	  The	  genetic	  distance	  does	  not	  always	  correlate	  with	  antigenic	  distance.	  More	  precisely,	  two	  viruses	  that	  are	  phylogenetically	  separated	  by	  many	  mutations	  may	  be	  equally	  well	  recognized	  by	  the	  immune	  system.	  On	  the	  other	  hand,	  a	  virus	  variant	  with	  a	  single	  point	  mutation	  may	   be	   poorly	   recognized	   by	   the	   immune	   system;	   the	   antigenic	   distance	   is	  large.	  	  	  
	  	  
Figure	   6:	   Phylogenetic	   tree	   of	  HA	   from	   Influenza	  A	  H3N2	   virus.	   Strains	  (sequence	  source:	  GISAID)	   isolated	   from	   all	   over	   the	   world	   between	   April	   2012	   and	   April	   2018	   are	   depicted	   as	  colored	   dots.	   Strains	   are	   colored	   for	   amino	   acid	   HA1	   128,	   where	   blue	   is	   alanine,	   turquoise	   is	  threonine	   and	   other	   colors	   represent	   other	   rare	   amino	   acids.	   Clades	   are	   labeled	   in	   grey;	   the	  2015/16	   vaccine	   contained	   the	   3c3.A	   representative	   A/Switzerland/9715293/2013,	   marked	  with	   a	   red	   cross.	   The	   vaccines	   in	   the	   following	   years	   contained	   a	   genetically	   different	   virus,	  A/Hong	   Kong/4801/2014	   in	   clade	   3c2.A,	   marked	   with	   a	   yellow	   cross.	   Figure	   created	   with	  nextstrain	  tool	  101.	  	  	  The	  visualization	  of	  antigenic	  distance	  in	  antigenic	  maps	  was	  introduced	  by	  Smith	  and	  colleagues	   102	   based	   on	   concepts	   proposed	   by	   Lapedes	   and	   Farber	   103.	   The	   maps	   are	  based	   on	   one	   single	   method	   to	   determine	   antigenic	   distance,	   the	   hemagglutination	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Pre-­‐existing	  immunity	  The	   exposure	   history	   of	   influenza	   infections	   endured	   and	   influenza	   vaccinations	  obtained,	   combined	  with	   the	   individual	   immunological	   status	   complicates	   the	  analysis	  of	  influenza	  vaccine	  responses	  in	  humans.	  Consequently,	  it	  is	  very	  difficult	  to	  predict	  if,	  and	  how	  much	  an	  individual	  would	  profit	  from	  vaccination.	  Some	  general	  observations	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are	   that	   infections	   induce	   more	   cross-­‐reactive	   immune	   responses	   and	   longer	   lasting	  memory	  compared	  to	  vaccination	  104.	  	  Also,	  antibody	  affinity	  and	  neutralization	  capacity	  slightly	   decrease	   with	   age	   105.	   Finally,	   in	   the	   special	   setting	   of	   infection	   with	   a	  recombined,	  pandemic	  virus,	  most	  people	  have	  no	  pre-­‐existing	  humoral	   immunity	  but	  may	  be	  partially	  protected	  by	  T	  cells	  targeting	  conserved	  epitopes	  73.	  	  	  The	   so	   far	   most	   comprehensive	   study	   on	   the	   impact	   of	   pre-­‐existing	   immunity	   on	  antibody	   response	   towards	   antigenically	   different	   viruses	   shows	   the	   extent	   of	   cross-­‐reactive	  antiviral	   responses	   (towards	  H3N2	  viruses	   from	  1968	   to	  2010)	   in	   relation	   to	  age,	  vaccination/infection	  status	  and	  longitudinally	  within	  individuals	  106.	  Individual	  or	  group	   data	   was	   represented	   as	   an	   antigenic	   landscape,	   an	   extension	   of	   the	   antigenic	  map	   and	   plots	   human	   HAI-­‐titers	   on	   top	   of	   the	   ferret-­‐derived	   antigenic	   distance	   data	  (Figure	  8).	  Some	  of	  the	  main	  findings:	  	   -­‐ Pre-­‐vaccination	   titers	   are	   usually	   not	   highest	   against	   the	   current	   antigenic	  cluster,	  but	  rather	  against	  the	  one	  before	  or	  the	  penultimate	  -­‐ Without	   vaccination	   or	   infection,	   the	   antigenic	   landscape	   is	   remarkably	   stable	  across	  six	  years	  -­‐ Upon	   infection	   with	   a	   H3N2-­‐virus,	   titers	   increase	   against	   recent	   viruses,	   but	  often	  also	  against	  very	  distant	  clusters	  -­‐ Vaccination	   with	   a	   virus	   belonging	   to	   an	   antigenic	   cluster	   to	   which	   there	   has	  been	   a	   few	   years	   of	   exposure	   leads	   to	   a	   “backboost”,	   similar	   to	   infection,	   but	  limited	  cross-­‐reactivity	  to	  the	  most	  recent	  cluster	  -­‐ Vaccination	  with	  an	  antigenically	  novel	  virus	  both	  increases	  titers	  against	  novel	  viruses	  and	  leads	  to	  a	  backboost	  -­‐ The	   latter	   holds	   true	   for	   two	   risk	   groups:	   The	   elderly	   and	   those	   with	   pre-­‐vaccination	  titers	  below	  40	  	  Summing	  up,	  these	  data	  suggest	  that	  vaccination	  with	  antigenically	  advanced	  variants	  is	  beneficial	  even	  if	  the	  circulating	  strains	  turn	  out	  to	  be	  of	  a	  pre-­‐existing	  antigenic	  cluster.	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Escape	  from	  the	  H3N2	  influenza	  vaccine	  response	  due	  to	  
a	   single	   amino	   acid	   change	   relates	   to	   a	   restricted	  
memory	  B	  cell	  repertoire	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Abstract	  
	  
Background:	   Rapidly	   evolving	   pathogens	   are	   prone	   to	   evade	   vaccination-­‐induced	  immune	   responses.	   Individual	   antibody	   repertoires	  may	   predict	   susceptibility	   to	   viral	  escape.	   Here,	   we	   aimed	   at	   investigating	   the	   extent	   of	   vaccination-­‐induced	   antibody	  cross-­‐reactivity	  against	  multiple	  vaccine	  strains	  and	  its	  relationship	  with	  viral	  sequence	  homology	  and	  the	  host’s	  B	  cell	  immune	  repertoire.	  	  
Methods:	   By	   means	   of	   a	   multiplex	   immunoassay,	   we	   profiled	   a	   2007/08	   influenza	  vaccine	   cohort	   for	   antibody	   responses	   targeting	   the	   Influenza	   A	   hemagglutinin	   (HA).	  The	   response	   to	   the	   strains	   contained	   in	   the	   respective	   vaccine	   and	   to	   influenza	   A	  viruses	  with	  different	  phylogenetic	  relatedness	  (five	  H1N1,	  eight	  H3N2)	  was	  assessed	  to	  estimate	  cross-­‐protection.	  The	  antibody	  repertoire	  was	  interrogated	  by	  BCR	  sequencing	  of	  memory	  B	  cells	  and	  plasmablasts	  in	  a	  subset	  of	  12	  subjects	  pre-­‐	  and	  post-­‐vaccination.	  Effects	   of	   repeated	   antigen	   exposure	   by	   vaccination	   were	   investigated	   in	   a	   second	  cohort	  in	  the	  2017/18	  influenza	  season.	  
Results:	  HA	  cross-­‐recognition	  was	  partly	  dependent	  on	  the	  pre-­‐existing	  antibody	  levels	  and	  the	  phylogenetic	  distance.	  Importantly,	  however,	  the	  T128N	  mutation	  resulted	  in	  a	  glycosylation	   change	   between	   the	   closely	   related	   HAs	   of	   H3N2	   A/Victoria/361/2011	  and	  A/Texas/50/2012	  and	  reduced	  the	  antibody	  response	  by	  more	  than	  half.	  This	  was	  most	  pronounced	  in	  vaccinated	  subjects	  with	  a	  skewed	  antibody	  repertoire	  of	  their	  pre-­‐vaccination	  memory	  B	  cells.	  Comparison	  of	  different	  vaccination	  cohorts	  between	  2008	  and	  2018	  indicated	  that	  vaccination	  with	  an	  N128-­‐containing	  vaccine	  strain	  in	  2014/15	  induced	  a	  response	  targeting	  this	  HA	  region.	  This	  recognition	  was	  however	  lost	  again	  in	  2017/18,	  indicating	  that	  no	  robust	  memory	  against	  this	  novel	  epitope	  was	  induced.	  	  
Conclusions:	   Vaccination	   induces	   cross-­‐reactivity	   against	   influenza	   strains	   closely	  related	  to	  the	  vaccine	  strains.	  Low	  antibody	  diversity	  might	  however	  make	  the	  response	  prone	   to	  escape	  by	  mutations	  at	   immunodominant	  sites.	  We	  propose	  an	  antigenic	  site	  that	  might	  be	  poorly	  recognized	  at	  population	  level	  if	  the	  respective	  clade	  expands.	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Introduction	  
	  	  Vaccination	  is	  a	  highly	  effective	  intervention	  to	  reduce	  infectious	  diseases	  at	  low	  costs.	  Mass	   vaccinations	   led	   to	   the	   containment	   or	   even	   elimination	   of	   pathogens	   from	  populations,	   saving	   millions	   of	   lives	   1.	   Vaccinations	   aim	   at	   protecting	   from	   infection,	  ideally	  by	  inducing	  pathogen-­‐neutralizing	  antibodies	  that	  interrupt	  the	  viral	  replication	  cycle	   2,3.	   In	   pathogens	   with	   a	   very	   high	   replication	   rate,	   such	   as	   influenza	   or	   HIV,	  mutations	  in	  genes	  encoding	  for	  viral	  surface	  glycoproteins	  occur	  frequently.	  When	  such	  mutations	   affect	   antibody-­‐binding	   sites,	   this	   may	   result	   in	   poorer	   recognition	   of	   the	  virus,	   a	   process	   commonly	   referred	   to	   as	   antigenic	   drift.	   Therefore,	   pathogens	  with	   a	  high	  number	  of	  related,	  but	  antigenically	  distinct	  strains	  remain	  a	  challenge	  to	  vaccine	  design	  1.	  	  Influenza	   virus	   is	   a	   highly	   variable	   virus,	   which	   can	   cause	   severe	   respiratory	   tract	  infections.	  It	  infects	  5	  to	  10%	  of	  all	  adults	  and	  20	  to	  30%	  of	  all	  children	  annually,	  hence,	  immunity	   against	   the	   virus	   is	   present	   in	   most	   individuals	   already	   at	   a	   young	   age	   4,5.	  Influenza	  A	  virus	  infection	  accounts	  for	  most	  seasonal	  influenza	  epidemics	  6.	   	  Based	  on	  two	  surface	  proteins,	  hemagglutinin	  (HA)	  and	  neuraminidase	  (NA),	  influenza	  A	  viruses	  are	   subdivided	   into	   different	   serotypes,	   of	   which	   only	   H1N1	   and	   H3N2	   are	   currently	  circulating	  in	  humans	  7.	  	  
Regularly	   updating	   the	   influenza	   vaccine	   composition	   to	   match	   currently	   circulating	  strains	  and	  yearly	  vaccinations	  aim	  at	  counteracting	  viral	  escape	  6.	  Vaccine	  effectiveness	  (VE)	   in	   an	   individual	   is	   typically	   estimated	   by	   applying	   an	   assumed	   surrogate	   of	  protection.	   For	   influenza	   vaccination,	   a	   hemagglutination	   inhibition	   (HAI)	   IgG	   titer	  >1:40	   is	   considered	   protective,	   although	   specifically	   it	   provided	   50%	  protection	   from	  experimental	   infection	   in	   young	   healthy	   subjects	   8.	   In	   a	   real-­‐life	   setting,	   titer-­‐based	  protection	  is	  lower	  9.	  VE	  estimates	  based	  on	  the	  comparison	  of	  the	  odds	  of	  vaccination	  between	   patients	   with	   influenza-­‐like	   symptoms	   positive	   or	   negative	   for	   the	   virus	   are	  more	   reliable	   (test-­‐negative	   design)	   10,11.	   Such	   estimates	   vary	   strongly	   between	  influenza	  serotypes,	  but	  overall	  effectiveness	  ranges	  from	  20	  to	  60%	  depending	  on	  the	  year	  12–17.	  	  Vaccine-­‐induced	   antibodies	   generally	   neutralize	   homologous	   strains	   within	   a	   given	  serotype,	   but	   can	   only	   provide	   a	   certain	   degree	   of	   cross-­‐protection	   against	   more	  distantly	  related	  circulating	  strains	  18.	  Currently,	  more	  than	  half	  a	  year	  is	  required	  from	  candidate	  strain	  selection	  until	  vaccine	  marketing.	  This	  substantially	  increases	  the	  risk	  for	  a	  mismatch	  between	  the	  epidemic	  viruses	  and	  the	  vaccine	  viruses	  selected	  based	  on	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surveillance	   data	   from	   the	   previous	   season	   19.	   Moreover,	   the	   viruses	   included	   in	  influenza	  vaccines	  are	  propagated	   in	   fertilized	  chicken	  eggs.	  This	  can	  result	   in	  vaccine	  virus	  adaptation	   to	  avian-­‐type	   receptors,	  which	  may	   induce	  poorly	  binding	  antibodies	  20,21.	   Taken	   together,	   fast	   virus	   evolution,	   time	   lag	   and	   mode	   of	   vaccine	   production	  contribute	  to	  the	  relatively	  poor	  clinical	  efficacy	  of	  the	  seasonal	  influenza	  vaccine.	  	  The	   individual	   cumulative	   exposure	   history	   of	   natural	   influenza	   contacts	   and/or	  vaccination	  shapes	   the	   influenza-­‐specific	  adaptive	  memory	   22.	  While	  natural	   infections	  induce	  a	  long-­‐lasting,	  broad	  immune	  response,	  the	  influenza	  vaccine	  response	  is	  skewed	  and	  of	   limited	  duration	  23.	  The	  vaccine-­‐induced	  memory	  response	  is	   influenced	  by	  age,	  previous	   infections,	   vaccinations	   and	   vaccine	   types	   24–26.	   A	   ‘back-­‐boost’	   effect	   of	   the	  antibody	   response	   towards	   viral	   strains	   encountered	   early	   in	   life	   has	   been	   well	  characterized	   27,28,	   exemplarily	   demonstrated	   in	   the	   better	   ability	   of	   elderly	   people	   to	  neutralize	   the	   reassorted	   A(H1N1)pdm09	   strain	   after	   the	   2009	   pandemic	   29.	   This	  suggests	   that	   the	  benefit	  of	  a	  vaccination	  depends	  on	  the	  exposure	  history	  of	   the	  host.	  High-­‐throughput	  B	   cell	   receptor	   (BCR)	   sequencing	   can	  be	  used	   to	   assess	   the	   antibody	  repertoire	  and	  track	  the	  expansion	  and	  contraction	  of	  B	  cell	  lineages	  (clonotypes)	  upon	  influenza	  vaccination	  30,31.	  The	  expanded	  lineages	  are	  constituted	  of	  replicating	  memory	  B	   cells	   and	   antibody-­‐secreting	   plasmablasts,	   both	   being	   highly	   enriched	   in	   influenza-­‐specific	  clonotypes	  32,33.	  The	  high	  degree	  of	  somatic	  hypermutation	  (SHM)	  suggest	  that	  the	  majority	  of	   influenza-­‐specific	  B	  cells	  derive	   from	  the	  memory	  pool	   32.	  However,	  de	  
novo	  recruitment	  is	  critical	  to	  control	  rapidly	  evolving	  viruses	  and	  probably	  is	  especially	  important	   in	   elderly	   people	   who	   tend	   to	   have	   a	   narrowed	   BCR	   repertoire	   with	   high	  levels	  of	  SHM	  34.	  So	  far,	  it	  is	  unknown	  whether	  the	  degree	  of	  cross-­‐reactivity	  is	  reflected	  in	   the	   BCR-­‐repertoire.	   Repeated	   challenge	   with	   very	   similar	   antigens	   may	   skew	   the	  antibody	  response	  towards	  conserved	  elements	  and	  prevent	  de	  novo	  responses	  (concept	  of	  the	  ‘original	  antigenic	  sin’)	  35,36.	  Indeed,	  repeated	  H3N2	  vaccination	  with	  a	  low	  degree	  of	   antigenic	   variation	   between	   vaccine	   strains	   was	   reported	   to	   reduce	   VE	   37,38	   and,	  irrespective	  of	  antigenic	  variation,	  reducing	  HAI	  titers	  39.	  	  In	   this	  study,	  we	  aimed	  at	  characterizing	  the	  breadth	  of	  B	  cell	  responses	   in	  vaccinated	  healthy	  donors.	  The	  degree	  of	  antibody	  cross-­‐reactivity	  against	  HA	  of	  influenza	  vaccine	  and	   closely	   related	   strains	   was	   assessed	   upon	   vaccination	   and	   related	   to	   the	  phylogenetic	  distance	  to	  the	  vaccine	  strains.	  Further,	  the	  relationship	  of	  cross-­‐reactivity	  with	   the	   individual’s	  antibody	  repertoire	  was	   investigated.	  Finally,	  we	  analyzed	  an	  HA	  variant	  that	  escaped	  vaccine-­‐induced	  humoral	  immunity.	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Methods	  
	  
Vaccination	  cohort	  and	  clinical	  samples	  Within	   prospective	   influenza	   vaccination	   cohorts	   of	   the	   seasons	   2007/2008	   40	   and	  2017/18,	   samples	   from	   healthy	   adults	   were	   analyzed.	   All	   subjects	   gave	   written	  informed	   consent	   and	   the	   study	   was	   IRB-­‐approved.	   Clinical	   characteristics	   of	   both	  cohorts	  are	  summarized	  in	  Supplementary	  Table	  S1.	  In	  addition,	  samples	  from	  various	  other	   influenza	   vaccination	   cohorts	   at	   the	   University	   Hospital	   Basel	   were	   used	   as	  indicated	   in	   the	   respective	   sections:	   2008/2009	   41,	   2009/2010	   41,	   and	   2014/15	  (unpublished).	  All	  subjects	  had	  no	  acute	  illness	  and	  no	  other	  vaccinations	  in	  the	  previous	  30	   days.	   In	   2007/08,	   all	   participants	   received	   vaccination	   with	   a	   trivalent	   virosomal	  vaccine	   (Inflexal	  V,	  Berna	  Biotech,	  Basel,	   Switzerland),	  whereas	   in	   the	  other	   seasons	  a	  non-­‐adjuvanted	   trivalent	   (2008/09	   and	   2009/10,	   Mutagrip,	   Sanofi	   Pasteur	   SA,	   Lyon,	  France)	   or	   quadrivalent	   (2014/15	   and	   2017/18)	   split	   vaccine	   was	   used	   (Agrippal,	  Seqirus,	   Maidenhead,	   UK	   and	   Fluarix	   Quadrivalent,	   GSK,	   Philadelphia,	   PA,	   USA	  respectively).	   For	   the	   individuals	   included	   in	   the	   2017/18	   cohort,	   vaccination	   history	  and	   influenza-­‐like	   illness	   (ILI)	   back	   to	   season	   2012/13	   were	   assessed	   using	   a	  standardized	   questionnaire.	   Plasma	   and	   peripheral	   blood	   mononuclear	   cells	   (PBMC)	  were	   collected	   immediately	   prior	   to	   vaccination	   and	   at	   day	   7	   and	   day	   28	   post-­‐vaccination.	   	  For	  the	  2007/08	  cohort,	  an	  additional	  sample	  from	  day	  14	  was	  available.	  Samples	  were	  cryopreserved	  until	  use.	  	  
Recombinant	  Influenza	  A	  Virus	  Hemagglutinin	  	  Full-­‐length	   (HA0)	   recombinant	   hemagglutinin	   (rHA)	   reflecting	   the	   influenza	   A	   H1N1	  and	  H3N2	  strains	  included	  in	  the	  seasonal	  influenza	  vaccine	  from	  2000/01	  to	  2014/15	  were	  ordered	  (Sino	  Biological	  Inc.,	  Bejing,	  China).	  Additionally,	  two	  pandemic	  influenza	  strains,	   i.e.	  an	  H1N1	  strain	   from	  1918	  (A/Brevig	  Mission/1/1918)	  and	  an	  H3N2	  strain	  from	  1968	  (A/Hong	  Kong/1/1968)	  were	   included	  as	  comparators	  resulting	   in	  a	  set	  of	  13	   rHA	   (overview	   in	   Figure	   1A).	   	   Based	   on	   the	   commercial	   availability,	   the	   five	  influenza	   A	   H1N1	   rHA	   were	   expressed	   in	   HEK	   cells	   and	   the	   eight	   influenza	   A	   H3N2	  strains	   in	   an	   insect	   baculovirus	   expression	   vector	   system	   (BEVS).	   	   H3N2	  A/Perth/16/2009	  was	  not	   commercially	  available	  at	   the	   time	  of	   the	   study	  design.	  For	  specific	   rescue	   experiments,	   HEK-­‐cell	   produced	   rHA-­‐proteins	   (HA1	   subunit)	   of	   the	  H3N2	   A/Victoria/361/2011	   and	   A/Texas/50/2012	   strains,	   as	  well	   as	   a	   custom-­‐made	  Texas	  N128T	  HA	   (reverse	  mutant)	  were	  used	   (all	   Sino	  Biological	   Inc.).	  The	  very	   same	  proteins	   were	   used	   to	   assess	   escape	   and	   rescue	   in	   the	   2017/18	   cohort.	   Detailed	  information	  is	  available	  in	  Supplementary	  Table	  S2.	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Multiplexed	  immunoassay	  	  The	   influenza	   A	   rHA	   of	   the	   different	   influenza	   A	   strains	   were	   coupled	   to	   different	  MagPlex®	   microspheres	   (Luminex	   corporation,	   Austin,	   TX,	   USA),	   hereafter	   termed	  ‘beads’	  throughout	  the	  manuscript.	  Coupling	  was	  performed	  mainly	  according	  to	  xMAP®	  cookbook	  (Luminex).	  An	  extended	  protocol	  and	  a	  detailed	  description	  of	  the	  validation	  are	  available	   in	   the	  Supplementary	  Methods.	  To	  measure	   the	  HA-­‐specific	  antibodies,	  plasma	  samples	  were	  first	  centrifuged	  at	  maximum	  speed	  and	  then	  diluted	  1:500	  in	  PBS	  with	   1%	   BSA	   (PBS-­‐BSA).	   20	   µL	   of	   diluted	   plasma	   was	   added	   to	   20	   μL	   of	   the	   bead	  mixture	   containing	   13	   different	   HA	   beads	   and	   BSA-­‐coated	   control	   beads	   in	   a	   96-­‐well	  plate	  and	  incubated	  for	  60	  minutes	  at	  RT	  on	  a	  plate	  shaker	  at	  800	  rpm.	  The	  beads	  were	  washed	  twice	  in	  100	  µL	  of	  PBS-­‐TBN	  buffer	  and	  then	  incubated	  with	  a	  PE-­‐labeled	  mouse	  anti-­‐human	  IgG	  Fc	  antibody	  (clone	  JDC-­‐10,	  9040-­‐09,	  SouthernBiotech,	  Birmingham,	  AL,	  USA)	  for	  another	  30	  minutes.	  Binding	  of	  influenza-­‐specific	  IgG	  antibodies	  was	  measured	  on	  a	  Luminex®	  100	  analyzer	  running	  on	  xPonent®	  software	  (Luminex	  Corporation).	  	  The	  extent	   of	   antibody-­‐binding	   is	   represented	   by	   the	   PE	   median	   fluorescence	   intensity	  (MFI).	   The	   vaccine	   response	   was	   calculated	   as	   background-­‐corrected	   (BSA-­‐coated	  beads)	  ΔMFI	  day	  28	  -­‐	  day	  0.	  Vaccine	  response	  against	  HA	  of	  the	  H1N1	  and	  H3N2	  vaccine	  strains	   was	   set	   to	   1	   and	   responses	   against	   the	   other	   strains	   were	   scaled	   to	   the	  respective	   vaccine	   strain	   response	   for	   each	   subject	   (negative	   values	   were	   set	   to	   0).	  Donors	  with	   a	   ΔMFI	   <	   25	   against	   the	   vaccine	   strain	  were	   considered	   non-­‐responders	  and	  excluded	  from	  data	  analysis.	  GraphPad	  Prism	  v.7	  (GraphPad	  Software,	  La	  Jolla,	  CA,	  USA)	  was	  used	  for	  statistical	  analysis	  and	  data	  presentation.	  	  
Influenza	  virus	  HA	  homology	  and	  phylogenetic	  analysis	  Influenza	   nucleotide	   sequences	   were	   accessed	   through	   the	   NCBI‘s	   influenza	   virus	  resource	  42.	  The	  strains	  and	  accession	  numbers	  are	  listed	  in	  Supplementary	  Table	  S3.	  	  Nucleotide	   sequences	  were	   aligned	   to	   Reference	  H1N1	   (GenBank	   Entry:	   ACP41105.1)	  and	   H3N2	   strains	   (UniProtKB/Swiss-­‐Prot:	   Q91MA7.1)	   using	   MUSCLE	   (MUltiple	  
Sequence	  Comparison	  by	  Log-­‐Expectation)	  and	  the	  alignment	  was	  fixed	  to	  preserve	  the	  reading	  frame	  by	  sweeping	  together	  1-­‐	  or	  2-­‐bp	  (or	  any	  non-­‐divisible-­‐by-­‐3	  bp)	  gaps	  that	  occurred	  in	  a	  <20-­‐bp	  window.	  Phylogenetic	  trees	  were	  generated	  using	  FastTree	  43.	  The	  branch	  support	  values	  were	  generated	  applying	  the	  Shimodaira-­‐Hasegawa	  test.	  For	  each	  strain,	   sequence	   homology	   was	   calculated	   compared	   to	   the	   vaccine	   strain	   (i.e.	  proportion	  of	  amino	  acids	  exactly	  matching	  the	  amino	  acid	   in	  the	  same	  position	  in	  the	  reference	   sequence).	   Frequency	   of	   clades	   and	  mutants	  were	   estimated	   and	   visualized	  with	   nextstrain	   tool	   44.	   N-­‐linked	   glycosylation	   sites	   were	   predicted	   by	   analyzing	   the	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sequence	  context	  of	  the	  Asn-­‐X-­‐Ser/Thr	  consensus	  sequence	  with	  the	  NetNglyc	  algorithm	  45,46.	  
	  
Multidimensional	  vaccine	  response	  vectors	  and	  hierarchical	  clustering	  Antibody	  binding	  profiles	  for	  each	  subject	  were	  generated,	  encompassing	  responses	  at	  day	   0,	   7,	   14	   and	   28	   post	   vaccination	   against	   all	   strains	   of	   a	   serotype	   26.	   Hierarchical	  clustering	   of	   the	   binding	   profile	  with	   the	   host	   factors	   age,	   gender,	   peak	   IgG	   and	   peak	  avidity	   against	   the	  vaccine	   strain	  and	  pre-­‐existing	   IgG	   levels	  was	  performed	  using	   the	  complete-­‐linkage	  algorithm.	  Avidity	  reflects	  the	  sum	  total	  of	  the	  binding	  strength	  of	  an	  antibody	  to	  its	  antigen	  at	  multiple	  sites	  and	  high	  avidity	  IgG	  may	  tolerate	  more	  epitope	  sequence	  variation,	   thus	  have	  higher	  cross-­‐reactivity.	  Avidity	  of	  the	  IgG	  responses	  was	  estimated	  calculating	  the	  avidity	  index	  following	  urea	  challenge	  (raw	  data	  not	  shown)	  47.	  Heatmaps	  were	  generated	  using	  either	  the	  R	  packages	  ComplexHeatmap	  48	  or	  NMF	  49.	  
	  
Fluorescence-­‐activated	  cell	  sorting	  of	  B	  cell	  subsets	  Cryopreserved	  PBMC	  from	  healthy	  donors	  before	  (day	  0)	  and	  after	  vaccination	  (day	  7),	  were	   thawed	   and	   rested	   over	   night.	   Cells	   were	   then	   stained	   with	   antibodies	   against	  CD14	   (FITC,	   clone	  MϕP9,	  345784),	  CD16	   (FITC,	   clone	  NKP15,	  335035)	  and	  CD27	   (PE,	  clone	  L128,	  340425),	  all	  from	  BD	  Biosciences,	  Franklin	  Lakes,	  NJ,	  USA	  and	  against	  CD3	  (Alexa	   Fluor	   488®,	   clone	   UCHT1,	   300415),	   CD19	   (Alexa	   Fluor	   700®,	   clone	   HIB19,	  302226),	   CD20	   (Brilliant	   Violet	   510TM,	   clone	   2H7,	   302340),	   CD38	   (APC,	   clone	   HIT2,	  303510)	  and	  IgD	  (PE-­‐Cy7,	  clone	  IA6-­‐2,	  348210),	  all	  from	  Biolegend,	  San	  Diego,	  CA,	  USA.	  Compensation	   was	   performed	   using	   single	   stained	   Antibody	   Capture	   Beads	  (VersaComp,	  B22804,	  Beckman	  Coulter,	  Brea,	  CA,	  USA).	  All	  B	   cell	   subsets	  were	   sorted	  into	   medium	   on	   a	   FACSAria®	   III	   (BD	   Biosciences)	   using	   a	   70	   μM	   nozzle.	   The	   gating	  strategy	  is	  indicated	  in	  Supplementary	  Figure	  S1.	  Cells	  were	  pelleted	  and	  kept	  at	  -­‐80°C	  until	  RNA	  extraction.	  	  
IgG-­‐BCR-­‐sequence	  library	  preparation	  IgG	  heavy	  chain	  libraries	  compatible	  for	  sequencing	  with	  the	  MiSeq	  platform	  (2x300bp	  paired-­‐end,	   Illumina,	   San	   Diego,	   CA,	   USA)	   were	   prepared	   similarly	   to	   a	   previously	  described	   two-­‐step	  primer	   extension	  method	   for	  mouse	   Ig	  heavy	   chains	   50.	   Total	  RNA	  from	   memory	   B	   cells	   (day	   0	   and	   7)	   and	   plasmablasts	   (day	   7)	   was	   isolated	   with	   the	  RNeasy®	  Plus	  Micro	  kit	  (74034,	  Qiagen,	  Hilden,	  Germany,	  without	  column-­‐based	  gDNA	  elimination	  but	  with	  adding	  200	  ng	  of	  carrier	  RNA	  according	  to	  manufacturer’s	  ‘Animal	  and	  Human	  Cells’	  protocol.	  Subsequently,	  the	  complete	  RNA	  was	  depleted	  from	  genomic	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DNA	  with	   RQ1	  RNAse-­‐Free	  DNAse	   (M6101,	   Promega,	  Madison,	  WI,	   USA).	   First-­‐strand	  cDNA	  was	  synthesized	  from	  total	  RNA	  by	  using	  AccuScript	  Hi-­‐Fi	  Reverse	  Transcriptase	  (200820,	  Agilent	  Technologies,	  Santa	  Clara,	  CA,	  USA)	  with	  oligo(dT)	  primers	  according	  to	   manufacturer’s	   protocol	   in	   triple	   volume.	   Following	   RT,	   a	   bead-­‐based	   nucleic	   acid	  clean-­‐up	  was	   carried	  out:	  The	   complete	  RT	  product	   (60	  μL)	  was	  mixed	  with	  48	  μL	  of	  SPRIselect	   magnetic	   beads	   (B23318,	   Beckman	   Coulter)	   on	   a	   custom-­‐made	   magnet	   in	  order	   to	  perform	  a	  0.8x	   left-­‐sided	  cleanup	  (i.e.	   remove	  smaller	  DNA	  fragments	  up	   to	  a	  certain	  threshold).	  The	  supernatant	  with	  the	  small	  fragments	  was	  discarded	  and	  bead-­‐bound	  DNA	  washed	  twice	  with	  85%	  ethanol	  and	  finally	  eluted	  in	  20	  μL	  of	  water.	  	  For	   PCR	   amplification	   of	   the	   rearranged	   heavy	   chain	   locus,	   a	   set	   of	   eight	   forward	  primers	   containing	   an	   overhang	   and	   annealing	   to	   framework	   region	   1	   51	   and	   reverse	  primers	  binding	  to	  Cγ1-­‐4,	  containing	  another	  overhang,	  were	  used	  in	  PCR	  1	  (complete	  primer	  list	  in	  Supplementary	  Table	  S4).	  In	  a	  reaction	  volume	  of	  25	  μL	  with	  5%	  DMSO,	  half	   of	   the	   purified	   cDNA	   was	   amplified	   with	   Q5®	   High-­‐Fidelity	   DNA	   Polymerase	  (M0491,	   New	   England	   Biolabs,	   Ipswich,	   MA,	   USA)	   by	   using	   the	   following	   settings:	  Activation	  at	  98°C	   for	  30s	   followed	  by	  4	  cycles	  of	  98°C	   for	  20s,	  48°C	   for	  40s,	  72°C	   for	  60s;	  4	   cycles	  of	  98°C	   for	  20s,	  53°C	   for	  40s,	  72°C	   for	  60s;	  12	   cycles	  of	   of	  98°C	   for	  20s,	  60°C	   for	  40s,	  72°C	   for	  60s	  and	  2	  minutes	  of	  extension	  at	  72°C.	  A	  bead-­‐based	  0.8x	   left-­‐sided	   cleanup	  was	  performed	  again	   followed	  by	   elution	   in	  20	  μL	  of	  water.	   PCR	  2	  was	  used	   to	   add	   Illumina	   adapter	   sequences	   and	   population-­‐specific	   Illumina	   indices.	  Complete	   PCR	   1	   product	   was	   amplified	   with	   Q5®	   DNA	   Polymerase	   in	   two	   parallel	  reactions	   of	   25	   μL	   volume	  with	   5%	  DMSO	   and	   the	   following	   conditions:	   Activation	   at	  98°C	  for	  30s	  followed	  by	  4	  cycles	  of	  98°C	  for	  20s,	  40°C	  for	  40s,	  72°C	  for	  60s;	  12	  cycles	  of	  98°C	  for	  20s,	  65°C	  for	  40s,	  72°C	  for	  60s	  and	  2	  minutes	  of	  extension	  at	  72°C.	  After	  0.8x	  SPRIselect	  left-­‐sided	  size	  selection	  and	  elution	  in	  20	  μL	  of	  water,	  the	  complete	  product	  of	  PCR	  2	  was	  loaded	  onto	  a	  1%	  agarose	  gel	  and	  purified	  with	  MinElute®	  Gel	  Extraction	  Kit	  (28604,	  Qiagen).	  DNA	  concentration	  of	  all	  purified	  PCR	  products	  was	  assessed	  with	  a	  QuantusTM	   Fluorometer	   using	   the	   QuantiFluor®	   ONE	   dsDNA	   System	   (E4870,	   both	  Promega).	  Regardless	  of	  concentration,	  2	  μL	  per	  sample	  was	  added	  to	  the	  final	  library.	  Before	   sequencing,	   DNA	   quality	   and	   quantity	   was	   verified	   on	   a	   Fragment	   AnalyzerTM	  (Advanced	   Analytical	   Technologies	   Inc.,	   Ankeny,	   IA,	   USA)	   using	   DNF-­‐473	   Standard	  Sensitivity	  NGS	  fragment	  analysis	  kit.	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BCR	  repertoire	  analysis	  Clonotype	   formation	   by	   CDRH3	   and	   error	   correction	   was	   performed	   as	   described	  previously	   52,53.	  For	  downstream	  analyses,	   functional	   clonotypes	  were	  only	  retained	   if:	  (i)	  they	  were	  composed	  of	  at	  least	  4	  amino	  acids,	  and	  (ii)	  had	  a	  minimal	  read	  count	  of	  2	  
50,54.	   Clonal	   overlap	   was	   defined	   as	     !∩!(!!!)/!,	   with	   the	   number	   of	   shared	   clonotypes	  between	  subjects	  A	  and	  B	  in	  the	  numerator	  and	  the	  mean	  of	  total	  clonotypes	  of	  subjects	  A	   and	   B	   in	   the	   denominator	   55.	   In	   a	   group	   of	   e.g.	   four	   subjects,	   six	   (3+2+1)	   clonal	  overlaps	   are	   calculated.	   Statistical	   analysis	   was	   performed	   using	   R.	   Graphics	   were	  generated	   using	   the	   R	   packages	   ggplot2	   56	   and	   RColorBrewer	   57.	   For	   all	   repertoire	  analyses,	  clones	  were	  defined	  by	  100%	  amino	  acid	  sequence	  identity	  of	  CDRH3	  regions	  53,54,58.	  CDRH3	  regions	  were	  annotated	  and	  defined	  by	  the	  MiXCR	  software	  52	  according	  to	   IMGT	   nomenclature	   59.	   Using	   Euclidean	   distance	   as	   a	   distance	   metric,	   hierarchical	  clustering	  was	  performed	  using	  the	  complete-­‐linkage	  clustering	  algorithm	  performed	  by	  the	   R	   function	   hclust().	   Hierarchical	   clustering	   was	   visualized	   using	   the	   NMF	   49.	  Statistical	   significance	   was	   tested	   using	   the	   Wilcoxon	   rank-­‐sum	   test	   if	   not	   indicated	  otherwise.	   P	   values	   lower	   than	   0.05	   were	   required	   for	   stating	   significant	   differences	  between	   groups.	   BCR	   sequencing	  data	  will	   be	  made	   freely	   available	   upon	  publication.	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Results	  
	  
Vaccine	  response	  and	  cross-­‐recognition	  of	  non-­‐vaccine	  strains	  Broad	   variant	   recognition	   defines	   a	   powerful	   vaccine	   against	   fast	   mutating	   viruses.	  Using	   a	  multiplexed,	   bead-­‐based	   immunoassay,	  we	   tested	   the	   vaccination-­‐induced	   IgG	  response	  (ΔMFI	  day	  28	  -­‐	  day	  0)	  against	  the	  2007/2008	  influenza	  A	  vaccine	  strains	  and	  their	   cross-­‐binding	   of	   strains	   that	   were	   included	   in	   previous	   and	   subsequent	   vaccine	  preparations,	   covering	  a	  period	   from	  2000/01	  –	  2014/15	   (Figure	   1A).	  Given	   the	  way	  vaccine	   strains	   are	   selected,	   these	   represent	   the	   antigenic	   variants	   of	   the	   viruses	  circulating	   in	   the	   human	   population	   during	   this	   time	   span.	   Additionally,	   we	   included	  two	  historic	  controls,	  H1N1	  A/Brevig	  Mission/1/1918	  and	  H3N2	  A/Hong	  Kong/1/1968,	  strains	   responsible	   for	   the	   Spanish	   flu	   and	   Hongkong	   flu	   pandemics.	   Together,	   this	  covered	   variable	   degrees	   of	   phylogenetic	   relatedness	   (Figure	   1B).	   For	   each	   of	   the	   24	  subjects,	  we	  tested	  reactivity	  against	  13	  different	  influenza	  A	  strains	  on	  four	  time-­‐points	  (pre-­‐vaccination	  =	  day	  0,	  and	  day	  7,	  14	  and	  28	  post-­‐vaccination),	  yielding	  a	  total	  of	  1248	  data	  points.	  Vaccination	  induced	  a	  significant	  increase	  of	  the	  vaccine	  strain-­‐specific	  MFI	  at	  day	  7,	  14	  and	  28	  with	  peak	  intensities	  at	  day	  14	  and	  28	  in	  most	  vaccinated	  subjects	  (p	  <	  0.001	   for	  H1N1	  and	  H3N2	  at	  all	   time	  points,	  Supplementary	   Figure	   S2).	  While	  not	  changing	   the	   statistic	   outcome,	   a	   few	   individuals	   (H1N1:	   four;	   H3N2:	   three)	   were	  excluded	  from	  subsequent	  analysis	  due	  to	  vaccine	  non-­‐response,	  defined	  as	  ΔMFI	  	  <	  25	  against	   the	  vaccine	   strain.	  To	  assess	   the	  degree	  of	   cross-­‐reactivity,	  we	  normalized	   the	  IgG	   vaccine	   response	   against	   each	   strain	   to	   the	   vaccine	   strain	   response	   (Figure	   1C).	  While	  both	  the	  historic	  (1918)	  and	  future	  (2009)	  pandemic	  H1N1	  viruses	  were	  poorly	  cross-­‐recognized	   (<25%	  of	   the	   vaccine	   strain	   response),	   the	   response	   to	   the	   previous	  and	   subsequently	   circulating	   H1N1	   strains	   (i.e.	   A/New	   Caledonia/20/99	   and	  A/Brisbane/59/2007)	  was	   comparable	   to	   the	   vaccine	   strain.	  H3N2	   cross-­‐binding	  was	  significantly	   lower	   against	   two	   previous	   vaccine	   strains	   (A/Fujian/411/2002	   and	  A/Moscow/10/1999)	   and	   the	   1968	   pandemic	   strain	   (A/Hong	   Kong/1/1968),	   while	  responses	   to	   vaccine	   viruses	   of	   the	   previous	   and	   two	   subsequent	   years	   were	  comparable	   to	   the	   vaccine	   strain	   response.	   A	   striking	   drop	   in	   cross-­‐recognition	   was	  observed	  to	  A/Texas/50/2012,	  the	  most	  recent	  of	  the	  strains	  tested	  (Figure	  1C).	  Taken	  together,	  our	  multiplexed,	  bead-­‐based	  assay	  reliably	  captured	  expected	  cross-­‐reactivity	  patterns	  and	  discovered	  putative	  escape	  variants.	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Impact	  of	  host	  factors	  on	  cross-­‐reactivity	  patterns	  To	   investigate	   whether	   specific	   host	   factors	   affect	   cross-­‐reactivity	   patterns,	   we	  generated	   individual	   antibody	   binding	   profiles	   for	   each	   subject	   26.	   The	   impact	   of	  predefined	   factors	   (age,	   gender,	   preexisting	   IgG	   /	   peak	   response	   against	   the	   vaccine	  strain	   and	   IgG	   avidity)	   on	   the	   response	   profile	   was	   then	   assessed	   using	   hierarchical	  clustering.	   Individuals	   loosely	   clustered	   for	  preexisting	   IgG	  and	  peak	   response	  against	  the	  vaccine	  strain,	  both	  for	  H1N1	  (Figure	  2A)	  and	  H3N2	  (Figure	  2B).	  Thus,	  the	  cross-­‐recognition	   profile	   was	   to	   some	   extent	   related	   to	   the	   quantity	   of	   antibody	   available.	  However,	   irrespective	   of	   IgG	   levels	   being	   high	   or	   low,	   some	   strains	   were	   poorly	  recognized	   by	   most	   individuals.	   This	   is	   exemplified	   by	   the	   very	   moderate	   response	  against	  the	  H3N2	  strains	  A/Fujian/411/07	  and	  A/Texas/10/2012	  including	  in	  subjects	  with	  robust	  vaccine	  responses	  (Figure	  2C).	  	  	  
Figure	  1:	  Influenza	  A	  vaccine	  strains	  included	  in	  the	  analysis.	  A)	  Timeline	  of	  all	  H1N1	  and	  H3N2	   strains	   included	   in	   vaccines	   between	   2000/01	   and	   2014/15	   including	   distantly	   related	  pandemic	   strains.	  The	   gap	   in	  H1N1	   in	   season	  2010/11	   accounts	   for	   vaccine	  adaptation	   to	   the	  pandemic	  2009	  swine	  flu.	  B)	  Phylogenetic	  trees	  based	  on	  HA	  amino	  acid	  sequences	  of	  all	  strains	  included	   in	   our	   analyses	   were	   generated	   with	   FastTree.	   C)	   Cross-­‐reactivity	   of	   the	   vaccine	  response	   for	  H1N1	   (top)	  and	  H3N2	   (bottom)	  28	  days	  after	  administration.	  Vaccine	  strains	  are	  shown	  in	  black.	  Statistical	  analysis	  with	  Wilcoxon	  signed	  rank	  test	  is	  selectively	  indicated	  	  (***	  p	  <	  0.001). 
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Low	  antibody	  cross-­‐reactivity	  is	  associated	  with	  a	  narrower	  memory	  BCR	  repertoire	  The	   acute	   response	   to	   inactivated	   influenza	   vaccination	   in	   adults	   is	   characterized	   by	  rapid	   proliferation	   of	   antibody-­‐secreting	   plasmablasts.	   In	   humans,	   the	   number	   of	  plasmablasts	   circulating	   in	   the	   periphery	   peaks	   7	   days	   post-­‐vaccination	   and	   is	  dominated	   by	   a	   recall	   of	   IgG	   memory	   responses	   33.	   Analyzing	   the	   B	   cell	   receptor	  repertoire	   of	   plasmablasts	   in	   this	   short	  window	   of	   opportunity	   offers	   a	   possibility	   to	  map	   the	  vaccine	  response	  on	  a	  clonal	   level	   33.	  We	  hypothesized	   that	   serum	  antibodies	  with	  high	  cross-­‐recognition	  capability	  are	  clonally	  more	  diverse.	  To	  test	  this,	  memory	  B	  cells	   	   (CD3/14/16-­‐	   CD19+	   CD20+	   IgD-­‐	   CD27+	   CD38-­‐)	   at	   day	   0	   and	   7	   and	   plasmablasts	  (CD3/14/16-­‐	   CD19+	   CD20-­‐	   IgD-­‐	   CD38++)	   at	   day	   7	   post-­‐vaccination	  were	   sorted	   from	   a	  subset	   of	   12	   vaccine-­‐responding	   individuals	   from	   the	   2007/08	   cohort	   and	   sequenced	  
Figure	   2:	   High	   IgG	   levels	   predict	   broad	   antibody	   binding	   profiles.	   A,	   B)	   Hierarchical	  clustering	   based	   on	   antibody-­‐binding	   profiles	   according	   to	   IgG-­‐levels	   at	   day	   0,	   7,	   14	   and	   28	  across	   all	   investigated	   H1N1	   (A)	   and	   H3N2	   (B)	   strains	   (left	   panels).	   Low	   quantiles	   of	   the	  investigated	   host	   factors	   are	   shown	   in	   light	   colors,	   high	   quantiles	   in	   dark	   colors.	   The	   cluster	  analysis	  reveals	  a	  group	  defined	  by	  high	  pre-­‐existing	  and	  peak	  IgG.	  The	  individuals	  in	  this	  group	  are	   characterized	   by	   quite	   broad	   and	   strong	   recognition	   of	   different	   strains,	   as	   shown	   in	   the	  strain-­‐resolved	  clusters	  (right	  panels,	  d28	  post	  vaccination,	  vaccine	  strains	  highlighted	   in	  red).	  
C)	  Relative	  vaccine	  responses	  against	  all	  measured	  H3N2	  strains	  in	  a	  subset	  of	  donors	  with	  high	  and	   broad	   vaccine	   response.	   Dark	   colors	   indicate	   a	   high,	   light	   colors	   indicate	   a	   low	   response	  against	   the	  respective	  strain.	  The	  Texas	  and	  Fujian	  strains	  are	  quite	  consistently	  poorly	  cross-­‐recognized. 
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for	  CDRH3.	  ‘High’	  and	  ‘low’	  cross-­‐reactivity	  groups	  were	  defined	  by	  median	  split	  of	  the	  loss	   in	   cross-­‐recognition	   (day	   28	   post-­‐vaccination)	   of	   A/Texas/50/2012.	   Texas	   cross-­‐recognition	  was	  chosen	  as	  the	  criterion,	  since	  it	  represented	  a	  future	  strain	  at	  the	  time	  of	  the	  vaccination.	  	  
	  
	  	  V-­‐gene	  usage	  and	  degree	  of	  somatic	  hypermutation	  was	  similar	  between	  groups	  and	  cell	  subsets	  (Supplementary	  Figure	  S3).	  High	  clonal	  overlap	  within	  a	  group	  is	  indicative	  of	  a	   narrow	   or	   more	   precisely	   skewed	   repertoire.	   Clonal	   overlap	   was	   highest	   among	  plasmablasts.	  This	  was	  irrespective	  of	  whether	  they	  belonged	  to	  the	  ‘high’	  or	  ‘low’	  cross-­‐reactivity	   group.	   In	   contrast,	   in	   the	   low	   cross-­‐reactivity	   group,	   clonal	   overlap	   within	  memory	  B	  cells	  (day	  0	  and	  7)	  was	  significantly	  higher	  than	  in	  the	  ‘high’	  cross-­‐reactivity	  group	   (Figure	   3A).	   Evenness	   profiles	   60	   for	   the	   plasmablast	   repertoires	   tended	   to	  cluster	  together	  with	  cross-­‐reactivity	  (Figure	  3B).	  High	  evenness	  is	  indicative	  of	  clonal	  expansion.	   While	   clonal	   overlap	   between	   plasmablast	   populations	   was	   comparable	  between	  the	  cross-­‐reactivity	  groups,	  the	  evenness	  profiles	  suggested	  a	  difference	  in	  the	  
Figure	  3:	  Lower	  BCR	  repertoire	  breadth	  may	  predispose	  to	  poorer	  cross-­‐reactivity.	  	  
A)	   Clonal	   overlap	   within	   highly	   (red)	   and	   poorly	   (turquoise)	   cross-­‐reactive	   groups	   (as	  defined	   in	  the	  main	  text)	   are	   shown	   for	  all	   sequenced	  B	   cell	  populations.	  Being	  enriched	  in	  influenza-­‐specific	  B	   cells,	   the	   clonal	  overlap	   is	   highest	  within	   plasmablast	  populations.	   It	   is	  only	  within	   the	  memory	  B	   cells	   (d0	  and	  d7)	  of	   the	   ‘low’	   group	   though,	  were	   the	  overlap	   is	  significantly	   higher	   than	   in	   the	   ‘high’	   group.	  Median	   (value	   on	   top),	   IQR	   and	  mean	   per	   cell	  population	   (dashed	   line)	   are	   shown.	   B)	   Hierarchical	   clustering	   of	   plasmablast	   evenness	  profiles	   according	   to	   cross-­‐reactivity	   group.	   While	   clonal	   overlap	   among	   plasmablasts	   is	  similar	  between	  the	  groups,	  the	  structure	  of	  the	  BCR-­‐repertoire	  seems	  to	  be	  altered. 
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structure	  of	  the	  BCR	  repertoire.	  For	  the	  low-­‐crossreactivity	  group,	  this	  could	  e.g	  indicate	  less	  clonal	  expansion	  or	  also	  more	  clonal	  expansion,	  but	  the	  expanded	  clonotypes	  would	  produce	  poorly	  cross-­‐recognizing	  antibodies	  based	  on	  or	  measurements.	  Combined,	  this	  suggests	   that	  subjects	  with	   low	  cross-­‐reactivity	  recruited	  their	  B	  cell	  vaccine	  response	  from	   a	   less	   diverse	   pool,	   eventually	   resulting	   in	   poorer	   responses	   against	   future	  antigenically	  novel	  strains	  (i.e.	  Texas).	  	  	  
Antigenic	  variation	  dictates	  cross-­‐reactivity	  on	  the	  population	  level	  Besides	  the	  individual	  antibody	  repertoire,	  antigenic	  similarity	  between	  two	  strains	  can	  explain	  strong	  cross-­‐recognition	  by	  the	  immune	  response.	  While	  overall	  Influenza	  A	  HA	  homology	  correlated	  strongly	  with	  the	  median	  relative	  response	  score	  of	  the	  21	  healthy	  subjects	  (r=0.76,	  p=0.003),	  this	  was	  biased	  by	  the	  few	  H1N1	  strains	  (r=1,	  p=0.02),	  two	  of	  which	  are	  pandemic	  strains	  (Figure	  4A).	  For	  H3N2	  overall	  sequence,	  homology	  and	  cross-­‐recognition	  were	  disconnected	  (r=0.5,	  p=0.2).	  Specifically,	  Texas	  and	  Fujian	  were	  poorly	  recognized	  (see	  also	  Figure	  1C)	  despite	  differing	  in	  only	  very	  few	  amino	  acids	  from	  the	  vaccine	  strain	  Wisconsin.	  However,	  overall	  sequence	  homology	  is	  an	  unreliable	  comparator,	  as	  the	  region	  of	  sequence	  variability,	  i.e.	  antigenically	  relevant	  structures,	  are	  more	  important	  61–63.	  Since	  Texas	  is	  the	  closest	  relative	  of	  the	  Victoria	  strain	  (Figure	  1B),	  which	  was	  strongly	  cross-­‐recognized	  in	  our	  vaccination	  cohort,	  we	  focused	  for	  further	  analyses	  on	  the	  antigenic	  differences	  between	  Victoria	  and	  Texas.	  The	  HA	  of	  the	  two	  strains	  only	  differ	  by	  seven	  amino	  acids	  (i.e.	  1.2	  %	  or	  7/566	  AA)	  (Figure	  4B).	  Five	  out	  of	  seven	  point	  mutations	  were	  located	  in	  close	  proximity	  to	  the	  receptor	  binding	  site.	  These	  regions	  are	  enriched	  for	  glycan	  attachment	  sites;	  N-­‐linked	  glycosylations	  are	  well	  known	  to	  alter	  the	  antigenicity	  of	  influenza	  viruses.	  Indeed,	  a	  T128N	  mutation	  between	  Victoria	  and	  Texas	  disrupted	  the	  Asn-­‐X-­‐Ser/Thr	  consensus	  sequence,	  thereby	  potentially	  disabling	  N-­‐linked	  glycosylation	  at	  N126	  (Figure	  4B).	  PAGE	  showed	  higher	  electrophoretic	  mobility	  of	  the	  Texas	  compared	  to	  Victoria	  HA,	  indicating	  that	  Texas	  indeed	  lost	  a	  glycan	  structure	  (Figure	  4C).	  Analysis	  with	  the	  phylogenetic	  tool	  nextstrain	  revealed	  that	  T128N	  is	  a	  very	  rare	  mutation	  but,	  based	  on	  sequence	  context	  analysis,	  is	  alike	  to	  the	  3c3	  clade-­‐defining	  mutation	  T128A	  in	  causing	  a	  glycosylation	  loss	  at	  N126.	  Clade	  3c3	  emerged	  end	  of	  2012	  and	  dominated	  the	  years	  2013	  and	  2014	  (Supplementary	  Figure	  
S4).	  To	  test	  whether	  this	  T128N	  mutation,	  and	  the	  resulting	  structural	  change,	  could	  be	  responsible	  for	  the	  reduced	  recognition	  of	  Texas,	  we	  compared	  the	  antibody	  response	  to	  Victoria,	  Texas	  and	  a	  Texas	  variant	  with	  a	  reverted	  mutation	  restoring	  the	  glycosylation	  site	  (N128T).	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  Indeed,	  antibody	  escape	  could	  be	  rescued,	  suggesting	  that	  the	  mutation	  at	  position	  128	  might	  affect	  the	  cross-­‐recognition	  (Figure	  4D).	  Next,	  we	  tested	  whether	  vaccination	  with	  a	  Texas-­‐like	  variant	  improves	  its	  recognition.	  In	  a	  vaccine	  cohort	  from	  2017/18,	  individuals	  that	  were	  always	  vaccinated	  between	  2013/14	  and	  2015/16	  were	  compared	  to	  those	  who	  received	  no	  vaccine	  in	  that	  period.	  In	  these	  three	  years,	  the	  H3N2	  vaccine	  strain	  was	  either	  A/Texas/50/2012-­‐like	  or	  
Figure	  4:	  Reduction	  of	  HA-­‐specific	  antibody	  response	  by	  a	  single	  glycosylation	  change.	  
A)	   Correlation	   between	   sequence	   homology	   and	  median	   antibody	   response	   relative	   to	   the	  H1N1	  and	  H3N2	  vaccine	   strains	  of	  2007/08.	  Antibody-­‐binding	  against	  H3N2	  strains	  Fujian	  and	   Texas	   is	   poor	   despite	   very	   high	   sequence	   homology	  B)	   Amino	   acid	   changes	   (orange)	  between	  the	  Victoria	  and	  Texas	  strain	  HA	  depicted	  on	  a	  surface	  representation	  of	  the	  Victoria	  HA	   monomer	   (PBD	   ID:	   4O5N).	   The	   T128N-­‐mutation	   (red)	   potentially	   leads	   to	   a	   loss	   of	  glycosylation	  at	  N126	  (blue).	  Yellow:	  HA	  receptor	  binding	  site	  C)	  Enzymatic	  cleavage	  of	  all	  N-­‐linked	  oligosaccharides	  results	  in	  similar	  PAGE	  migration	  patterns	  between	  recombinant	  HA1	  of	  Victoria	  and	  Texas	  (lanes	  A	  and	  B).	  When	  not	  modified,	  Texas	  HA	  migrates	  faster	  indicating	  loss	  of	  a	  glycan	  structure	  (lanes	  C	  and	  D).	  D)	  Vaccine	  response	  at	  day	  28	  was	  assessed	  both	  against	   Texas	   relative	   to	   Victoria	   and	   upon	   insertion	   of	   the	   N128T-­‐mutation	   (T128	   as	   in	  Victoria)	   into	   the	   Texas	   HA1.	   Antibody-­‐binding	   is	   significantly	   increased	   in	   Texas	   N128T	  (2007/08	  cohort,	  n	  =	  15,	  Wilcoxon	  signed	  rank	  test).	  E)	  Same	  setting	  as	  in	  D	  but	  with	  subjects	  of	  a	  2017/18	  	  vaccine	  cohort	  never	  (n	  =	  9)	  or	  3x	  vaccinated	  with	  Texas-­‐like	  strains	  (n	  =	  19).	  
F)	  Analysis	  of	  Texas	  cross-­‐recognition	  including	  3	  seasons	  in	  between	  (08/09	  n	  =	  6;	  09/10	  n	  =	   9;	   14/15	   n	   =	   5).	   While	   being	   low	   until	   2009/10,	   the	   relative	   response	   increased	  significantly	   upon	   vaccination	   with	   a	   Texas-­‐like	   strain	   in	   2014/15	   (Friedman	   Test	   with	  Dunn’s	  correction).	  ***	  p	  <	  0.001,	  **	  p	  <	  0.01,	  *	  p	  <	  0.05	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A/Switzerland/9715293/2013-­‐like,	  bearing	  an	  N-­‐W-­‐N-­‐motif	  (N126/N128,	  Texas)	  or	  an	  N-­‐W-­‐A-­‐motif	  (N126/A128,	  Switzerland)	  both	  abrogating	  glycosylation	  at	  N126.	  However,	  we	  found	  no	  difference	  in	  the	  cross-­‐reactivity	  between	  these	  two	  groups	  (Figure	  4E).	  Finally,	  we	  analyzed	  Texas	  cross-­‐recognition	  in	  vaccination	  cohorts	  of	  years	  in	  between	  (Figure	  4F).	  In	  2008/09	  and	  2009/10,	  when	  the	  H3N2	  strain	  contained	  an	  N-­‐W-­‐T-­‐motif	  (N126/T128,	  Victoria-­‐like),	  the	  lower	  antibody-­‐binding	  to	  Texas	  (N128)	  compared	  to	  Victoria	  (T128)	  was	  sustained.	  In	  contrast,	  in	  2014/15,	  where	  the	  vaccine	  contained	  a	  Texas-­‐matched	  N-­‐W-­‐N-­‐motif,	  the	  drop	  in	  Texas	  recognition	  was	  substantially	  reduced.	  Therefore,	  following	  the	  adaptation	  of	  the	  vaccine	  strain,	  the	  response	  against	  the	  escaped	  epitope	  could	  be	  rescued.	  Based	  on	  the	  data	  of	  2017/18	  (Figure	  4E),	  the	  durability	  of	  the	  Texas-­‐adapted	  response	  was	  limited	  though,	  turning	  back	  to	  the	  levels	  before	  emergence	  of	  the	  3c3	  clade.	  	  	  
	  
Discussion	  	  In	   our	   2007/08	   cohort,	   vaccination	   generally	   induced	   a	   broad	   antibody	   response	  targeting	   not	   only	   the	   vaccine	   strain,	   but	   also	   closely	   related	   strains	   of	   the	   same	  serotype.	   As	   expected,	   cross-­‐reactivity	  waned	   against	   strains	   separated	   by	   decades	   of	  antigenic	   drift	   (e.g.	   A/Hong	  Kong/1/1968)	   or	   reassorted	   variants	   (antigenic	   shift,	   e.g.	  A/California/7/2009).	   The	   variability	   in	   the	   intensity	   and	   breadth	   of	   cross-­‐reactivity	  within	  the	  cohort	  accounts	  for	  the	  individual	  influenza	  infection	  and	  vaccination	  history.	  There	   was,	   however,	   HA	   of	   strains	   that	   were	   poorly	   recognized	   despite	   high	   overall	  homology	  to	  the	  vaccine	  strain.	  We	  focused	  on	  A/Texas/50/2012,	  being	  a	  novel	  strain	  at	  that	   time	   and	   also	   not	   being	   integrated	   into	   a	   known	   antigenic	   cluster	   yet	   27,64.	   Being	  located	   within	   an	   antigenic	   site	   close	   to	   the	   receptor-­‐binding	   site,	   a	   mutation	   from	  threonine	  to	  asparagine	  at	  position	  128	  was	  suspected	  to	  induce	  an	  antigenic	  shift	  61,65.	  Indeed,	  T128N	  seemed	  to	  disrupt	  glycosylation	  at	  position	  126	  and	  was	  responsible	  for	  the	   loss	   of	   recognition.	   Those	   individuals	  with	   especially	   poor	   cross-­‐reactivity	   against	  Texas	  recruited	  their	  antigen-­‐specific	  B	  cells	  from	  a	  more	  narrow	  pool	  of	  memory	  B	  cells	  generating	  a	  plasmablast	  population	  with	  altered	  BCR	  repertoire	  structure.	  So	  far,	  BCR-­‐repertoires	   have	   been	   used	   to	   trace	   vaccine	   responses,	   also	   at	   the	   level	   of	   antigen-­‐specificity,	  but	  not	  in	  the	  context	  of	  cross-­‐reactivity	  30,32,66.	  Overlaying	  HA-­‐specific	  BCR-­‐repertoires	   with	   plasmablast	   BCR	   repertoires	   would	   be	   highly	   informative	   about	   the	  numbers	   of	   lineages	   targeting	   HA	   and	   whether	   these	   numbers	   are	   reduced	   in	  individuals	  mounting	  poorly	  cross-­‐reactive	  responses.	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T128N	  probably	   also	  mimics	   the	  T128A	  mutation	  with	   regard	   to	   glycan	   loss	   at	  N126.	  T128A	  defines	  H3N2	  clade	  3c3	  that	  emerged	  end	  of	  2012	  and	  constituted	  the	  majority	  of	  H3N2	  viral	  isolates	  in	  the	  years	  2013	  and	  2014	  (Supplementary	  Figure	  S4).	  The	  idea	  that	  immune	  evasion	  due	  to	  loss	  of	  a	  glycosylation	  site	  was	  enabling	  the	  fast	  expansion	  of	  the	  clade	  is	  intriguing.	  Moreover,	  our	  measurements	  from	  2017/18	  show,	  that	  despite	  being	   exposed	   to	   viruses	   of	   the	   3c3-­‐clade	   by	   repetitive	   vaccination	   or	   infection,	   the	  population	  responds	  again	  poorly	  towards	  the	  Texas	  strain	  carrying	  T128N.	  We	  suggest	  that	  upon	  B	  cell	  memory	  recall,	  “Texas-­‐specific”	  B	  cells	  to	  the	  region	  around	  N(126)-­‐W-­‐N(128)	  cannot	  access	  their	  cognate	  epitope	  anymore	  due	  to	  glycosylation	  at	  N126	  and	  are	   consequently	   not	   positively	   selected.	   This	   glycan-­‐mediated	   masking	   of	   an	  antigenically	  relevant	  site	  could	  prepare	  the	  ground	  for	  another	  expansion	  of	  clade	  3c3.	  While	  our	  immunoassay	  quantifies	  antibody-­‐binding	  to	  HA,	  it	  does	  not	  inform	  about	  the	  neutralization	   capacity	  of	   these	   antibodies.	   Since	  we	  used	   recombinant	  HA	  monomers	  rather	   than	   stabilized	  HA-­‐trimers,	   a	   proportion	  of	   binding	   antibodies	  might	  moreover	  have	  been	  missed	  or	   led	  to	   false-­‐positive	  signals.	  However,	   it	   is	  established	  that	  ELISA	  IgG	   binding	   titers	   correlate	   with	   neutralizing	   antibody	   titers	   and	   since	   binding	   is	   a	  prerequisite	  for	  neutralization,	  the	  reduced	  binding	  to	  T128N-­‐mutants	  likely	  translates	  to	  poor	  neutralization	  in	  an	  infection	  setting	  67.	  	  The	  2017/18	  cohort	  was	  designed	  to	  further	  investigate	  effects	  of	  repetitive	  vaccination	  with	   similar	   epitopes	   on	   the	   evolution	   of	   the	   immune	   response.	   This	   allowed	   to	   test	  whether	  repetitive	  exposure	  to	  the	  H3N2	  N-­‐W-­‐N/N-­‐W-­‐A-­‐motif	  might	  have	  affected	  the	  variant	  recognition,	  which	  was	  however	  not	  the	  case	  in	  this	  setting.	  For	  H1N1,	  the	  other	  influenza	   A	   strain	   included	   in	   the	   vaccine,	   the	   2017/18	   vaccine	   provided	   a	   unique	  opportunity	   to	   test	   the	   influence	   of	   exposure	   history:	   In	   the	   five	   previous	   seasons,	  vaccines	  included	  HA	  of	  an	  A/Christchurch/16/2010-­‐like	  virus	  that	  was	  changed	  to	  HA	  from	   an	   A/Michigan/45/2015-­‐like	   virus	   in	   2017/18.	   We	   did	   not	   find	   preferential	  targeting	   of	   the	   former	   in	   subjects	   repeatedly	   vaccinated	   with	   the	   Christchurch-­‐like	  strain	   (data	  not	   shown).	  However,	  detecting	  effects	  of	   repetitive	  exposure	  depends	  on	  alterations	   in	   the	  antigenicity	  between	  the	  two	  strains,	  which	  we	  did	  not	  assess	   in	   the	  H1N1	  setting.	  Moreover,	  effects	  may	  have	  been	  disguised	  by	  vaccinations	  and	  infections	  preceding	   our	   time	   window	   from	   2012/13	   until	   2017/18.	   Preferential	   reactivity	   to	  antigenically	  senior	  strains	  (i.e.	  encountered	  early	  in	  life)	  upon	  vaccination,	  concomitant	  with	   good	   recognition	   of	   novel	   variants	   when	   using	   antigenically	   advanced	   vaccine	  strains	  27,	  has	  been	  reported	  in	  many	  settings	  27,29,68.	  Concluding,	   we	   established	   a	   multiplexed,	   high-­‐throughput	   method	   to	   screen	   for	   and	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Bead	  coupling	  The	  influenza	  A	  rHA	  of	  the	  different	  influenza	  A	  strains	  was	  coupled	  to	  MagPlex®	  microspheres	  (Luminex	   corporation,	   Austin,	   TX,	   USA),	   carboxylated	   polystyrene	   microparticles	   (hereafter	  termed	   ‘beads’	   throughout	   the	   manuscript),	   mainly	   following	   the	   manufacturer’s	   instructions	  (xMAP®	  cookbook,	  3rd	  edtion,	  chapter	  4.2)	  with	  some	  alterations	  and	  amendments:	  MES	  buffer	  instead	   of	   sodium	   phosphate	   buffer	   was	   used	   to	   activate	   the	   carboxylic	   acids	   on	   the	   beads.	  Generally,	   1.25	  μg	  of	  HA	  protein	  was	   coupled	  onto	  5M	  of	  beads	   in	   a	   volume	  of	  500	  μL	  of	  MES	  buffer,	  since	  it	  showed	  to	  generate	  the	  strongest	  signals	  in	  the	  immunoassay.	  For	  the	  rHA-­‐beads	  exposed	  to	  plasma	  from	  2017/2018,	  beads	  were	  downscaled	  to	  1.25M	  with	  the	  same	  volume	  and	  amount	  of	  protein	  used.	   In	  order	  to	  adjust	  protein	   load	  per	  bead	  between	  bead	  types	  (see	  next	  paragraph),	  also	  amount	  of	  protein	  and	  coupling	  volume	  had	  to	  be	  altered	  in	  some	  cases.	  
	  
Coupling	  validation	  In	   experiments	   where	   signals	   were	   compared	   between	   different	   types	   of	   beads	   (i.e.	   against	  different	  rHA),	  equal	  protein	  load	  between	  bead	  types	  had	  to	  be	  assured.	  This	  was	  accomplished	  by	  incubating	  beads	  with	  a	  broadly	  cross-­‐reactive	  antibody	  against	  stem	  (1	  μg/mL,	  86001-­‐RM01,	  Sino	  Biological)	  (HA0	  rHA	  only)	  and	  an	  anti-­‐His	  antibody	  (1	  μg/mL,	  A00174,	  GenScript)	  (all	  rHA)	  followed	  by	  incubation	  with	  a	  PE-­‐labeled	  anti-­‐rabbit	  IgG	  antibody	  (1	  μg/mL,	  406421,	  Biolegend)	  according	  to	  the	  protocol	  in	  the	  next	  paragraph.	  
	  
Multiplexed	  immunoassay:	  Extended	  protocol	  	  Three	  multiplexed	  bead	  sets	  were	  prepared	  to	  measure	  i)	  cross-­‐reactivity	  in	  the	  2007/08	  cohort	  (13	  HA-­‐coupled	  bead	  types,	  together	  with	  BSA-­‐coupled	  and	  uncoupled	  beads),	  ii)	  cross-­‐reactivity	  in	   the	   2017/18	   cohort	   (2	   bead	   types)	   and	   iii)	   viral	   escape	   in	   all	   investigated	   cohorts	   (3	   bead	  types).	   Human	   plasma	   samples	   were	   centrifuged	   for	   10	   min	   at	   4	   °C	   in	   a	   microcentrifuge	   at	  maximum	  speed	  prior	   to	  use	  and	   then	  diluted	  1:500	   in	  PBS	  with	  1%	  BSA	   (PBS-­‐BSA).	  20	  µL	  of	  diluted	   plasma	  were	   added	   to	   20	   μL	   of	   bead	  mixture	   (50	   beads/μL	   of	   each	   type)	   in	   a	   96-­‐well	  plate	  and	  incubated	  for	  60	  minutes	  at	  RT	  on	  a	  plate	  shaker	  at	  800	  rpm.	  The	  beads	  were	  washed	  twice	  in	  100	  µL	  PBS-­‐TBN	  buffer	  (0.1%	  BSA,	  0.02%	  TWEEN®-­‐20,	  0.05%	  sodium	  azide,	  pH	  7.4).	  A	  PE-­‐labeled	   mouse	   anti-­‐human	   IgG	   Fc	   antibody	   (clone	   JDC-­‐10,	   9040-­‐09,	   SouthernBiotech,	  Birmingham,	  AL,	  USA)	  was	  added	  at	  1	  μg/mL	   in	  PBS-­‐BSA	  and	   incubated	   for	  30	  min.	  at	  RT	  and	  800	  rpm.	  Binding	  of	  influenza-­‐specific	  IgG	  antibodies	  was	  measured	  on	  a	  Luminex®	  100	  analyzer	  running	   on	   xPonent®	   software	   (Luminex	   Corporation).	   	   The	   extent	   of	   antibody-­‐binding	   is	  represented	  by	  the	  PE	  median	  fluorescence	  intensity	  (MFI).	  The	  vaccine	  response	  was	  calculated	  as	  background-­‐corrected	  (BSA-­‐coated	  beads)	  ΔMFI	  day	  28	  -­‐	  day	  0.	  Vaccine	  response	  against	  HA	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of	  the	  H1N1	  and	  H3N2	  vaccine	  strains	  was	  set	  to	  1	  and	  responses	  against	  the	  other	  strains	  were	  scaled	   to	   the	   respective	   vaccine	   strain	   response	   for	   each	   subject.	   Donors	   with	   a	   ΔMFI	   <	   25	  against	   the	   vaccine	   strain	   were	   considered	   non-­‐responders	   and	   excluded	   from	   data	   analysis.	  GraphPad	  Prism	  v.7	  (GraphPad	  Software,	  La	  Jolla,	  CA,	  USA)	  was	  used	  for	  statistical	  analysis	  and	  data	  presentation.	  	  
Fluorescence-­‐activated	  cell	  sorting	  of	  B	  cell	  subsets	  and	  antigen-­‐specific	  B	  cells	  Cryopreserved	   PBMC	   from	   healthy	   donors	   before	   (day	   0)	   and	   after	   vaccination	   (day	   7),	   were	  thawed	   and	   rested	   over	   night.	   The	   next	  morning,	   cell	   count	   and	   viability	  was	   determined	   and	  cells	  were	  stained	  with	  antibodies	  against	  CD14	  (FITC,	  clone	  MϕP9,	  345784),	  CD16	  (FITC,	  clone	  NKP15,	  335035)	  and	  CD27	  (PE,	  clone	  L128,	  340425),	  all	   from	  BD	  Biosciences	  and	  against	  CD3	  (Alexa	   Fluor	   488®,	   clone	   UCHT1,	   300415),	   CD19	   (Alexa	   Fluor	   700®,	   clone	   HIB19,	   302226),	  CD20	  (Brilliant	  Violet	  510TM,	  clone	  2H7,	  302340),	  CD38	  (APC,	  clone	  HIT2,	  303510)	  and	  IgD	  (PE-­‐Cy7,	   clone	   IA6-­‐2,	   348210),	   all	   from	   Biolegend.	   For	   HA-­‐specific	   staining,	   d7	   PBMC	   were	   first	  incubated	  in	  PBS	  with	  100	  mU/mL	  of	  Neuraminidase	  (N5631-­‐1UN,	  Sigma	  Aldrich,	  St.	  Louis,	  MO,	  USA)	   for	   1	   hour	   at	   37°C	   to	   reduce	   non-­‐specific	   HA-­‐binding	   1.	   Then,	   cells	   were	   stained	   with	  antibodies	  against	  CD3	  (Alexa	  Fluor	  700®,	  clone	  OKT3,	  317340)	  and	  CD19	  (PE-­‐Cy7,	  clone	  HIB19,	  302216),	   FITC-­‐coupled	   HA	   from	   H1N1	   A/Michigan/45/2015	   and	   PE-­‐coupled	   HA	   from	   H3N2	  A/Hongkong/4801/2014.	   Conjugation	   was	   performed	   with	   Lightning-­‐Link	   Fluorescein/R-­‐PE	  antibody	   labeling	   kit	   (707-­‐0030	   and	   703-­‐0030,	   Expedeon,	   San	   Diego,	   CA,	   USA)	   according	   to	  manufacturer’s	   instructions	   (protein	   concentration	   4x	   lower	   than	   recommended).	   Before	   HA-­‐staining,	   sialic	   acids	   on	   PBMC	  were	   removed	  with	   100	  mU/mL	   neuraminidase	   (N5631,	   Sigma	  Aldrich)	   at	   37°C	   for	   one	   hour	   in	   order	   to	   reduce	   unspecific	   staining.	   Compensation	   was	  performed	  using	  single	  stained	  Antibody	  Capture	  Beads	  (VersaComp,	  B22804,	  Beckman	  Coulter).	  All	  B	  cell	  subsets	  were	  sorted	  into	  medium	  on	  a	  FACSAria®	  III	  (BD	  Biosciences)	  using	  a	  70	  μM	  nozzle.	   The	   gating	   strategy	   is	   indicated	   in	   Supplementary	   Figure	   S1.	   Cells	   were	   pelleted	   and	  kept	  at	  -­‐80°C	  until	  RNA	  extraction.	  	  
IgG-­‐BCR-­‐sequence	  library	  preparation:	  Extended	  protocol	  IgG	  heavy	  chain	   libraries	   compatible	   for	   sequencing	  with	   the	   Illumina	  MiSeq	  platform	  (paired-­‐end	   2x	   300	   bp)	  were	   prepared	   similarly	   to	   a	   previously	   described	   two-­‐step	   primer	   extension	  method	  for	  mouse	  Ig	  heavy	  chains	  2.	  This	  method	  proved	  to	  enable	  high	  amplification	  efficiency	  and	  broad	   capture	   of	   repertoire	   diversity.	  Due	   to	   the	   extended	   scope	   and	   in	   order	   to	   increase	  yield,	   some	   procedures	   were	   different	   in	   the	   2017/18	   cohort	   and	   are	   depicted	   in	   [brackets].	  Total	   RNA	   from	   [naïve	   B	   cells	   (day	   0)],	   memory	   B	   cells	   (day	   0	   and	   7	   (only	   07/08)	   and	  plasmablasts,	  [H1-­‐	  and	  H3-­‐specific	  B	  cells	  (day	  7)]	  was	  isolated	  with	  the	  RNeasy®	  Plus	  Micro	  kit	  (74034,	  Qiagen,	  without	  column-­‐based	  gDNA	  elimination	  but	  with	  adding	  200	  ng	  of	  carrier	  RNA	  (in	   the	   2007/08	   cohort	   only)	   according	   to	  manufacturer’s	   ‘Animal	   and	  Human	   Cells’	   protocol.	  Subsequently,	  the	  complete	  RNA	  was	  depleted	  from	  genomic	  DNA	  with	  RQ1	  RNAse-­‐Free	  DNAse	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(M6101,	  Promega)	  according	  to	  protocol.	  First-­‐strand	  cDNA	  was	  synthesized	  from	  total	  RNA	  by	  using	   AccuScript	   Hi-­‐Fi	   Reverse	   Transcriptase	   (200820,	   Agilent	   Technologies)	   with	   oligo(dT)	  primers	   according	   to	   manufacturer’s	   protocol	   in	   triple	   volume.	   Following	   RT,	   a	   bead-­‐based	  nucleic	  acid	  clean-­‐up	  was	  carried	  out:	  The	  complete	  RT	  product	  (60	  μL)	  was	  mixed	  with	  48	  μL	  of	  SPRIselect	  magnetic	   beads	   (B23318,	   Beckman	   Coulter)	   on	   a	   custom-­‐made	  magnet	   in	   order	   to	  perform	  a	  0.8x	  left-­‐sided	  clean-­‐up	  (i.e.	  remove	  smaller	  DNA	  fragments	  up	  to	  a	  certain	  threshold).	  The	   supernatant	  with	   the	   small	   fragments	  was	   discarded	   and	   bead-­‐bound	   DNA	  washed	   twice	  with	  85%	  Ethanol	  and	  finally	  eluted	  in	  20	  μL	  of	  water.	  	  For	   PCR	   amplification	   of	   the	   rearranged	   heavy	   chain	   locus,	   a	   set	   of	   eight	   forward	   primers	  containing	  an	  overhang	  and	  annealing	  to	   framework	  region	  1	  3	  and	  reverse	  primers	  binding	  to	  Cγ1-­‐4	  [and	  Cμ	  (for	  naïve	  and	  memory	  B	  cells)],	  containing	  another	  overhang,	  were	  used	  in	  PCR	  1	  (complete	  primer	  list	  in	  Supplementary	  Table	  S2).	  In	  a	  reaction	  volume	  of	  25	  μl	  with	  5%	  DMSO	  [and	  100	  ng	  of	  the	  ssDNA-­‐stabilizing	  enzyme	  ET	  SSB	  (M2401,	  New	  England	  Biolabs,	  Ipswich,	  MA,	  USA)],	  half	  [a	  third]	  of	  the	  purified	  cDNA	  was	  amplified	  with	  Q5®	  High-­‐Fidelity	  DNA	  Polymerase	  (M0491,	   New	   England	   Biolabs)	   by	   using	   the	   following	   settings:	   Activation	   at	   98°C	   for	   30s	  followed	  by	  4	  [6]	  cycles	  of	  98°C	  for	  20s,	  48°C	  for	  40s,	  72°C	  for	  60s;	  4	  [6]	  cycles	  of	  98°C	  for	  20s,	  53°C	   for	  40s,	   72°C	   for	  60s;	  12	   [14]	   cycles	  of	   of	   98°C	   for	  20s,	   60°C	   for	  40s,	   72°C	   for	  60s	   and	  2	  minutes	  of	  extension	  at	  72°C.	  After	  this	  overall	  20	  [26]	  cycles,	  a	  bead-­‐based	  0.8x	  left-­‐sided	  clean-­‐up	  was	  performed	  again	  followed	  by	  elution	  in	  20	  μL	  of	  water	  [separation	  on	  a	  1%	  agarose	  gel	  stained	  with	   SYBR®	  Safe	   (S33102,	   Invitrogen)	  was	   carried	   out	   followed	  by	   purification	   of	   the	  appropriately	  sized	  bands	  (around	  500	  bp).	  MinElute®	  Gel	  Extraction	  Kit	   (28604,	  Qiagen)	  was	  used,	   elution	   in	   10	   μL	   of	   water].	   PCR	   2	   was	   used	   to	   add	   Illumina	   adapter	   sequences	   and	  population-­‐specific	   Illumina	   indices	   (TruSeq	   index	   reverse	  primers,	  RPI1-­‐16,	   18-­‐37).	   Complete	  PCR	  1	  product	  was	  amplified	  with	  Q5®	  DNA	  Polymerase	  in	  two	  parallel	  [one]	  reaction(s)	  of	  25	  μL	  volume	  with	  5%	  DMSO	  with	  the	  following	  conditions:	  Activation	  at	  98°C	  for	  30s	  followed	  by	  4	  [6]	  cycles	  of	  98°C	  for	  20s,	  40°C	  for	  40s,	  72°C	  for	  60s;	  12	  [16]	  cycles	  of	  98°C	  for	  20s,	  65°C	  for	  40s,	  72°C	   for	  60s	  and	  2	  minutes	  of	   extension	  at	  72°C.	  After	  0.8x	  SPRIselect	   left-­‐sided	   size	   selection	  and	  elution	  in	  20	  μL	  of	  water	  (only	  07/08),	  the	  complete	  product	  of	  PCR	  2	  was	  mixed	  with	  6	  μL	  of	   30%	   glycerol	   and	   gel-­‐purified	   as	   described	   above.	   DNA	   concentration	   of	   all	   purified	   PCR	  products	   was	   assessed	   with	   a	   QuantusTM	   Fluorometer	   using	   the	   QuantiFluor®	   ONE	   dsDNA	  System	   (E4870,	   both	   Promega).	   Regardless	   of	   concentration	   [concentration	   of	   individual	  libraries	  were	   diluted	   to	   account	   for	   input	   cell	   number	  while	   aiming	   at	   a	  minimal	   sequencing	  depth	  of	  10	  and	  highest	  possible	  concentration	  of	  the	  final	  library],	  2	  μL	  per	  sample	  was	  added	  to	  the	   final	   library	  and	   its	  quality	  and	  quantity	  was	  verified	  on	  a	  Fragment	  AnalyzerTM	  (Advanced	  Analytical	  Technologies	  Inc.,	  Ankeny,	  IA,	  USA)	  using	  DNF-­‐473	  Standard	  Sensitivity	  NGS	  fragment	  analysis	  kit.	  The	  number	  of	  successful	  paired-­‐end	  reads	  in	  the	  2007/08	  run	  ranged	  from	  346	  to	  373’695	  (memory	  B	  cells)	  and	  99’666	  to	  1’080’549	  (plasmablasts).	  
	  
Focus	  I:	  Breadth	  and	  limitations	  of	  the	  influenza	  vaccine-­‐induced	  immune	  response	  	  
	   48	  
ELISpot	  for	  antigen-­‐specific	  B	  cells	  PVDF	  plates	  (3654-­‐WP-­‐10,	  Mabtech,	  Nacka	  Strand,	  Sweden)	  were	  activated	  with	  20	  μL	  of	  35%	  ethanol	   per	  well	   for	   one	  minute.	   Subsequently,	   plates	  were	  washed	   five	   times	  with	  water	   and	  supplied	   with	   50	   μL/well	   of	   antigen	   in	   PBS	   at	   a	   concentration	   of	   2.5	   μg/mL.	   HA0	   of	  A/Michigan/45/2015	  (H1N1)	  and	  A/Hong	  Kong/4801/2014	  (H3N2)	  were	  used,	  as	  well	  as	  anti-­‐human	   IgG	   (clone	  MT91/145,	   3850-­‐3-­‐250,	  Mabtech)	   as	   a	   positive	   control.	   Plates	  were	   coated	  over	  night	  at	  4°C.	  Afterwards,	  plates	  were	  washed	  five	  times	  with	  PBS	  and	  blocked	  by	  addition	  of	  200	  μL	  of	  RPMI	  with	  10%	  FCS	  (incubation	  at	  37°C	  for	  2	  hours).	  H1-­‐	  and	  H3-­‐specific	  and	  HA-­‐negative	  B	  cells	  were	  sorted	  into	  RPMI	  (+	  10%	  FCS)	  and	  activated	  at	  37°C	   for	   three	   days	   in	   the	   presence	   of	   25’000	   autologous	   CD19-­‐	   feeder	   cells,	   IL-­‐21	   (200-­‐21,	  Peprotech,	  London,	  UK)	  and	  CD40L	  (SRP8044,	  Sigma	  Aldrich)	  at	  a	  concentration	  of	  100	  ng/mL.	  Then,	  antigen-­‐specific	  B	  cells	  were	  thoroughly	  washed	  and	  around	  100	  B	  cells	  (based	  on	  counts	  by	   flow	   cytometry)	   in	   200	   μL	   of	   RPMI	   were	   added	   per	   well	   to	   the	   coated	   and	   blocked	   PVDF	  plates.	   Incubation	   for	   six	  hours	  at	  37°C.	  Subsequently,	   the	  plates	  were	  washed	   twice	  with	  PBS,	  twice	   with	   PBS	   containing	   0.05%	   Tween	   (PBS/Tween)	   and	   again	   twice	   with	   PBS.	   100	   μL	   (1	  μg/mL)	  of	   biotinylated	   anti-­‐human	   IgG	  antibody	   (clone	  MT78/145,	  3850-­‐6-­‐250,	  Mabtech)	  was	  added	  for	  90	  minutes	  at	  room	  temperature	  (RT).	  After	  five	  times	  washing	  with	  PBS/Tween,	  100	  μL	   of	   Streptavidin-­‐ALP	   (alkaline	   phosphatase,	   12100018,	   Lophius	   Biosciences,	   Regensburg,	  Germany)	  at	  1	  μg/mL	  was	  added	  for	  one	  hour	  at	  RT.	  Then,	  plates	  were	  three	  times	  washed	  with	  PBS/Tween,	  three	  times	  with	  PBS,	  plate	  bottom	  cover	  was	  removed	  and	  membranes	  rinsed	  with	  deionized	  water.	  Afterwards,	  50	  μL	  of	  filtered	  BCIP/NBT	  (ALP-­‐substrate,	  3650-­‐10,	  Mabtech)	  was	  added.	  Incubation	  for	  7	  minutes	  at	  RT	  in	  the	  dark.	  After	  extensively	  rinsing	  with	  deionized	  water,	  plates	  were	  dried	  and	  analyzed	  on	  an	  AID	  EliSpot	  Reader	  System	  ELR07	  (AID	  GmbH,	  Strassberg,	  Germany)	  with	  EliSpot	  Reader	  software	  (v.7,	  AID	  GmbH).	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   2007/2008	   2017/2018	  
Study	  participants	  (n)	   24	   48	  
Age:	  median	  +	  (range)	   34	  (22	  -­‐	  76)	   43	  (25	  -­‐	  85)	  
%	  female	   46%	   N.A.	  
No	  vaccine	  response	  H1N1	   4	   10	  
No	  vaccine	  response	  H3N2	   3	   5	  
0x	  vaccinated	  (12/13	  –	  16/17)	   N.A.	   7	  
1x	  vaccinated	  (12/13	  –	  16/17)	   N.A.	   4	  
2x	  vaccinated	  (12/13	  –	  16/17)	   N.A.	   7	  
3x	  vaccinated	  (12/13	  –	  16/17)	   N.A.	   7	  
4x	  vaccinated	  (12/13	  –	  16/17)	   N.A.	   6	  
5x	  vaccinated	  (12/13	  –	  16/17)	   N.A.	   17	  
	   	   	  	  
Supplementary	  Table	  S1:	  Characteristics	  of	  the	  2007/08	  and	  2017/18	  vaccination	  cohorts.	  Data	   for	   the	  healthy	   subjects	   included	   into	   the	   cohorts	   is	   shown.	  Vaccination	  history	  was	  only	  established	  in	  the	  2017/18	  cohort.	  N.A:	  not	  available.	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Strain	  (H1N1)	   	  HA0/HA1	   Expression	  	   Provider	   Article	  Nr.	  
A/Brevig	  Mission/1/1918	   HA0	   HEK	  cells	   Sino	  Biological	  Inc.	   11068-­‐V08H	  
A/New	  Caledonia/20/1999	   HA0	   HEK	  cells	   Sino	  Biological	  Inc.	   11683-­‐V08H	  
A/Solomon	  Islands/3/2006	   HA0	   HEK	  cells	   Sino	  Biological	  Inc.	   11708-­‐V08H	  
A/Brisbane/59/2007	   HA0	   HEK	  cells	   Sino	  Biological	  Inc.	   11052-­‐V08H	  
A/California/07/2009	   HA0	   HEK	  cells	   Sino	  Biological	  Inc.	   11085-­‐V08H	  
A/California/07/2009	   HA0	   HEK	  cells	   eEnzyme	  LLC	   IA-­‐SW-­‐12P	  	  
A/Michigan/45/2015	   HA0	   HEK	  cells	   eEnzyme	  LLC	   IA-­‐H1-­‐M15WP	  
	   	   	   	   	  	  
Strain	  (H3N2)	   HA0/HA1	   Expression	  	   Provider	   Article	  Nr.	  
A/Hong	  Kong/1/1968	   HA0	   BEVS	   Sino	  Biological	  Inc.	   40116-­‐V08B	  
A/Moscow/10/1999	   HA0	   BEVS	   Sino	  Biological	  Inc.	   40154-­‐V08B	  
A/Fujian/411/2002	   HA0	   BEVS	   Sino	  Biological	  Inc.	   40120-­‐V08B	  
A/California/7/2004	   HA0	   BEVS	   Sino	  Biological	  Inc.	   40118-­‐V08B	  
A/Wisconsin/67/2005	   HA0	   BEVS	   Sino	  Biological	  Inc.	   11972-­‐V08B	  
A/Brisbane/10/2007	   HA0	   BEVS	   Sino	  Biological	  Inc.	   11056-­‐V08B	  
A/Victoria/361/2011	   HA0	   BEVS	   Sino	  Biological	  Inc.	   40145-­‐V08B	  
A/Texas/50/2012	   HA0	   BEVS	   Sino	  Biological	  Inc.	   40354-­‐V08B	  
A/Victoria/361/2011	   HA1	   HEK	  cells	   Sino	  Biological	  Inc.	   40145-­‐V08H1	  
A/Texas/50/2012	   HA1	   HEK	  cells	   Sino	  Biological	  Inc.	   40354-­‐V08H1	  
A/Texas/50/2012	  N128T	   HA1	   HEK	  cells	   Sino	  Biological	  Inc.	   Custom-­‐made	  
A/H3N2/Hongkong/4801/2014	  
	  
HA1	   HEK	  cells	   Sino	  Biological	  Inc.	   40555-­‐V08H	  
	  	  
Supplementary	  Table	  S2:	  List	  of	  recombinant	  hemagglutinin	  from	  H1N1-­‐	  and	  H3N2-­‐strains	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Strain	  (H1N1)	   Accession	  
number	  
A/Brevig	  Mission/1/1918	   AF116575	  
A/New	  Caledonia/20/1999	   CY033622	  
A/Solomon	  Islands/3/2006	   EU124177	  
A/Brisbane/59/2007	   CY058487	  
A/California/07/2009	   FJ969540	  
	  	  	  	  	  
Supplementary	   Table	   S3:	   List	   of	   strains	   included	   to	   calculate	   sequence	   homology	   and	  
phylogenetic	   relatedness.	  Accession	  numbers	  are	  indicated	  for	  HA	  amino	  acid	  sequences.	  The	  strains	  correspond	  to	  those	  included	  in	  the	  multiplexed	  immunoassay.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Strain	  (H3N2)	   Accession	  	  
number	  
A/Hong	  Kong/1/1968	   CY033996	  
A/Moscow/10/1999	   DQ487341	  
A/Fujian/411/2002	   CY112933	  
A/California/7/2004	   EU103820	  
A/Wisconsin/67/2005	   CY034116	  
A/Brisbane/10/2007	   Y035022	  
A/Victoria/361/2011	   KJ942680	  
A/Texas/50/2012	   KC892248	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Supplementary	  Table	  S4:	  List	  of	  primers	   for	  generation	  of	   IgG	  heavy	  chain	   libraries.	  Our	  primer	  extension	  method	  was	  adapted	  from	  a	  previously	  published	  report	  for	  mouse	  IgG	  2.	  The	  primers	  specific	  for	  the	  variable	  region	  were	  published	  by	  Ippolito	  et	  al.	  4	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Supplementary	  Figure	  S1:	  Gating	  strategy	  for	  FACS.	  One	  flow-­‐panel	  (upper	  part)	  was	  used	  to	  stain	  for	  naïve	  and	  memory	  B	  cells	  (d0)	  and	  plasmablasts	  (d7),	  the	  second	  panel	  (lower	  part)	  to	  stain	   for	   H1-­‐	   and	   H3-­‐specific	   B	   cells	   (d7).	   Gates	   are	   shown	   in	   red	   within	   doublet-­‐negative	  lymphocytes.	  10’000	  events	  per	  image	  are	  shown,	  hence	  events	  per	  gate	  are	  not	  representative	  for	  proportions	  of	  B	  cell	  subsets.	  Figure	  created	  with	  FlowJo	  v.10,	  FlowJo,	  LLC.	  	  	  	  	  	  	  	  	  	  	  
	  	  
Supplementary	  Figure	  S2:	  Subjects	  included	  into	  the	  2007/08	  react	  towards	  the	  influenza	  
A	   components	   of	   the	   vaccine.	   Vaccine	   responses	   are	   shown	   as	   background	   corrected	   MFI-­‐values	   before	   and	   at	   three	   time	   points	   post-­‐vaccination.	   Four	   donors	   did	   not	   respond	   to	   the	  H1N1	  component	   (left	  panel)	  of	   the	  2007/08	  vaccine,	   three	  not	   to	   the	  H3N2	  component	   (right	  panel).	  Median	  with	  IQR	  is	   indicated.	  Antibody	  levels	  are	  slightly	  higher	  at	  day	  14	  compared	  to	  day	  28.	  P	  values	  were	  estimated	  with	  Wilcoxon	  signed	  rank	  test	  (***	  p	  >	  0.001)	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Supplementary	  Figure	  S3:	  V	  gene	  usage	  and	  somatic	  hypermutation	   in	  B	  cell	   subsets.	  A)	  Frequency	   of	   V	   genes	   present	   in	   the	   sequenced	   BCR	   between	   cell	   populations	   and	   reactivity	  groups.	  Yellow	  bars	   indicate	   significantly	  different	  usage	  but	   further	   analysis	  was	  not	  pursued	  since	   usage	   was	   never	   higher	   for	   the	   high-­‐crossreactivity	   group	   (which	   might	   have	   indicated	  broadly	   cross-­‐reactive	   antibodies).	   B)	   Degree	   of	   somatic	   hypermutation	   (SHM,	   amino	   acids	  changed	   compared	   to	   germline	   sequence	   across	   the	   sequenced	   region)	   between	   B	   cell	  populations	  and	  reactivity	  groups.	  	  	  	  	  	  	  	  	  	  	  
	  
	  
Supplementary	  Figure	  S4:	  Frequency	  of	  viral	   isolates	  belonging	  to	  H3N2	  clade	  3c3.	  Clade	  3c3-­‐strains	   are	   defined	   by	   the	  T128A-­‐mutation.	   The	   frequency	   of	   128A	   is	   shown	   in	   blue	   from	  April	  2012	  until	  April	  2018	  based	  on	  HA-­‐sequences	  from	  2084	  viral	  isolates	  worldwide.	  After	  its	  emergence	   in	   2012,	   3c3	  was	   the	  most	   abundant	   clade	   in	   the	   following	   two	   years.	   Vaccination	  period	   (northern	   and	   southern	   hemisphere)	   using	   a	   clade-­‐matched	   strain	   based	   on	   the	   motif	  surrounding	   position	   128,	   i.e.	   N-­‐W-­‐N128	   (Texas-­‐like)	   or	   N-­‐W-­‐A128	   (Switzerland-­‐like)	   is	  indicated	   with	   the	   syringe.	   Figure	   made	   with	   nextstrain	   tool	   5	   based	   on	   HA	   sequence	   data	  deposited	  in	  the	  GISAID	  database	  6.	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Discussion	  	  
Complementary	  comments	  In	  our	  manuscript,	  the	  focus	  was	  set	  on	  analyzing	  the	  breadth	  of	  the	  vaccine-­‐induced	  B	  cell	   response	  against	   influenza	  A	  and	  determining	  possible	  gaps	   representing	  putative	  escape	   variants.	   This	   was	   done	   by	   retrospectively	   harnessing	   a	   2007/08	   vaccination	  cohort	   and	   measuring	   vaccine	   responses	   against	   HA,	   the	   main	   antibody	   target,	   from	  multiple	   strains	   in	   a	   multiplexed	   antibody-­‐binding	   assay.	   This	   approach	   had	   the	  advantage	   that	   we	   could	   not	   only	   test	   strains	   that	   were	   previously	   circulating	   in	   the	  population,	   but	   also	   antigenically	   drifted	   strains	   that	   emerged	   in	   the	   years	   following	  vaccination.	  The	   reactivity	  against	  most	  of	   the	   tested	   strains	  was	  quite	  heterogeneous	  across	   the	  whole	  cohort,	   implying	   factors	  beyond	   the	  antigenic	  properties	  of	   the	  virus	  affecting	  cross-­‐reactivity.	  High	  pre-­‐existing	  IgG	   levels	  had	  a	  positive	  effect	  on	  antibody	  cross-­‐reactivity,	  as	  previously	  described	  107.	  Beyond	  that	  and	  not	  specifically	  assessed,	  it	  is	  plausible	  that	  age,	  number	  and	  type	  of	  vaccinations	  and	  infections	  contributed	  to	  the	  observed	  heterogeneity	  104,106,108.	  	  	  In	  contrast,	  the	  antigenic	  properties	  of	  A/Texas/50/2012,	  a	  future	  strain	  at	  time	  point	  of	  vaccination,	   outbalance	   the	   effects	   of	   pre-­‐existing	   immunity.	   Specifically,	   its	  hemagglutinin	   was	   poorly	   recognized	   by	   most	   subjects	   due	   to	   the	   T128N	   mutation	  leading	  to	  a	  loss	  of	  glycosylation	  at	  position	  N126.	  Sequence	  context	  analysis	  suggests	  a	  likewise	   loss	   of	   glycosylation	   in	   all	   strains	   of	   the	   3c3	   clade	   (A128)	   109,	   potentially	  contributing	  to	  its	  fast	  expansion	  in	  2013.	  We	  showed	  recognition	  of	  the	  Texas	  variant	  to	  be	  increased	  in	  2014/15,	  after	  inclusion	  of	  a	  matched	  strain	  into	  the	  vaccine,	  only	  to	  drop	  back	   to	   pre-­‐vaccination	   levels	   in	   2017/18.	   This	   lack	   of	  memory	   formation	   could	  indicate	   inaccessibility	   to	   the	   epitope	   for	   N128(Texas)-­‐specific	   B	   cells.	   Shielding	   of	  epitopes	  by	  emergence	  of	  N-­‐linked	  glycosylation	  is	  well	  known	  for	  influenza	  HA	  89,110.	  In	  contrast,	  the	  proportion	  of	  antibodies	  targeting	  preceding	  strains	  (e.g.	  Victoria)	  but	  not	  Texas	   must	   have	   been	   at	   least	   partially	   directed	   against	   carbohydrates.	   Anti-­‐carbohydrate	  antibodies	  are	  not	  so	  frequent,	  but	  they	  can	  be	  of	  high	  affinity	  and	  are	  well	  studied	  in	  the	  HIV	  field	  111,112.	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BCR-­‐repertoires	  and	  repetitive	  vaccination	  The	  2017/18	  cohort	  was	  a	  pilot	  study	  to	  prospectively	   investigate	  effects	  of	  repetitive	  vaccine	  exposure	  to	  antibody	  cross-­‐reactivity	  and	  the	  structure	  of	  the	  B	  cell	  repertoire.	  Since	   vaccine	   history	  was	   inquired	   back	   until	   season	  2012/13,	   i.e.	   vaccinations	   of	   the	  five	  seasons	  before	  2017/18	  were	  known;	  we	  were	  already	  able	  to	  address	  some	  points	  relating	  to	  vaccination	  history.	  Indeed,	  the	  situation	  for	  H1N1	  was	  very	  interesting:	  from	  2012/13	   on,	   vaccines	   included	  HA	   of	   an	   A/Christchurch/16/2010-­‐like	   virus	   that	  was	  altered	  to	  HA	  from	  an	  A/Michigan/45/2015-­‐like	  virus	  in	  2017/18.	  We	  did,	  however,	  not	  find	   preferential	   targeting	   of	   Christchurch	   in	   subjects	   repeatedly	   vaccinated	  with	   this	  strain,	  probably	  reflecting	   the	   lack	  of	  antigenicity	  of	   the	  sites	  altered	  between	   the	   two	  strains.	   After	   2012/13,	   the	   H3N2	   strain	   was	   adapted	   three	   times	   until	   2017/18.	  Between	   2013/14	   and	   2015/16,	   vaccinations	   included	   strains	   very	   likely	   lacking	  glycosylation	  at	  position	  N126.	  Again,	  in	  those	  subjects	  vaccinated	  in	  all	  three	  respective	  seasons,	  we	  could	  not	  find	  differences	  in	  the	  response	  to	  these	  strains	  (precisely:	  Texas).	  Possible	  reasons	  were	  discussed	  above.	  	  We	  adapted	  our	  protocol	  that	  we	  used	  for	  preparing	  the	  BCR	  sequencing	  libraries	  from	  2007/08	   in	   a	   way	   to	   increase	   the	   yield	   of	   the	   PCR-­‐products	   (see	   Supplementary	  
Methods).	   By	   using	   this	   altered	  protocol,	  we	   generated	  BCR-­‐repertoire	   libraries	   from	  sorted	   naïve	   and	  memory	   B	   cells	   (day	   0)	   and	   plasmablasts	   (day	   7)	   from	   23	   subjects	  included	  in	  the	  2017/18	  cohort	  with	  especially	  few	  or	  many	  vaccinations	  in	  the	  last	  five	  years.	   From	   16	   of	   them,	   we	   also	   produced	   libraries	   from	   sorted	   HA-­‐specific	   B	   cells.	  These	   were	   labeled	   and	   sorted	   according	   to	   a	   strategy	   we	   based	   on	   a	   previously	  published	   protocol	   113.	   Specifically,	   we	   coupled	   recombinant	   HA	   from	  A/Michigan/45/2015	   and	   A/Hong	   Kong/4801/2014,	   the	   current	   H1N1	   and	   H3N2	  vaccine	  strains	  to	  PE	  and	  FITC	  respectively	  (Supplementary	  Methods).	  Enrichment	  for	  antigen-­‐specific	  B	  cells	  was	  confirmed	  by	  EliSpot	  (Supplementary	  Methods	  and	  Figure	  
9).	  Brief,	  HA-­‐specific	  B	  cells	  were	  activated	  for	  3	  days	  in	  the	  presence	  of	  100	  ng/mL	  of	  IL-­‐21	  and	  CD40L.	  Around	  100	  B	  cells	  were	  then	  incubated	  for	  six	  hours	  on	  plates	  coated	  with	   H1	   (Michigan),	   H3	   (Hong	   Kong)	   or	   anti-­‐human	   IgG	   Fc	   antibodies	   as	   a	   positive	  control.	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Figure	  9:	  Sorted	  HA-­‐positive	  B	  cells	  produce	  IgG	  antibodies	  against	  their	  cognate	  antigen.	  EliSpot	  data	  is	  shown	  for	  one	  vaccinated	  donor	  (d21	  post-­‐vaccination).	  One	  well	  per	  condition	  is	  depicted	   with	   the	   respective	   spot	   number	   indicated.	   Samples	   were	   tested	   in	   duplicates;	   the	  specificity	  of	  HA-­‐positive	  B	  cells	   is	  calculated	  as	  the	  proportion	  of	  H1/H3-­‐specific	  spots	  of	  total	  αIgG	  spots.	  	  	  At	  time	  point	  of	  thesis	  submission,	  the	  BCR	  sequencing	  is	  still	  pending	  for	  the	  2017/18	  cohort.	  If	  successful,	  it	  will	  allow	  us	  to	  track	  the	  extent	  of	  B	  cell	  lineage	  recruitment	  from	  the	  memory	  or	  naïve	  B	  cell	  pool	  to	  the	  plasmablast	  population.	  We	  would	  also	  be	  able	  to	  confirm	   whether	   those	   individuals	   with	   poor	   cross-­‐reactivity	   (again	   against	  A/Texas/50/2012	   or	   novel	   putative	   escape	   variants,	   ongoing	   project	   not	   discussed	  here)	   present	   with	   a	   narrower	   BCR	   repertoire.	   Finally,	   the	   availability	   of	   HA-­‐specific	  BCR	  sequences	  would	  allow	  us	  to	  validate	  the	  expanded	  B	  cell	  lineages	  and	  investigate	  whether	   e.g.	   repeated	   vaccination	   has	   an	   effect	   on	   the	   HA-­‐specific	   repertoire	  composition.	  
	  
	  
Vaccine	  preparations	  If	   confirmed	   in	   a	   prospective	   setting	   over	   several	   influenza	   vaccination	   seasons,	   our	  finding	  of	  altered	  antigenicity	  due	  to	  glycosylation	  changes	  may	   inform	  vaccine	  design	  regarding	   viral	   strain	   selection.	   Since	   influenza	   A	   viruses	   frequently	   change	   their	  glycosylation	   pattern	   110,114,	   it	  might	   be	   beneficial	   to	   include	  multiple	   current	   variants	  per	  serotype	   in	   the	  vaccine	   to	  account	   for	  potential	  escape	  variants.	  The	  possibility	   to	  elicit	   vaccine-­‐induced	   immune	   responses	   against	   several	   strains	   in	   parallel	   has	   been	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demonstrated	  e.g.	  against	  HIV-­‐1	  or	  Streptococcus	  pneumoniae	  115,116.	  However,	  since	  the	  vast	  majority	  of	  all	  influenza	  vaccine	  doses	  administered	  are	  currently	  produced	  in	  the	  conventional	  way	  in	  fertilized	  chicken	  eggs,	  controlled	  generation	  of	  multiple	  strains	  per	  serotype	  at	  once	  is	  not	  possible	  74.	  While	  being	  safe	  and	  involving	  low	  production	  costs,	  these	   vaccines	   have	   a	   second	   limitation:	   The	   propagation	   of	   virus	   in	   eggs	   can	   lead	   to	  adaptive	  mutations	  for	  avian-­‐type	  sialic	  acid	  to	  galactose	  linkage	  (SAα2,3Gal)	  present	  on	  cells	  in	  the	  amniotic	  fluid	  77.	  This	  can	  alter	  antigenicity	  against	  viruses	  adapted	  to	  human	  sialic	  acid	  linkage	  (SAα2,6Gal)	  resulting	  in	  lower	  protection	  78,80.	  Third,	  around	  8	  months	  are	  required	  from	  evaluating	  the	  surveillance	  data	  over	  deciding	  and	  testing	  candidate	  vaccine	  viruses	  until	  marketing	  of	  a	  vaccine	  in	  sufficient	  quantities	  117.	  Therefore,	  efforts	  have	  been	  undertaken	  to	  produce	  alternative	  vaccines.	  	  There	   are	   now	   two	   FDA-­‐approved	   seasonal	   influenza	   vaccines	   available	   that	   use	  recombinant	   technology	   and	   therefore	   circumvent	   the	  need	   for	   eggs	   118.	  One	   is	   a	   split	  vaccine	   that	   is	   produced	   in	   MDCK	   cells.	   The	   other	   one	   contains	   only	   hemagglutinin,	  which	   is	   produced	   in	   an	   insect	   cell	   line	  with	   help	   of	   a	   Baculovirus	   expression	   vector.	  Hence,	  problems	  with	  egg-­‐adapted	  variants	  do	  not	  arise	  anymore	  and	  production	  speed	  is	  increased.	  These	  technologies	  would	  also	  allow	  the	  production	  of	  multiple	  strains	  for	  vaccine	   inclusion,	   however,	   only	   the	   WHO-­‐proposed	   variants	   are	   included	   in	   the	  vaccines	  currently.	  	  Besides	  altering	   the	  production	  mode,	   a	   lot	  of	   research	  has	  been	   invested	   in	  directing	  the	   vaccine	   response	   against	   highly	   conserved	   structures.	   One	   strategy	   is	   to	   induce	  broader	   and	   maybe	   even	   heterosubtypic	   (across	   serotypes)	   B	   cell	   protection.	  Conventional	  vaccination,	  and	  also	  infection,	  induces	  undetectable	  or	  very	  low	  amounts	  of	   antibodies	   targeting	  NA,	  NP,	  M	  or	   the	   very	   conserved	  HA	   stem	   119,120.	  Nevertheless,	  bnAbs	  targeting	  the	  HA	  stalk	  have	  been	  described,	  some	  even	  recognizing	  all	  known	  HA	  subtypes	   121,122.	   They	   often	   seem	   to	   act	   through	   Fc-­‐mediated	   effector	   functions	   123.	   A	  stable	   trimeric	   form	   of	   the	   H1	   HA2-­‐domain	   could	   be	   engineered	   for	   potential	  vaccination	   use,	   showed	   binding	   of	   known	   stem-­‐targeting	  monoclonal	   antibodies	   and	  reduced	   infection-­‐induced	   fever	   in	  non-­‐human	  primates	   124,125.	   Interestingly,	   following	  the	   2009	   pandemic	   with	   reassorted	   H1N1	   virus,	   the	   production	   of	   stem-­‐specific	  antibodies,	  even	  with	  neutralizing	  capacity,	  was	  boosted	  in	  infected	  individuals	  126.	  This	  led	  to	  the	  assumption	  that	  the	  antigenicity	  of	  the	  HA-­‐stem	  can	  be	  augmented	  if	  there	  is	  no	  memory	  recall	  for	  the	  head	  region,	  i.e.	  that	  the	  head	  region	  consists	  of	  a	  protein	  not	  yet	   encountered	   by	   the	   immune	   system	   such	   as	   in	   the	   2009	   pandemic.	   Indeed,	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vaccination	   with	   an	   H5N1	   virus,	   where	   the	   head	   region	   was	   unknown	   to	   the	   host’s	  immune	   system,	   showed	   to	   boost	   the	   level	   of	   anti-­‐stem	   antibodies	   127.	   Unfortunately,	  upon	   re-­‐vaccination	   with	   H5N1,	   the	   humoral	   response	   against	   the	   head	   region	  dominated	   again.	   This	   phenomenon	   might	   be	   due	   to	   the	   lower	   capability	   of	   stem-­‐specific	  memory	  B	  cells	  to	  bind	  to	  their	  target	  during	  recall	  due	  to	  steric	  hindrance	  108.	  Probably	   also	   because	   they	   do	   not	   work	   optimally	   in	   individuals	   with	   preexisting	  influenza	   virus	   immunity	   (i.e.	   the	   majority	   of	   people),	   stalk-­‐based	   vaccines	   are	   not	  evaluated	  in	  clinical	  trials	  yet.	  	  The	  development	  of	  a	  broadly	  applicable	  T	  cell	  vaccine	  is	  particularly	  challenging,	  given	  the	   varying	   distribution	   of	   HLA-­‐genotypes	   across	   populations.	   Nevertheless,	   since	   T	  cells	   seem	   to	   be	   responding	   to	   very	   conserved	   viral	   targets	   70–72,	   a	   vaccine	   inducing	  cytotoxic	   T	   cells	   would	   likely	   be	   very	   useful	   against	   pandemic	   viruses	   and	   have	   the	  potential	  as	  a	  universal	  vaccine	  128.	  Live-­‐attenuated	  vaccines	  increase	  the	  proportion	  of	  influenza-­‐specific	  T	  cells	  to	  some	  extent	  129.	  A	  vector-­‐based	  vaccine	  enabling	  synthesis	  of	  influenza	   NP	   and	  M1	   showed	   an	   increase	   in	   lytic	   virus-­‐specific	   T	   cells	   and	   conferred	  some	  protection	  against	  viral	  challenge	  in	  a	  small	  cohort	  130,131.	  A	  peptide-­‐based	  vaccine	  covering	   highly	   conserved	   regions	   of	  multiple	   influenza	   A	   protein	   showed	   a	   negative	  correlation	  between	  T	  cell	   responses	  and	  viral	   shedding	  but	  did	  not	   confer	  protection	  132.	  	  	  Taken	   together,	   broader	   protection	   against	   antigenically	   different	   viruses	   –	   emerging	  clades	  or	   antigenically	   shifted	  pandemic	   variants	   –	  may	  be	   gained	  by	   the	   induction	  of	  bnAbs	  against	  conserved	  structures	  such	  as	   the	  HA-­‐stalk.	  However,	   the	  memory	  B	  cell	  response	   is	   predominantly	   targeted	   towards	   the	   HA-­‐head	   region,	   likely	   also	   due	   to	  sterical	   reasons.	   The	   possibility	   for	   simultaneous	   production	   of	   multiple	   strains	   in	  mammalian	   cell	   lines	   could	   increase	   the	   breadth	   of	   neutralizing	   head-­‐specific	  antibodies.	  T	  cell	  help	  might	  be	  increased	  with	  live-­‐attenuated	  vaccines	  or	  vector-­‐based	  vaccines.	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FOCUS	  II:	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  ANTIGEN-­‐SPECIFIC	  IMMUNE	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Clinical	  and	  epidemiological	  features	  Giant	   cell	   arteritis	   (GCA)	   is	   an	   inflammatory	  disease	  affecting	  medium-­‐sized	  and	   large	  arteries.	   Patients	   typically	   present	  with	   a	   systemic	   inflammation	   in	   combination	  with	  strong	   headaches,	   jaw	   pain	   when	   chewing	   (‘jaw	   claudication’)	   and	   scalp	   tenderness	  together	   with	   polymyalgia	   rheumatica	   (PMR,	   muscle	   pain	   of	   the	   shoulders).	   Less	  frequent	  symptoms	  depend	  also	  on	  the	  localization	  of	  the	  arteritis;	  these	  include	  ocular	  symptoms	  such	  as	  transient	  (‘amaurosis	  fugax’)	  or	  permanent	  vision	  loss,	  stroke	  or	  limb	  claudication.	  Such	   ischemic	  events	  are	  the	  most	   feared	  complications	  of	  GCA.	  They	  are	  caused	   by	   intima	   (innermost	   artery	   layer)	   hyperplasia	   induced	   by	   the	   local	   immune	  response	  133,134.	  	  The	  disease	  is	  almost	  exclusively	  occurring	  in	  people	  above	  50	  years	  of	  age	  and	  women	  are	   more	   often	   affected	   than	   men.	   Incidence	   is	   highest	   in	   Caucasians,	   especially	   in	  people	  of	  Northern	  European	  descent,	   going	  up	   to	  27/100’000	   in	   those	  older	   than	  50	  years	  135,136.	  In	  Japan,	  incidence	  was	  reported	  to	  be	  only	  1.47/100’000	  137.	  	  Disease	  diagnosis	  relies	  on	  the	  clinical	  presentation,	  imaging	  findings	  showing	  inflamed	  large	  arteries	  and	  most	  importantly	  on	  the	  histology	  of	  an	  affected	  artery,	  typically	  the	  temporal	  artery	  (TA).	  For	  study	  purposes,	  classification	  criteria	  have	  been	  established.	  These	  include	  age	  above	  50	  at	  disease	  onset,	  new	  onset	  of	  localized	  headache,	  temporal	  artery	   tenderness,	   elevated	  erythrocyte	   sedimentation	   rate	   and	  positive	  TA	  biopsy.	  At	  least	   three	  out	   five	   criteria	   should	  be	   fulfilled.	  A	  positive	  TA	  biopsy	  shows	   transmural	  infiltrates	   of	   CD4+	   T	   cells	   and	   presence	   of	   multinucleated	   giant	   cells	   that	   gave	   the	  disease	   its	   name	   138.	   Arterial	   wall	   layers	   and	   characteristic	   GCA	   histopathology	   are	  shown	  in	  Figure	  10A-­‐C.	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Figure	   10:	   Arterial	  wall	   pathology	   in	  GCA.	   A)	  H&E-­‐staining	  of	  a	  cross-­‐sectional	  slide	   from	  a	  temporal	   artery	   with	   almost	   complete	   luminal	   occlusion.	   The	   names	   of	   the	   wall	   layers	   are	  indicated.	  B)	   GCA-­‐TA	   staining	   with	   an	   antibody	   against	   CD4	   showing	   a	   high	   degree	   of	   T	   cell	  infiltration.	  C)	  TA	  H&E-­‐staining	  showing	  the	  GCA-­‐typical	  giant	  cells,	  multinucleated	  structures	  of	  fused	  macrophages	   (indicated	  with	   black	   arrows).	  D)	   Summary	   of	   the	   interplay	   of	   innate	   and	  adaptive	   immune	   response	   leading	   to	   the	   observed	   immunopathology.	   Figures	   A	   and	   B	   show	  histological	   slides	  of	  our	  own,	  C	   is	   from	  an	  online	  pathology	  picture	  deposit	   139	  and	   figure	  D	   is	  adapted	  from	  Weyand	  et	  al.,	  NEJM	  2003	  134.	  	  
	  
	  
Disease	  pathogenesis	  Blood	   vessels	   are	   indispensable	   for	   delivering	   oxygen,	   nutrients,	   electrolytes,	   immune	  effectors	   etc.	   to	   all	   organs	   throughout	   the	   body.	   Consequently,	   damage	   to	   arteries	  especially	   of	   larger	   size	   absolutely	   needs	   to	   be	   prevented.	   In	   this	   context,	   the	   media	  (muscular	   layer	   of	   an	   artery)	   is	   often	   spared	   from	   inflammatory	   processes;	   it	   is	  considered	  an	  immunoprivileged	  zone	  due	  to	  tolerogenic	  dendritic	  cells	  140.	  This	   is	  not	  the	  case	  in	  GCA.	  	  The	   external	   elastic	   lamina	   that	   separates	   the	   adventitia	   from	   the	  media	   is	   lined	  with	  vascular	  dendritic	  cells,	  a	  tissue-­‐resident	  APC.	  Under	  homeostatic	  conditions,	  they	  are	  in	  an	  inactivated	  state	  and	  send	  inhibitory	  signals	  upon	  encounter	  with	  T	  cells.	  However,	  in	   case	   of	   PMR	   and	   GCA,	   those	   DCs	   become	   activated	   and	   produce	   the	   chemokines	  CCL19	   and	   CCL21	   that	   attract	   T	   cells	   through	   the	   vasa	   vasorum,	   small	   blood	   vessels	  pervading	  the	  adventitia	  and	  media	  layers	  of	  larger	  arteries	  140,141.	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The	  attracted	  T	  cells	  are	  of	  the	  Th1-­‐	  and	  Th17-­‐type;	  they	  mainly	  produce	  IFN-­‐γ	  and	  IL-­‐17,	  respectively,	  which	  have	  pleiotropic	  effects.	  For	  example,	  IFN-­‐γ	  is	  a	  potent	  inducer	  of	  macrophage	   activation	   and	   can	   trigger	   apoptosis	   in	   vascular	   smooth	   muscle	   cells	  (VSMC)	   or	  mediate	   their	  migration	   towards	   the	   vessel	   lumen.	   Activated	  macrophages	  produce	   IL-­‐1β	   and	   IL-­‐6,	   which	   may	   induce	   Th17-­‐polarization.	   Further,	   macrophages	  contribute	   to	   vessel	  wall	   damage	   by	   the	   production	   of	   reactive	   oxygen	   species	   (ROS)	  and	  matrix	  metalloproteinases	  (MMP)	  134,141	  (Figure	  10D).	  	  GCA	  is	  treated	  with	  high	  doses	  of	  glucocorticoids,	  which	  usually	  leads	  to	  a	  pronounced	  amelioration	  of	  acute	  disease	  manifestations.	  Before	  onset	  of	   treatment,	  both	  Th1	  and	  Th17	  cells	  can	  be	  found	  in	  the	  TA	  lesions.	  Glucocorticoids	  are	  potent	   in	  shutting	  down	  the	  Th17-­‐response,	  but	  Th1	  cells	  persist	  in	  TA	  during	  treatment,	  remaining	  a	  threat	  for	  ischemic	   events	   142.	   In	   an	   experimental	   model	   of	   GCA	   involving	   transplantation	   of	  human	   TAs	   to	   SCID-­‐mice,	   it	   has	   been	   found	   that	   NOTCH-­‐signalling	   is	   important	   in	  keeping	  T	  cells	  in	  the	  artery	  143.	  Moreover,	  by	  blocking	  the	  immune-­‐inhibitory	  PD-­‐1/PD-­‐L1	  checkpoint,	  disease	  was	  exacerbated.	  Artery-­‐infiltrating	  T	  cells	  show	  high	  expression	  of	  PD-­‐1	  concomitant	  with	  low	  expression	  of	  PD-­‐L1	  of	  the	  surrounding	  cells,	  resulting	  in	  a	   lack	   of	   inhibitory	   signals	   144.	   Combined,	   these	   data	   suggest	   that	   both	   a	   local	   and	  systemic	   immune	   dysregulation	   and	   a	   breakdown	   of	   tolerance	   in	   the	   artery	   are	  prerequisites	  for	  developing	  GCA.	  	  	  	  	  
Evidence	  for	  involvement	  of	  specific	  antigens	  While	   the	   chain	   of	   events	   leading	   to	   the	   GCA	   phenotype	   is	   quite	   well	   described,	   it	   is	  poorly	  understood	  what	  triggers	  the	  immunopathology	  observed	  in	  the	  affected	  vessels.	  Further,	   the	   strict	   tissue	   confinement	   of	   the	   disease	   suggests	   tissue-­‐specific	  microenvironments	  to	  be	  important.	  	  	  Infiltration	   of	   CD4+	   T	   cells	   in	   affected	   vessels	   is	   a	   hallmark	   of	   GCA	   141.	   CD4+	   T	   cells	  recognize	  antigen	   that	   is	  presented	   in	  peptide	   form	  on	  HLA	  class	   II	  proteins.	  Possibly,	  the	   infiltrating	  T	   cells	   recognize	   a	   tissue-­‐restricted	   antigen.	  Numerous	  HLA	  alleles	   are	  present	   in	   the	   general	   population,	   and	   not	   all	   of	   them	   are	   able	   to	   present	   the	   same	  peptides	  145.	  Several	  HLA	  class	  II	  alleles	  have	  been	  found	  to	  be	  overrepresented	  in	  GCA	  patients	   compared	   to	   controls,	   most	   significantly	   an	   allele	   of	   the	   HLA-­‐DR	   beta-­‐chain	  defined	  by	  a	  histidine	  at	  position	  13	  (HLA-­‐DRB1*04)	  8,146.	  Comparing	  GCA-­‐patients	  with	  controls,	  HLA-­‐DRB1*04	  showed	  an	  odds	  ratio	  of	  1.92	  in	  a	  pan-­‐European	  cohort	  8.	  This	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supports	  the	  idea	  of	  a	  specific	  antigen	  being	  presented.	  Early	  work	  has	  shown	  that	  the	  same	  expanded	  T	  cell	  clonotypes	  can	  be	  found	  in	  temporal	  artery	  specimens	  at	  different	  foci	   of	   the	   lesions	   and	   occasionally	   are	   also	   shared	   between	   different	   patients	   147,148.	  Clonal	  expansion	  is	  indicative	  of	  recent	  antigen	  encounter.	  	  	  All	   this	   evidence	   cannot	   explain	   why	   the	   respective	   T	   cells	   have	   been	   activated.	   In	  artery-­‐engrafted	  SCID	  mice,	  it	  was	  shown	  that	  T	  cells	  could	  be	  attracted	  from	  a	  GCA-­‐TA	  to	   a	   previously	   not	   infiltrated	   PMR-­‐TA.	   This	   effect	   was	  mediated	   by	   the	   activation	   of	  vascular	   dendritic	   cells,	   as	   shown	   by	   abrogating	   DC-­‐activation	   with	   an	   anti-­‐CD83	  antibody	   140.	   Vascular	   DCs	   have	   an	   inactivated	   phenotype	   in	   healthy	   arteries	   and,	  opposed	  to	  GCA-­‐arteries,	  do	  not	  express	  HLA-­‐DR	  149.	   	  Therefore,	  vascular	  DC	  activation	  likely	  followed	  by	  antigen	  presentation	  seems	  to	  be	  an	  early	  event	  of	  GCA	  pathogenesis.	  Moreover,	   transplantation	   of	   a	   healthy	   temporal	   artery	   followed	   by	   LPS	   injection	   and	  adoptive	  T	  cell	  transfer	  not	  only	  attracted	  T	  cells	  to	  the	  TA	  but	  fully	  mimicked	  a	  typical	  GCA-­‐artery	  phenotype	  150.	  	  	  Since	   especially	   TLR4-­‐stimulation	   through	   LPS	   induced	   a	   GCA	   phenotype,	   TLR	  expression	   analysis	   was	   carried	   out	   on	   a	   series	   of	   medium-­‐sized	   and	   large	   human	  arteries	   from	   different	   locations.	   The	   expression	   profile	   was	   very	   heterogeneous,	   but	  TLR4	  expression	  was	  ubiquitous,	   supporting	   its	   role	   in	  vascular	  DC	  activation	  but	  still	  not	  explaining	  why	  small	   vessels	  are	  never	  affected	  by	  GCA	   151.	  The	  vasa	  vasorum	  are	  required	   for	   blood	   supply	   to	   the	   vessel	   wall	   once	   a	   critical	   vessel	   diameter	   has	   been	  reached	   152.	   It	   has	   been	   shown	   that	   the	   adventitial	   vascular	   DCs,	   but	   not	   the	   intimal	  vascular	   DCs,	   are	   required	   for	   TLR4-­‐induced	   DC-­‐activation	   151.	   This	   could	   partially	  explain	   GCA	   tissue	   tropism	   to	  medium-­‐sized	   and	   large	   arteries	   only,	   since	   delivery	   of	  microbial	   particles	   through	   the	   vasa	   vasorum	   to	   activate	   adventitial	   DCs	   might	   be	  required.	  	  All	   this	   findings	   together	   with	   the	   strongly	   differing	   disease	   prevalence	   among	  ethnicities	  suggest	   that	  specific	  antigens	  are	  being	  presented	  and	  might	  be	  relevant	   in	  disease	   pathogenesis.	   Several	   infectious	   agents	   have	   been	   suggested	   as	   candidates;	  Parvovirus	   B19	   due	   to	   similar	   cyclic	   fluctuations	   in	   incidence	   like	   GCA	   153,	  Chlamydia	  
pneumoniae	   due	   to	   overlapping	   symptoms	   with	   GCA	   and	   serological	   findings	   154	   and	  
Varicella	  zoster	  virus	  (VZV)	  because	  of	  its	  ability	  to	  induce	  vasculitides	  155.	  Although	  the	  respective	  authors	  show	  PCR-­‐	  or	  histology-­‐based	  proof	  for	  presence	  of	  VZV	  in	  the	  GCA	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TAs,	   these	   findings	   have	   been	   challenged	   by	   others	   156,157.	   Functional	   proof	   for	   T	   cell	  reactivity	  towards	  any	  microorganism	  is	  lacking	  so	  far.	  	  This	   part	   of	   the	   thesis	   is	   dedicated	   to	   the	   investigation	   of	   antigen-­‐specific	   adaptive	  immune	  responses	  in	  GCA.	  Specifically,	  this	  included	  the	  following	  steps	  	   A) Assessing	  the	  reactivity	  of	  peripheral	  T	  cells	  against	  self-­‐	  and	  viral	  proteins,	  specifically	   from	  VZV	   being	   epidemiologically	   and	   histologically	   implicated	  in	  GCA	  pathogenesis	  (Bigler	  MB	  et	  al.,	  Arthritis	  &	  Rheumatology	  2018)	  B) Sequencing	   the	   TCR-­‐repertoire	   directly	   at	   the	   site	   of	   inflammation	   (TA,	  aorta)	   to	   investigate	   the	  presence	  of	  expanded	  clones	   that	  are	   indicative	  of	  antigen-­‐induced	  proliferation	  (Bigler	  MB	  et	  al.,	  unpublished	  data)	  C) Defining	   the	   role	   of	   autoantibodies	   against	   14-­‐3-­‐3	   protein	   that	   have	   been	  implicated	   in	   complicated	   large	   vessel	   vasculitis	   (LVV),	   a	   disease-­‐entity	  including	   also	   and	   most	   frequently	   GCA	   (Kistner	   A	   and	   Bigler	   MB	   et	   al.,	  Rheumatology	  2017)	  	  Given	   the	   importance	   of	   TLR4-­‐signalling	   in	   inducing	   the	   GCA	   phenotype,	   we	   also	  investigated	   the	   LPS	   plasma	   levels	   and,	   as	   a	   consequence,	   immune	   responses	   against	  gram-­‐negative	  bacteria	  in	  our	  cohort.	  These	  results	  are	  presented	  in	  the	  appendix.	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We thank Dr. Karim and colleagues for their thoughtful
comments on our article, including their mention of a patient
with longstanding IgG4-RD who developed secondary (AA)
amyloidosis, presumably as a consequence of well-established,
untreated inflammation (Karim F, Clahsen-van Groningen M,
van Laar JA. AA amyloidosis and IgG4-related disease. N Engl
J Med 2017;376:599–600). We completely agree with Karim
et al regarding the destructive nature of IgG4-RD that goes
undiagnosed, particularly its ability to cause both endocrine and
exocrine failure of the pancreas, end-stage liver disease from the
effects of biliary tract disease, chronic renal failure from the
effects of tubulointerstitial nephritis, vision loss and deleterious
cosmetic issues from orbital disease, chronic pain from retro-
peritoneal fibrosis, and so on.
Indeed, because IgG4-RD has been recognized as a
unique disease entity for less than 15 years, the full toll from
this condition in terms of damage from both the disease itself
and its therapy is still being described. We note that IgG4-RD
patients with elevated levels of serum CRP are the exception
rather than the rule (Wallace ZS, Deshpande V, Mattoo H,
Mahajan VS, Kulikova M, Pillai S, et al. IgG4-related disease:
clinical and laboratory features in one hundred twenty-five
patients. Arthritis Rheumatol 2015;67:2466–75). The more
common scenario is the finding of an extremely high ESR—the
effect of hypergammaglobulinemia of both IgG4 and IgG1
(and sometimes all 4 IgG subclasses)—in the setting of normal
CRP levels.
Because any indolent and chronic inflammatory state
can result in secondary amyloidosis, we agree that IgG4-RD in
the case reported by Karim and colleagues was likely related to
the subsequent development of amyloidosis. The current rarity
of secondary amyloidosis and the growing, but still inadequate,
awareness of IgG4-RD may partially explain why this was the
first published connection between these entities. To our knowl-
edge, serum amyloid A concentrations have not been measured
systematically in other cohorts, including in our own. The case
reported by Karim and colleagues underscores the importance
of early recognition of IgG4-RD and control of the associated
inflammation as early and as effectively as possible. The utility
of serum amyloid A as a biomarker of interest in IgG4-RD
requires further investigation.
Cory A. Perugino, DO




Varicella zoster virus–specific T cell responses in
untreated giant cell arteritis: comment on the article
by England et al
To the Editor:
Giant cell arteritis (GCA) is a large vessel vasculitis of
unknown cause. Although infections have long been suspected
to be potential disease triggers, a disease-causing pathogen has
not been identified to date (1). Recently, investigators in sev-
eral studies reported varicella zoster virus (VZV) particles in
artery biopsy specimens (2). Similar to other herpesviruses,
VZV has a very high prevalence and remains dormant in a
latent stage controlled by the immune system. Loss of T cell–
mediated virus control results in herpes zoster (shingles).
The study by England et al (3) now provides epidemio-
logic evidence for a potential association between VZV and
GCA. The authors used 2 independent health care provider data
sets (Medicare and MarketScan). In these databases, prior her-
pes zoster events were associated with a diagnosis of GCA (haz-
ard ratios 2.16 and 1.99 in the 2 data sets, respectively) (3). Use
of antiviral drugs or vaccination did not alter the risk of GCA.
T cells are important in the pathogenesis of GCA (4).
Genetic association studies and strict tissue tropism suggest that it
is an antigen-driven disease (4,5). The antigen could be either a
self antigen or a pathogen-derived antigen that is expressed only
in the large arteries. The immunopathology and epidemiologic
data implicate VZV as a potential immune target. We hypothe-
sized that cross-reactive VZV-specific T cell immunity may con-
tribute to the pathogenesis of GCA. If our hypothesis were shown
to be true, we expected the number of VZV-reactive Tcells to be
increased in patients with GCA compared to control patients.
We compared the frequency of VZV-specific peripheral
blood T cells in 32 patients, all of whom provided informed con-
sent to participate in our prospective GCA cohort study. These
patients included the following: 15 patients with newly diagnosed
GCA (all of whom had received prednisone treatment for < 5
days at the time of sample collection [median 0 days, mean 1
day]), 60% with biopsy-proven GCA, mean age 74.4 years), 10
control patients with inflammatory disease (5 with polymyalgia
rheumatica, 2 with autoinflammatory disease, 1 with aortitis, 1 with
myelodysplastic syndrome, and 1 with antineutrophil cytoplasmic
antibody–associated vasculitis (mean age 66.5 years), and 7 control
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patients with noninflammatory disease (mean age 72.0 years). We
quantified antigen-specific T cells using an interferon-c (IFNc)
enzyme-linked immunospot (ELISpot) assay. Live attenuated vari-
cella vaccine (200 plaque-forming units/ml) and the immunodomi-
nant glycoprotein E (1 lg/ml) were used as VZVantigens (6).
Additionally, we stimulated T cells with an aortic
explant–derived protein extract from a patient with GCA. This
represented a source for potential self and/or VZV antigens.
Aortic wall proteins were fractionated in phosphate buffered sa-
line by size-exclusion chromatography (Superdex 200 column;
GE Healthcare) into 5 pools (P1–P5), each of which was sepa-
rately added to the cells (range >500 kd [P1] to <10 kd [P5]; 10
lg/ml). Influenza vaccine antigen (0.4 lg/ml) was used as an
unrelated comparator. Staphylococcal enterotoxin B (0.5 lg/
ml)–treated wells served as a positive control. Preliminary exper-
iments indicated high reactivity with the aortic wall protein
extracts. To exclude nonspecific stimulation, we adapted the
standard IFNc ELISpot protocol (7) as follows: peripheral blood
mononuclear cells (PBMCs) (75,000/well) were preincubated
with the antigen overnight. On day 2, we added autologous
PBMCs (50,000/well), followed by incubation for 36 hours on
the ELISpot plates. This procedure reduced nonspecific IFNc
production. The response against viral antigens was not affected
(data not shown).
The median VZV (glycoprotein E, vaccine) and Flu-
(TIV) T cell reactivity was higher in patients with noninflamma-
tory disease compared to those with GCA, with no statistically
significant differences (Figure 1A). Control patients with nonin-
flammatory disease had stronger Tcell responses to aortic extract
(P = 0.0006 and 0.0036 for pools 4 and 5, respectively) (Fig-
ure 1B). Such reduced peripheral T cell reactivity could reflect
immunosenescence or exhaustion, which may result in loss of
VZV control. The responses in control patients with inflammatory
disease were, however, comparable to those in GCA patients. This
suggested that systemic inflammation might blunt the reactivity.
However, strong antigen-independent T cell stimulation with
phorbol myristate acetate resulted in comparable IFNc and inter-
leukin-17 effector functions in all 3 study groups (data not shown).
In conclusion, we observed no GCA-specific alterations
in VZV- or aortic protein–specific T cell reactivity. Our results
provide evidence against involvement of VZV-specific (or cross-
reactive) effector T cells in the pathogenesis of GCA. We
focused only on IFNc-producing T cells; other effector cells
might be present at different frequencies. It is further possible
that VZV- or aortic tissue–specific Tcells concentrate at the site
of inflammation. Thus, assessment of the peripheral blood com-
partment may miss these cells. This would, however, not explain
the comparable VZV- and aortic protein–reactive Tcell frequen-
cies in GCA and other inflammatory conditions.
In the study by England et al, only a minority (<6%) of
the GCA patients had a herpes zoster event in the year prior to
GCA diagnosis. Such patients may show Tcell reactivity profiles
distinct from those observed in our study population but the dif-
ferences might have been missed due to our small sample size.
However, based on the studies showing the presence of VZV in
almost all GCA biopsy specimens, we expected to observe a sig-
nal even when studying a small patient population. Notably, sev-
eral other groups of investigators observed no VZV, antigen, or
genome in temporal arteries (8–10). The truth probably lies
somewhere in between, and as stated in the England article,
VZV (and other viruses) may be a trigger for GCA but is not
the only one.
Supported by the Swiss National Science Foundation (SNSF)
(grant PZ00P3-173517 to Dr. Berger). Dr. Recher's work is supported by
SNSF grant PP00P3_144863. Dr. Mehling's work is supported by SNSF
grant PZ00P3_154733.
Marc B. Bigler, MSc





Christoph T. Berger, MD
University of Basel
and University Hospital Basel
Basel, Switzerland
1. Van Timmeren MM, Heeringa P, Kallenberg CG. Infectious trig-
gers for vasculitis. Curr Opin Rheumatol 2014;26:416–23.
2. Gilden D, Nagel MA. Varicella zoster virus triggers the immuno-
pathology of giant cell arteritis. Curr Opin Rheumatol 2016;28:
376–82.
3. England BR, Mikuls TR, Xie F, Yang S, Chen L, Curtis JR. Her-




Figure 1. Varicella zoster virus (VZV) T cell reactivity in patients with
giant cell arteritis (solid circles), control patients with inflammatory dis-
ease (shaded circles), and control patients with noninflammatory dis-
ease (open circles). A, T cell reactivity against VZV and influenza
vaccine, assessed by interferon-c enzyme-linked immunospot assay. B,
T cell responses to aortic wall proteins. Aortic wall proteins were frac-
tionated into 5 pools, and each pool was added separately to the cells.
Cells treated with medium alone were used for background correction.
Each data point represents a single patient. Horizontal lines show
the median. * = P < 0.05; ** = P < 0.01; *** = P < 0.001. SFC =
spot-forming cell; PBMC = peripheral blood mononuclear cell;
GlyE = glycoprotein E; Flu = influenza vaccine (vac) antigen.
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We thank Dr. Bigler and his colleagues for their interest
in our study and for sharing the results from their laboratory.
The authors proposed evaluating a biologic mechanism linking
VZV to GCA through assessment of cross-reactive VZV-specific
Tcell immunity, hypothesizing that the number of VZV-reactive
T cells would be increased in GCA patients relative to controls.
Using a small sample of GCA and control patients (with inflam-
matory or noninflammatory disease), the authors tested this
hypothesis through the quantification of VZV-specific T cells
and T cell reactivity (in response to stimulation with a protein
extract from an aortic tissue specimen obtained from a single
GCA patient) in vitro, finding no significant differences between
GCA and control patients.
In our study, prior herpes zoster reactivation was
observed in only a minority of GCA patients, which led to our
interpretation that despite our finding of a significant association
between GCA and herpes zoster, there was a low population-
attributable risk. Thus, one possible explanation for the null
findings by Bigler et al is that the protein extract from the single
GCA patient did not contain VZV or VZV cross-reactive
antigens.
As Bigler and colleagues point out (and we acknowl-
edged in our article), there have been conflicting reports on
the presence of VZV in the temporal arteries of GCA
patients. Given the epidemiologic associations observed in our
study, we look forward to additional translational research
studies investigating potential mechanistic links between VZV
and GCA.
Bryant R. England, MD
Ted R. Mikuls, MD, MSPH
University of Nebraska Medical Center
and Veterans Affairs Nebraska–
Western Iowa Health Care System
Omaha, NE
Jeffrey R. Curtis, MD, MS, MPH
University of Alabama at Birmingham
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Single-strain versus multistrain probiotic
supplementation treatment strategy for rheumatoid
arthritis: comment on the article by Marietta et al
To the Editor:
We read with interest the recent article by Marietta
et al on gut microbial dysbiosis as a key factor in the pathogen-
esis of inflammatory diseases such as rheumatoid arthritis (RA)
(1). Altered microbiota, well described in RA patients, seem
associated with perturbation of certain metabolic pathways, and
the therapies addressed to correct gut microbiome dysbiosis
could help in the maintenance of immune homeostasis of the
host (1).
In particular, the authors discussed the ability of Prevo-
tella histicola to modulate the systemic and mucosal immune
response (by suppression of antigen-specific Th17 responses
and increased transcription of interleukin-10) in an animal
model. On this basis, they suggested a possible role of this
human gut commensal in treatment strategies for RA (1).
According to the authors, a “single bacterium” is what
seems to make the “difference” in the balance of microbiota; in
our opinion, however, this should be a subject of discussion. In
fact, what they observed could just be the “readjustment of
the microbiota,” and the concept of Prevotella “monotherapy” is
potentially misleading, since the administration of this microor-
ganism as well as others could be just a way to induce a shift in
the balance of flora from proinflammatory to antiinflammatory.
In fact, even in the different setting of HIV disease, but notably
in human subjects, it has been shown that supplementing
antiretroviral therapy with Prevotella-free multistrain probiotics
(Streptococcus faecium and Streptococcus salivarius subspecies
thermophilus; bifidobacteria—represented by Bifidobacterium
breve, Bifidobacterium infantis, and Bifidobacterium longum; Lac-
tobacillus acidophilus, Lactobacillus plantarum, Lactobacillus
casei, and Lactobacillus delbrueckii subspecies bulgaricus [Alfa-
sigma]) reduces the levels of immune activation on CD4+ T lym-
phocytes for both of the markers CD38 and HLA–DR and their
simultaneous expression, with plasma levels of lipopolysaccha-
ride binding protein and high-sensitivity C-reactive protein nor-
malizing to values comparable to those in controls (2).
Multistrain probiotic supplementation (L plantarum [De Simone
Formulation {DSM} 24730], S salivarius subspecies thermophilus
[DSM 24731], B breve [DSM 24732], Lactobacillus paracasei
[DSM 24733], L delbrueckii subspecies bulgaricus [DSM 24734],
L acidophilus [DSM 24735], B longum [DSM 24736], B infantis
[DSM 24737] [DuPont]) is also associated with a reduction of
enterocyte apoptosis and density of intraepithelial lymphocytes,
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Introduction	  The	   histological	   findings	   of	   CD4+	   T	   cell	   infiltration	   and	   vascular	   DC	   activation	   in	  combination	  with	  the	  repeated	  detection	  of	  identical	  T	  cell	  clones	  in	  arteries	  at	  different	  locations	   and	   the	   disease	   association	   of	  HLA-­‐alleles	   highlight	   the	   relevance	   of	   CD4+	   T	  cells	   to	   disease	   pathogenesis.	   The	   seminal	   studies	   identifying	   identical	   clones	   in	   TA	  biopsies	  date	  back	  more	  than	  20	  years	  147,148.	  We	  hypothesized	  that,	  if	  specific	  antigens	  were	   recognized	   in	   the	   inflamed	   areas,	   dividing	   antigen-­‐specific	   T	   cells	   should	   be	  present.	   By	   means	   of	   high-­‐throughput	   sequencing,	   expanded	   dominant	   T	   cell	   clones	  could	   be	   detected	   and	   the	   presence	   of	   public	   clones	   investigated.	   This	   would	   inform	  subsequent	   analyses	   on	   both	   screening	   for	   antigens	   that	   may	   be	   targeted	   by	   the	  respective	  T	  cell	  clones	  and	  tracking	  disease-­‐associated	  TCRs	  in	  the	  peripheral	  blood	  as	  a	  biomarker	  for	  disease	  activity.	  We	  aimed	  at	  sequencing	  the	  TCR	  beta	  chain	  repertoire	  from	  TA	  biopsies	  or	  aorta	  explants	  from	  newly	  diagnosed	  GCA	  patients.	  Complementary,	  we	   performed	   TCR	   sequencing	   on	   matched	   bulk	   peripheral	   blood	   CD4+	   T	   cells	   and	  CCR6+/CD161+/	   CD4+	  T	   cells	   that	   have	   been	   found	   enriched	   in	   the	   affected	   vessels	   as	  well	  in	  the	  peripheral	  blood	  of	  GCA	  patients	  158.	  
	  
	  
Methods	  OCT-­‐embedded	   TA	   samples	   were	   cut	   into	   slices	   of	   20	   μM	   thickness.	   Granulomatous	  infiltration	  and	  the	  histological	  diagnosis	  of	  GCA	  had	  been	  confirmed	  previously	  by	  an	  experienced	   pathologist	   on	   H&E	   stainings.	   Isolation	   of	   gDNA	   was	   performed	   with	  QIAamp	  DNA	  micro	  kit	  (56304,	  Qiagen,	  Hilden,	  Germany	  -­‐	  protocol:	  Isolation	  of	  genomic	  DNA	  from	  tissues)	  including	  removal	  of	  OCT	  in	  the	  lysate	  supernatant	  with	  QIAshredder	  columns	   before	   ethanol	   precipitation.	   CD4+/CCR6-­‐/CD161-­‐	   (“bulk”)	   and	  CD4+/CCR6+/CD161+	   (“specific”)	   T	   cells	   were	   sorted	   by	   FACS	   (FACSAriaTM,	   BD	  biosciences,	   Franklin	   Lakes,	  NJ,	   USA).	   Antibodies	  were	   against	   CD3	   (PE,	   clone	  UCHT1,	  555333,	  BD	  biosciences),	  CD4	  (APC,	  clone	  OKT4,	  317416),	  CCR6	  (PE-­‐Cy7,	  clone	  G034E3,	  353418)	  and	  CD161	  (Alexa	  Fluor	  488,	  clone	  HP-­‐3G10,	  339924,	  all	  three	  Biolegend,	  San	  Diego,	  CA,	  USA).	  Genomic	  DNA	  from	  bulk	  T	  cells	  were	  isolated	  with	  QIAamp	  DNA	  blood	  mini	   kit	   (51106,	  Qiagen	   -­‐	   protocol:	  DNA	  purification	   from	  blood	  or	   body	   fluids),	   from	  specific	  T	   cells	  with	  QIAamp	  DNA	  micro	   kit	   (protocol:	   Isolation	  of	   genomic	  DNA	   from	  small	  volumes	  of	  blood).	  	  Amplification	   and	   sequencing	   of	   TCRB	   CDR3	   regions	   was	   performed	   using	   the	  immunoSEQ®	   Platform	   (Adaptive	   Biotechnologies,	   Seattle,	   WA).	   The	   immunoSEQ	  
Focus	  II:	  Unraveling	  antigen-­‐specific	  immune	  responses	  in	  giant	  cell	  arteritis	  
	   	  72	  
Platform	  combines	  multiplex	  PCR	  with	  high-­‐throughput	  sequencing	  and	  a	  sophisticated	  bioinformatics	  pipeline	  for	  recombination	  analysis	  159,160.	  	  A	  candida-­‐specific	  T	  cell	  line	  used	  to	  establish	  the	  clonal	  tracking	  PCR	  was	  a	  gift	  from	  C.	  Stühler.	  RNA	  was	  isolated	  with	  QIAamp	  RNA	  blood	  mini	  kit	  (52304,	  Qiagen)	  and	  cDNA	  was	   generated	   with	   GoScriptTM	   reverse	   transcriptase	   (A5003,	   Promega,	   Madison,	   WI,	  USA).	  To	  determine	   the	  TCR	  beta	  chain	  sequence	  /	  confirm	  that	   it	   is	  a	  clone,	  5’-­‐RACE-­‐PCR	  (5’/3’	  RACE	  kit,	  03	  353	  621	  001,	  Roche,	  Basel,	  Switzerland)	  was	  performed	  with	  the	  following	   primers	   targeting	   TRBC:	   Primer	   1:	   5’-­‐TTCCCATCAGCCGCCCAAACCTAA-­‐3’	  Primer	   2:	   5’-­‐ATCTGGAGTCATTGAGGGCG-­‐3’.	   VDJ-­‐recombination	  was	   assessed	  with	   the	  IMGT	   V-­‐Quest	   tool	   161	   and	   confirmed	   with	   primers	   TRBV04_fw	   5’-­‐CCTGAATGCCCCAACAGCTCTCTC-­‐3’	  ,	  TRBV07_fw	  5’-­‐TCTCAGGTGTGATCCAAATTCGGG-­‐3’	  and	  primer	  1.	  In	  vitro	  clonal	  tracking	  was	  performed	  by	  spiking	  1	  million	  down	  to	  1	  cell	  of	  the	  clonal	  cell	  line	  into	  1M	  PBMC	  of	  non-­‐related	  donors.	  Genomic	  DNA	  was	  isolated	  as	  described	  and	  clone	  gDNA	  amplified	  with	  GoTaq®	  qPCR	  master	  mix	  (A6001,	  Promega).	  Primers:	   K1_SYBR_F	   5’-­‐CCCAGTGATCGCTTCTCTGC-­‐3’;	   K1_SYBR_R	   5’-­‐GTCTCTCCCAATGAGAGGCTG-­‐3’.	  	  
	  
TCR-­‐sequencing	   indicates	   recent	   antigen	   encounter	   in	   GCA-­‐affected	  
arteries	  Due	   to	   the	   limited	   T	   cell	   number	   in	   the	   biopsies,	   it	   was	   not	   feasible	   to	   investigate	  antigen-­‐specific	   T	   cell	   responses	   at	   the	   site	   of	   inflammation,	   and	   these	   analyses	  were	  carried	  out	  on	  peripheral	  T	  cells	  (see	  part	  A).	  We	  tried	  to	  circumvent	  this	  limitation	  by	  a	  TCR-­‐centered	  approach.	  We	  could	  access	  OCT-­‐embedded	  (optimal	  cutting	  temperature,	  a	  synthetic	  resin)	  TA-­‐tissue	  to	  perform	  TCR	  analysis.	  Diagnostic	  TA-­‐biopsies	  of	  patients	  with	   suspected	   GCA	   are	   formalin-­‐fixed	   and	   paraffin-­‐embedded	   (FFPE).	   Attempts	   to	  perform	   TCR	   sequencing	   on	   such	   samples	   were	   impeded	   by	   too	   low	   DNA	   quality.	  Therefore,	  we	  adapted	  the	  protocol:	  if	  the	  patient	  gives	  informed	  consent,	  a	  part	  of	  the	  biopsy	  is	  embedded	  in	  OCT.	  Once	  the	  diagnosis	  of	  GCA	  is	  definite	  on	  the	  FFPE	  material,	  we	   can	   access	   the	   OCT	   tissue	   for	   research,	   containing	   far	   less	   damaged	   nucleic	   acids	  (Figure	  11A).	  	  The	   TCR	   beta	   chain	   repertoire	   of	   inflamed	   arteries	   (4	   TAs,	   1	   aorta),	   matched	   bulk	  peripheral	   CD4+	   T	   cells	   (“bulk”)	   and	   CD161+/CCR6+	   CD4+	   T	   cells	   (“specific”)	   was	  sequenced	  from	  five	  biopsy-­‐proven	  GCA-­‐patients	  (Gating	  strategy:	  Figure	  11B).	  	  
Focus	  II:	  Unraveling	  antigen-­‐specific	  immune	  responses	  in	  giant	  cell	  arteritis	  
	   	  73	  
	  	  
	  	  
Figure	  11:	  Preparation	  of	  genomic	  DNA	  from	  artery	  and	  peripheral	  T	  cells.	  A)	  Bioanalyzer	  profiles	  for	  gDNA	  fragments	  isolated	  from	  FFPE-­‐	  or	  OCT-­‐embedded	  temporal	  artery	  samples.	  The	  prominent	  peaks	  are	  DNA	  length	  markers.	  B)	  Gating	  strategy	  to	  sort	  for	  bulk	  and	  CCR6+/CD161+	  CD4+	  T	  cells	   for	   subsequent	  gDNA-­‐isolation.	  Cells	  were	  obtained	  before	  onset	  of	  glucocorticoid	  treatment.	  Gates	  are	  shown	  in	  red	  within	  doublet-­‐negative	  CD3+	  CD4+	  T	  cells.	  Figure	  created	  with	  FlowJo	  v.10,	  FlowJo,	  LLC.	  	  	  	  The	   proportion	   of	   clonally	   expanded	   T	   cells,	   indicative	   of	   recent	   or	   ongoing	   antigen	  encounter,	   is	   highest	   in	   the	   artery	   compartment	   in	   4	   out	   of	   5	   patients	  with	   the	  most	  expanded	  clone	  constituting	  between	  2.6%	  and	  7.2%	  of	  total	  TA/aorta	  TCR-­‐sequences.	  Some	   expanded	   clones	   in	   the	   TA	   are	   unique	   to	   this	   compartment,	  while	   others	   could	  also	   be	   found	   expanded	   in	   the	   CD161+/CCR6+	   and/or	   in	   the	   bulk	   CD4+	   T	   cells	   (see	  
Figure	   12A).	  Therefore,	   the	   clonal	   repertoire	   found	   in	   the	  TA	  does	  not	   simply	  mirror	  expanded	  clones	  in	  the	  bulk	  population	  but	  rather	  suggests	  a	  tissue-­‐specific	  expansion	  of	  T	  cells.	  Finally,	  we	  did	  find	  21	  public	  clones	  that	  were	  shared	  between	  a	  maximum	  of	  two	  donors,	  but	  none	  of	  them	  was	  expanded	  in	  both	  (Figure	  12B).	  	  	  	  A	  direct	  application	  of	  the	  detection	  of	  a	  patient-­‐specific	  expanded	  T	  cell	  clone	  could	  be	  to	  monitor	  such	  potentially	  harmful	  T	  cell	  clones	  over	   the	  disease	  course.	  To	  establish	  peripheral	  clonal	  T	  cell	   tracking,	  1	  million	  of	  PBMC	  of	  an	  unrelated	  donor	  were	  spiked	  with	  decreasing	  amounts	  of	  cells	  from	  a	  candida-­‐specific	  T	  cell	  clone.	  Across	  a	  range	  of	  one	  cell	  to	  a	  million,	  we	  could	  establish	  a	  detection	  sensitivity	  of	  1:100’000	  (Figure	  13).	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Figure	   12:	   T	   cell	   clonal	   overlap	   among	  
compartments	   and	   patients.	   A)	   Scatter	   plots	  showing	   frequency	  of	  expanded	  clones	  (at	   least	  two	   sequences)	   in	   the	   TA	   vs.	   bulk	   or	   specific	  compartments	   of	   a	   representative	   donor.	   The	  number	  and	  frequencies	  of	  clonotypes	  unique	  to	  the	   TA	   (blue),	   unique	   to	   the	   bulk	   or	   specific	  population	   (orange)	   or	   shared	   between	   two	  (purple)	   are	   depicted.	   Reading	   examples:	   The	  top	   expanded	  TA	   clone	   (red	   arrow)	   constitutes	  7.2%	  of	   total	  sequences,	  but	   is	  not	  expanded	   in	  the	  bulk	  or	  specific	  population.	  Another	  clone	  (blue	  arrow)	  is	  considerably	  expanded	  in	  all	  three	  compartments	  (Ranks:	  8	  (TA),	  2	  (specific),	  11(bulk).	  B)	  Venn	  diagram	  showing	  clonal	  overlaps	  between	  the	  four	  TA	  samples	  (aorta	  sample	  not	  shown	  due	  to	  space	  reasons).	  Expanded	  and	  not	  expanded	   clones	   are	   included.	   Reading	   example:	   GCA-­‐patient	   “red”	   shares	   seven	   out	   of	   1316	  clones:	   three	  with	   “yellow”,	   four	  with	   “blue”	   and	  none	  with	   “green”.	  All	   overlaps	  are	  on	  amino	  acid	   level	   with	   productive	   rearrangements	   only	   (=	   functional	   TCRs).	   Figures	   were	  made	   with	  immunoSEQ	  analyzer.	  	  	  	  
Figure	   13:	   A	   specific	   T	   cell	   clone	  
can	  be	  reliably	  detected	  at	  very	  low	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Characteristics of autoantibodies targeting 14-3-3
proteins and their association with clinical features in
newly diagnosed giant cell arteritis
Anne Kistner1,*, Marc B. Bigler1,*, Kathrin Glatz2, Simon B. Egli1, Fabian
S. Baldin3, Florian A. Marquardsen3, Matthias Mehling4, Katharina M. Rentsch5,
Daniel Staub6, Markus Aschwanden6, Mike Recher3,7, Thomas Daikeler8 and
Christoph T. Berger1,9
Abstract
Objectives. Autoantibodies are useful biomarkers for diagnosing and monitoring treatment in some auto-
immune diseases. Antibodies against isoforms of 14-3-3 protein have been proposed as biomarkers for
the presence of aortic aneurysm in large-vessel vasculitis (LVV). Here, we aimed to evaluate the diagnostic
role and potential immunopathological involvement of anti14-3-3 antibodies in newly diagnosed LVV
patients.
Methods. Antibodies against three isoforms of 14-3-3 (g, " and z) were measured in 90 subjects: 48 GCA
and 3 Takayasu’s arteritis (TA) patients, and 39 controls (non-inflammatory and inflammatory diseases),
using a multiplexed bead-based immunoassay and immunoprecipitation studies. The positive cut-off value
was defined based on young healthy controls. Anti14-3-3 IgG antibodies in LVV patients were compared
with those in controls in order to assess their diagnostic performance, and the relationship of anti14-3-3
IgG antibodies to the immunohistopathology of artery explants was assessed.
Results. Antibodies against all three 14-3-3 isoforms were detected in LVV patients as well as in age-
matched inflammatory and non-inflammatory controls. Among LVV patients, detection of antibodies tar-
geting 14-3-3 " and z was associated with more severe disease. Detection of antibodies against 14-3-3 g
was linked to latent Toxoplasma gondii infection, a parasite that secrets a 14-3-3 homologue, suggesting
potential cross-reactivity.
Conclusion. Detection of antibodies against 14-3-3 proteins at the time of LVV diagnosis is not disease-
specific. Their presence at high levels in LVV patients with stroke, aortitis and—in a previous study—an-
eurysm formation may indicate an association with extensive tissue destruction. The relevance of 14-3-3
antibodies in non-LVV patients needs to be investigated in larger cohorts.
Key words: large-vessel vasculitis, giant cell arteritis, Takayasu’s arteritis, autoantibodies, 14-3-3 proteins,
aortic aneurysm, multiplex, protein pulldown, toxoplasmosis, stroke
Rheumatology key messages
. Antibodies against 14-3-3 isoforms are detectable in newly diagnosed GCA, but also in age-matched disease
controls.
. Antibodies against human 14-3-3g and 14-3-3 secreted by Toxoplasma might cross-react in GCA.
. Presence of anti14-3-3" and anti14-3-3z in large-vessel vasculitis is associated with aortitis and stroke.
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Several autoimmune diseases are defined by autoantibo-
dies in the context of agreeing clinical presentations. SLE
and ANCA-associated vasculitis (AAV) are paradigmatic
diseases, where the presence of anti-DNA antibodies
and ANCA, respectively, are useful in diagnosis, patient
stratification or treatment decisions [1]. To date, no such
biomarker exists in large-vessel vasculitis (LVV) syn-
dromes, that is, Takayasu’s arteritis (TA) and GCA. LVV
patients present with a systemic inflammatory syndrome
and variable ischaemic symptoms induced by vascular
occlusion [2]. The aetiology remains unknown, but both
innate and adaptive immune dysregulation has been
implicated in the immunopathogenesis [3]. Diagnosing
LVV can be challenging; hence, there is a strong need
for biomarkers as diagnostic tools and for guiding clinical
decisions.
Recently, Chakravarti et al. [4] reported autoantibodies
against 14-3-3 proteins in sera of LVV patients who under-
went surgical aortic aneurysm repair. Thoracic aortic an-
eurysm formation is a late complication of GCA, often
manifesting years after diagnosis [5]. In the majority
(78%) of these selected LVV patients, antibody reactivity
against a protein of the aortic wall, identified as the ", z
and—to a lesser extent—g isoforms of the 14-3-3 protein
was detected. Since these autoantibodies were largely
absent in controls (non-inflammatory aortic aneurysms
and inflammatory disease controls such as SLE or AAV),
the authors concluded that anti14-3-3 antibodies could
be used as biomarkers and might be involved in
LVV pathogenesis or aneurysm formation. Whether
anti14-3-3 antibodies are causally involved in aneurysm
formation, or a consequence of immune damage in LVV-
associated aneurysms, was not addressed in this study.
Here we explored the diagnostic potential of anti14-3-3-
IgG antibodies in LVV, and assessed their potential role in
disease pathogenesis.
Methods
Clinical cohort and controls
This study was IRB approved (Ethics Committee of
Northwest and Central Switzerland 239/09), and all parti-
cipants gave informed consent in accordance with the
Declaration of Helsinki. A total of 90 subjects were inves-
tigated: 48 GCA and 3 TA patients; 20 inflammatory dis-
ease controls (mostly patients with initial suspicion of LVV
that was not confirmed), 9 age-matched non-inflamma-
tory disease controls and 10 healthy volunteers <40
years old. Detailed patient characteristics are given in
supplementary Tables S1 and S2, available at
Rheumatology Online.
Multiplexed fluorescent bead-based immunoassay
Anti14-3-3 isoform IgGs [4] were measured with a cus-
tomized multiplexed bead-based immunoassay. The 14-
3-3 isoforms g (Abcam, ab166880), " (Sigma-Aldrich,
E2033; and Abcam, ab73802) and z (Sigma-Aldrich,
Z3402) were coated on Magnetic MagPlex-microspheres
(Luminex). Beads coated with an influenza haemagglutinin
[Wisconsin 67/2005 (Sino Biologicals, 11972-V08H)]
served as a non-related antigen control, and BSA-
coated beads as negative controls. Multiplexed bead
assays were performed with 10-fold-diluted plasma
according to the Luminex xMAP Cookbook. Anti-human
IgG-phycoerythrin (PE) (SouthernBiotech, #1030-09) was
used for detection, and a polyclonal pan-anti14-3-3 [Cell
Signaling Technology (CST), #8312] as a positive control
on a Luminex-200 system (xPONENT software). Results
were expressed as background-corrected median fluor-
escence intensities (MFIs): [MFIexperimental]  [MFIBSA]. For
the correlations with clinical findings, the positive cut-off
was defined as >(mean + 3 S.D.) of the young healthy con-
trols. In selected samples with anti14-3-3 antibodies
detectable above threshold, plasma was serially diluted
to determine the antibody titre, defined as the last dilution
at which 14-3-3 antibodies were detectable.
Immunoprecipitations of 14-3-3 antibodies
To immunoprecipitate 14-3-3 antibodies, plasma samples
were diluted 10-fold in PBS to 100 ml and supplemented
with 20 ml of protein Acoated agarose beads (CST,
#9863). After antibody pull-down for 2 h on a rotating
wheel at 4 C, beads were washed, and incubated in
100 ml PBS with 1 mg of the recombinant human 14-3-3
isoforms overnight at 4 C under constant rotation. After
washing and boiling, eluates were analysed by western
blotting using polyclonal pan-anti14-3-3 detection
antibody.
Measurement of total IgG and Toxoplasma-specific IgG
Total IgG was measured using a ready-to-use ELISA
(ZeptoMetrix Corporation, Cat. No. 0801197). The
Toxoplasma-specific IgG (threshold for positivity>6.5 IU/
ml) was measured using an automated chemilumines-
cence immunoassay (Immulite2000 Siemens).
Protein sequence and structure analysis
Amino acid sequences of human 14-3-3g (NP_036611), 14-
3-3" (NP_006752), 14-3-3z (NP_001129174) and secreted
T. gondii 14-3-3 (BAA25996) were aligned with Clustal
Omega (European Bioinformatics Institute). Amino acids
containing potential cross-reactive antibody-binding sites
between human and the T. gondii 14-3-3 isoforms were
defined as: identical or of the same category (i.e. acidic/
basic, polar/non-polar) between Toxoplasma and the
respective human isoform, but different amino acid cate-
gory in the two other isoforms (supplementary Fig. S1,
available at Rheumatology Online). Positions of candidate
amino acids in the respective isoforms were visualized with
PyMOL (v. 1.7, Schro¨dinger LLC) in the following pdb-files:
2B05 (14-3-3g), 3UAL (14-3-3") and 4WRQ (14-3-3z).
Histology and semi-quantitative analysis of the inflamma-
tory infiltrate
Temporal artery biopsies (n= 11) from biopsy-proven GCA
and large-vessel explants (LVEs) (n= 4: three aortae, one
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carotid artery) from two GCA and two TA patients were
stained with HE (haematoxylin/eosin), or immunohisto-
chemistry to quantify B cells (anti-CD20, Clone L26;
Ventana/Roche 760-2531) and plasma cells (anti-CD138,
Clone: B-A38; Ventana/Roche 760-4248) was performed.
Inflammation was scored using a 5-point score: 0 for no
positive lymphocytes/CD20+ B cells/CD138+ plasma cells;
1 for occasional positive cells; 2 for a moderate number; 3
for a large number; or 4 for a very large number of positive
cells [6].
Statistical analysis
Multiple groups were compared using non-parametric
group comparison (KruskalWallis test) with Dunn’s cor-
rection. Spearman ranks correlation was performed to
test for a correlation between anti14-3-3 IgG levels
assessed by western blot vs multiplexed bead-assay.
Chi-square tests were applied to compare clinical mani-
festations between different groups.
Results
Detection of antibodies against 14-3-3 isoforms in newly
diagnosed GCA and control groups
Compared with the cut-off defined in young, healthy
volunteers, we detected elevated 14-3-3-specific antibo-
dies against the g, " and z isoforms in 12, 30 and 30% of
GCA, and 0, 67 and 67% of TA patients, respectively
(Fig. 1A and supplementary Fig. S2, available at
Rheumatology Online). Frequency of a positive test (ser-
oprevalence) and the absolute antibody levels were not
higher in GCA patients when compared with age-matched
inflammatory or non-inflammatory controls. Moreover,
antibody levels in five GCA patients with longer-lasting
disease were not higher than in recently diagnosed
patients (Fig. 1A). Notably, antibody titres were also simi-
lar in GCA and controls (supplementary Fig. S3, available
at Rheumatology Online), and the results were compar-
able when only including GCA subjects without any prior
glucocorticoid treatment. Data from antibody immunopre-
cipitation assays [4] correlated well with the MFI obtained
in the multiplex assay, thus validating our findings (Fig. 1B
and C). Notably, binding reactivity of anti14-3-3-IgG was
relatively low, as indicated by comparison with the reac-
tivity of IgG binding with an influenza protein, and showed
no increase over the first year after diagnosis (Fig. 1D).
High levels of anti-14-3-3, but not " or , antibodies was
associated with latent Toxoplasma infection
The concept of molecular mimicry proposes that a patho-
gen-specific immune response cross-reacts against self-
proteins. Toxoplasma gondii, a widespread opportunistic
parasite causing asymptomatic latent infection in immu-
nocompetent hosts, has been linked to autoimmune dis-
eases, including vasculitis [7]. This parasite secretes a
14-3-3 homologue, and detection of anti14-3-3 antibo-
dies in patients with recent Toxoplasma infection has been
reported [8]. Therefore, we next tested whether subjects
with high anti14-3-3 responses were more likely to be
Toxoplasma seropositive. In the entire cohort,
antiToxoplasma-IgG was detected in 48% (40 of 83
tested). Intriguingly, 14-3-3g antibody-positive subjects
were significantly enriched for Toxoplasma seropositivity
compared with 14-3-3g antibody-negative subjects (80%
vs 40.6%, P= 0.008; Fig. 2A). In contrast, when stratified
based on antibody-positivity against 14-3-3" or 14-3-3z,
no difference was observed (Fig. 2A). All three 14-3-3 iso-
forms have a sequence similarity of 7476% to the
Toxoplasma isoform. Searching for evidence of potential
cross-reactivity, we compared the sequences of the dif-
ferent isoforms and mapped amino acids diverging
between Toxoplasma/14-3-3g vs 14-3-3"/14-3-3z on the
3D protein structure. Indeed, a cluster of three amino
acids, conserved between the Toxoplasma 14-3-3 and
14-3-3g protein, was arranged in close proximity to each
other (Fig. 2B). No similarly enriched region was detected
between Toxoplasma 14-3-3 and the other human
isoforms (supplementary Fig. S4, available at
Rheumatology Online). The seroprevalence and the in
silico structural analysis combined suggested that anti-
14-3-3g responses might, to some extent, be driven by
cross-reactive antiToxoplasma-14-3-3 antibodies.
Are 14-3-3 antibodies the consequence of tissue remo-
delling in complicating large-vessel inflammation?
Thoracic aortic aneurysm occurs in 12% of GCA
patients as a late complication [5]. Since autoantibodies
can be induced secondarily via antigen release from
damaged tissue, and in light of the report of high preva-
lence of 14-3-3" and 14-3-3z antibodies in subjects with
manifest aneurysm [4], we assessed whether these anti-
bodies were associated with clinical manifestations. We
found that 71% (10/14) of patients with anti-14-3-3" who
underwent imaging of the aorta (i.e. MRI, PET-CT or CT,
which was performed in 38 out of the 52 LLV patients) had
a finding compatible with aortitis (Fig. 2C), while this was
only the case in 29% (7/24) of those with anti-14-3-3"
below the threshold. Moreover, four out of 52 LVV patients
had a stroke, all were anti-14-3-3" positive, and three
were also 14-3-3-z positive (Fig. 2D). Other clinical fea-
tures, including cardiovascular risk factors, jaw claudica-
tion, vision disturbances, polymyalgia or inflammation
markers were equally distributed (data not shown).
Interestingly, B cells and plasma cells, that is, potential
sources of autoantibodies, were more abundant in LVEs
of patients with aortitis or carotis affection as compared
with inflamed temporal artery biopsies (Fig. 2E and F), and
tertiary lymph follicles—indicative of a locally induced
immune response—were almost exclusively found in the
LVE (Fig. 2G).
Discussion
Availability of a specific diagnostic or prognostic biomar-
ker is an unmet need in LVV. Anti-14-3-3 antibodies have
been found in LVV patients with aortic aneurysm. Here we
tested for such antibodies in GCA and TA patients at
the time of diagnosis. We found that antibodies against
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14-3-3 isoforms were detectable in LVV patients, but are
also present at similar levels and with comparable fre-
quency in age-matched controls, limiting their use as
diagnostic biomarkers.
In contrast to the study by Chakravarti et al., our
patients were sampled at the time of diagnosis, and only
two patients had aortic aneurysm. Thus, our study does
not inform whether high anti-14-3-3 IgG levels present
early in disease may be involved in subsequent aneurysm
formation. However, increased reactivity against 14-3-3z
and 14-3-3" proteins in patients with LVV-associated thor-
acic aortic aneurysms may also be elicited following the
release of the respective immunological targets in the set-
ting of severe aortic damage. In this scenario, an inflam-
matory process would be a prerequisite for autoantibody
formation, as Chakravarti et al. found no 14-3-3 antibodies
in controls with non-inflammatory aneurysm. Although
anti-14-3-3 antibodies were not LVV-specific, antibodies
targeting 14-3-3z and 14-3-3" were more frequent in
patients with aortitis (14-3-3") and/or stroke (14-3-3z
and 14-3-3"), compatible with a model where 14-3-3 auto-
antibodies were induced as a consequence of tissue
damage. Notably, in conditions associated with destruc-
tion of neuronal tissue, substantial amounts of variable 14-
3-3 isoforms—including ", g and z—can be released [9,
10], and 14-3-3 was upregulated in inflamed parts of the
aorta [4]. This might directly impact tissue remodelling,
because 14-3-3 release influences activity of MMPs [11],
which likewise are crucial in LVV pathogenesis [12]. The
finding of lymph-follicles in the wall of large arteries further
hints at a locally triggered immune response by antigens
released in damaged vasculitis-associated tissue. It is
possible that other forms of (vascular) tissue damage,
such as arteriosclerosis, explain increased anti-14-3-3
antibody levels in age-matched controls. The present
study was, however, underpowered to perform these rele-
vant subgroup analyses.
Intriguingly, subjects with antibodies against the 14-3-
3g isoform had a high seroprevalence of T. gondii com-
pared with the general population (3050% Toxoplasma
FIG. 1 Anti14-3-3-IgG in newly diagnosed GCA
(A) Isoform-specific anti14-3-3-IgG levels [median fluorescence intensity (MFI)] in GCA patients, including some with
long-standing disease (closed circles), TA, inflammatory (IFNL), non-inflammatory (non-IFNL) and young healthy controls
(*P< 0.05). Dotted line indicates positivity cut-off. (B) Example western blots from immunoprecipitation of 14-3-3 iso-
formspecific-IgG from a GCA and a TA patient. (C) Correlation with multiplex assay. n = 42 measurements (i.e. isoforms
g, e, z) in 14 patients. (D) Longitudinal anti14-3-3 and influenza haemagglutinin-IgG (Flu) in a subset of n= 13 anti14-3-
3-IgGpositive GCA patients at diagnosis. TA: Takayasu’s arteritis.
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FIG. 2 Clinical associations with 14-3-3 antibody positivity
(A) Toxoplasma gondii seroprevalence in patients with/without 14-3-3 IgG (percentage per group). (B) The 14-3-3 crystal
structure: ‘dark grey’ = conserved between isoforms; ‘red’ = identical and ‘yellow’ = similar amino-acids only between
Toxoplasma and human 14-3-3g. Potential cross-reactive bindingsite Toxoplasma/human 14-3-3g is illustrated in higher
magnification. Anti14-3-3-IgG positivity associated with aortitis (C) and stroke (D) in LVV (percentage with event stra-
tified by anti14-3-3-IgG positivity/negativity). (E) Large-vessel explants (LVEs, n= 4) and temporal artery biopsy (TAB,
n= 11) were compared in HE, B cell (CD20) and plasma cell (CD138) stainings using (F) a score from 0 (no inflammation)
to 4 (strong inflammation). LVV: large-vessel vasculitis; HE: haematoxylin/eosin.
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IgG positive) [13, 14], raising the possibility of cross-
reactive antibodies. Indeed, we found a potentially immu-
nogenic region shared between the Toxoplasma and the
human 14-3-3g protein—but not the other two iso-
forms—thus precluding anti14-3-3g-IgG as a widely
applicable biomarker. Cross-reactivity with other existing
14-3-3 isoforms cannot be excluded based on our data,
and may be a general limitation to their use in populations
with high Toxoplasma seroprevalence.
Whether the presence of 14-3-3" and/or z antibodies
precedes aortic aneurysm formation in LVV, and/or may
be present in elderly patients with other inflammatory
large-vessel disease, including extensive arteriosclerosis,
needs to be tested longitudinally in large cohorts. This
could validate anti-14-3-3 antibodies as a potential aneur-
ysm biomarker, helping patient stratification for follow-up
imaging studies, and possibly indicating patients that
might benefit from B celldepleting strategies in addition
to conventional therapy.
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TA	   INFL	   non-­‐INFL	   young	  healthy	  
Patients,	  n	   43	   5	   3	   20	   9	   10	  
Age,	  years,	  	  
median	  (range)	  
75	  	  (56-­‐91)	  	   71	  	  (63-­‐75)	  	   31	  	  (19-­‐53)	   63	  	  (49-­‐86)	   72	  	  (59-­‐76)	   29	  	  (25-­‐38)	  
Sex,	  female,	  
n	  (%)	   25	  (58)	   5	  (100)	   3	  (100)	   11(55)	  	   3	  (33)	   3	  (30)	  
PDN	  treated	  samples,	  
n	  (%)	   20	  (46)	   5	  (100)	   2	  (66)	   3	  (15)	   1	  (11)	   0	  (0)	  
Days	  on	  PDN,	  	  	  
median	  (range)	  
0	  	  (0-­‐38)	   Years	   Years	   0	  	  (0-­‐17)	   0	  	  (0-­‐18)	   ND	  
Histologya	  done,	  
n	  (%)	   39	  (91)	   4	  (80)	   	  2	  	  (67)	   9	  (44)	   2	  (22)	   ND	  Histologically	  confirmedb,	  	  n	  (%)	   30/39	  (77)	   3/4	  (75)	   2/2	  (100)	   0/9	  (0)	   0/2	  (0)	   ND	  
CRP	  in	  mg/l,	  	  
median	  (range)	   63	  	  (10-­‐364)	   86	  	  (9-­‐184)	   8.6c	   71	  	  (4-­‐152)	   1.5	  	  (0.3-­‐3)	   ND	  
ESR	  in	  mm/h,	  	  
median	  (range)	   76	  	  (14-­‐120)	   86	  	  (20-­‐98)	   56c	   	  61	  	  (10-­‐120)	   8	  	  (1-­‐24)	   ND	  
active	  PMR	   16	  (37)	   1	  (20)	   0	  	  (0)	   13	  	  (65)	  	   0	  (0)	   0	  (0)	  
a	  includes	  temporal	  artery	  biopsies	  and	  large	  vessel	  explants;	  b	  n=	  biopsy	  positives	  of	  those	  who	  had	  a	  biopsy.	  c	  CRP	  and	  ESR	  at	  time	  of	  study	  blood	  draw	  only	  available	  for	  1/3,	  but	  these	  were	  in	  stable	  disease	  for	  >6	  months.	  TA:	  Takayasu	  arteritis;	  INFL:	  inflammatory	  control;	  non-­‐INFL:	  non-­‐inflammatory	  control;	  PDN:	  prednisone;	  ND:	  not	  done	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AION:	  anterior	  ischemic	  optic	  neuropathy	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
	   	  
Inflammatory	  Controls	  (n=20)	   n	  cases	  
PMR	  /	  atypical	  PMR	   12	  
Periaortitis	  /	  Aortitis	   2	  
ANCA-­‐associated	  Vasculitis	   1	  
Inflammatory	  Syndrome	   1	  
Interstitial	  Pneumopathy/-­‐itis	   1	  
Tooth	  infection	  and	  abscess	  	   1	  
Metastatic	  prostate	  cancer	   1	  
Infection	  &	  chronic	  neck	  pain	   1	  
Non-­‐inflammatory	  Controls	  (n=9)	   	  
chronic	  pain	  disorder	   3	  
Non-­‐inflammatory	  shoulder	  pain	   2	  
Tendinopathy	   1	  
cardioembolic	  AION	   1	  
non-­‐inflammatory	  stroke	   1	  
Check-­‐up	   1	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Supplementary	  Figure	  S1:	  Linear	  alignment	  of	  the	  amino	  acid	  sequences	  of	  the	  
human	  and	  Toxoplasma	  gondii	  14-­‐3-­‐3	  isoforms	  
	  Multiple	  sequence	  alignment	  of	  Toxoplasma	  gondii	  14-­‐3-­‐3	  and	  the	  human	  γ,	  ε	  and	  ζ	  isoforms	  is	  shown.	  Amino	  acids	  identical	  between	  all	  four	  proteins	  are	  depicted	  with	  an	  asterisk.	  Amino	  acids	  of	  interest	  are	  shown	  for	  the	  comparison	  Toxoplasma	  /	  14-­‐3-­‐3γ.	  The	  color	  code	  corresponds	  to	  the	  coloring	  used	  in	  Figure	  2B:	  conserved	  regions	  are	  shown	  in	  grey;	  Amino	  acids	  being	  identical	  between	  Toxoplasma	  and	  14-­‐3-­‐3γ	  but	  having	  a	  different	  class	  in	  14-­‐3-­‐3ε	  and	  -­‐ζ	  are	  highlighted	  in	  red.	  Those	  being	  biochemically	  similar	  (i.e.	  in	  terms	  of	  charge,	  polarization,	  etc…)	  between	  Toxoplasma	  and	  14-­‐3-­‐3γ	  (e.g.	  D	  and	  E,	  two	  acidic	  amino	  acids)	  but	  having	  a	  different	  class	  in	  14-­‐3-­‐3ε	  and	  -­‐ζ	  are	  shown	  in	  yellow.	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Toxoplasma I P K T S - - D S E S K V F Y Y K M K G D Y Y R Y I S E F S G E E G K K Q A A D Q A Q E S Y Q K A T E T A E A E L P S T
14-3-3 γ I K N C S E T Q Y * * * * * * L * * * * * * Y * * L A * V A T G E K R A T V V E S S E K A * S E A H E I S K E H M Q P *
14-3-3 ε I P A A N - - T G * * * * * * Y * * * * * * H * * L A * F A T G N D R K E A A E N S L V A * K A A S D I A M T E L P P *
14-3-3 ζ I P N A S - - Q A * * * * * * L * * * * * * Y * * L A * V A A G D D K K G I V D Q S Q Q A * Q E A F E I S K K E M Q P *
Toxoplasma H P I R L G L A L N Y S V F F Y E I L N L P Q Q A C E M A K R A F D D A I T E F D N V S E D S Y K D S T L I M Q L L R D
14-3-3 γ * * * * * * * * * * Y * * * Y * * * Q * A * E Q * * H L * * T * * * D * * A * L * T L N * D * * * * * * * * * * * * * *
14-3-3 ε * * * * * * * * * * F * * * Y * * * L * S * D R * * R L * * A * * * D * * A * L * T L S * E * * * * * * * * * * * * * *
14-3-3 ζ * * * * * * * * * * F * * * Y * * * L * S * E K * * S L * * T * * * E * * A * L * T L S * E * * * * * * * * * * * * * *
Toxoplasma N L T L W T -
14-3-3 γ * * * * * * -
14-3-3 ε * * * * * * -
14-3-3 ζ * * * * * * S
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Supplementary	  Figure	  S2:	  Seroprevalence	  of	  14-­‐3-­‐3	  antibodies	  was	  comparable	  
between	  LVV	  and	  controls.	  
	  An	  antibody	  level	  above	  mean+3SD	  of	  the	  young	  healthy	  group	  was	  considered	  as	  positive.	  TA	  patients	  had	  no	  14-­‐3-­‐3γ	  antibodies	  but	  2/3	  had	  antibodies	  against	  one	  of	  the	  other	  isoforms.	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Supplementary	  Figure	  S3:	  Anti-­‐14-­‐3-­‐3	  antibody	  titers	  are	  not	  higher	  in	  LVV	  
compared	  to	  age-­‐matched	  controls.	  	  
	  Twofold	  serial	  dilutions	  of	  plasma	  of	  patients	  with	  high	  14-­‐3-­‐3	  antibodies	  against	  (A)	  14-­‐3-­‐3γ,	  (B)	  14-­‐3-­‐3ε	  and	  (C)	  14-­‐3-­‐3ζ	  were	  performed	  to	  determine	  the	  titer.	  Positivity	  was	  defined	  as	  mean+3SD	  of	  the	  10	  young	  healthy	  controls.	  To	  increase	  the	  power,	  GCA	  and	  TA	  patients	  were	  merged	  to	  a	  LVV	  group	  and	  all	  controls	  were	  merged	  to	  a	  control	  group.	  LVV:	  large	  vessel	  vasculitis;	  CTRL:	  control	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Supplementary	  Figure	  S4:	  Conservation	  visualization	  of	  the	  different	  human	  and	  
Toxoplasma	  14-­‐3-­‐3	  isoforms	  
The	  crystal	  structure	  of	  the	  human	  14-­‐3-­‐3ε	  (A)	  and	  human	  14-­‐3-­‐3ζ	  protein	  (B)	  are	  shown	  from	  the	  same	  perspective.	  Specific	  regions	  were	  color-­‐coded	  analog	  to	  Figure	  2B:	  Surface	  stained	  in	  dark	  grey	  depicts	  conserved	  regions.	  Amino	  acids	  are	  highlighted	  in	  color,	  when	  they	  are	  identical	  (red)	  or	  similar	  (same	  amino	  acid	  class,	  yellow)	  in	  
Toxoplasma	  14-­‐3-­‐3	  and	  14-­‐3-­‐3ε,	  but	  different	  in	  14-­‐3-­‐3γ	  and	  -­‐ζ	  (A)	  or	  identical	  in	  in	  
Toxoplasma	  14-­‐3-­‐3	  and	  14-­‐3-­‐3ζ,	  but	  different	  in	  14-­‐3-­‐3γ	  and	  -­‐ε	  respectively	  (B).	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Discussion	  	  
	   	  
Antigen-­‐specific	  responses	  in	  GCA	  A	   straightforward	  way	   to	   investigate	   Th1	   cell	   reactivity	   against	   specific	   antigens	   is	   to	  measure	   IFN-­‐γ	   production	   upon	   exposure	   to	   antigen	   presented	   on	  APC.	   Among	   other	  pathogens,	   Varicella	   zoster	   virus	   (VZV)	   has	   been	   implicated	   in	   GCA	   pathogenesis	   155.	  When	  PBMC	  were	  directly	  exposed	  to	  unprocessed	  self-­‐proteins,	  IFN-­‐γ	  production	  was	  extremely	  high,	  indicating	  TCR-­‐independent	  activation.	  This	  prompted	  us	  to	  use	  a	  two-­‐step	   protocol	   were	   we	   pre-­‐incubated	   PBMC	   (including	   APC)	   with	   antigen	   over	   night,	  washed	   the	   cells	   and	   added	   them	   to	   autologous	   PBMC	   on	   anti-­‐IFN-­‐γ	   coated	   EliSpot	  plates.	   The	   investigated	   antigens	  were	   recombinant	   VZV	   Glycoprotein	   E,	   shown	   to	   be	  highly	   immunogenic	   162,	   a	   vaccine	   preparation	   against	   VZV	   (Varilrix),	   an	   influenza	  vaccine	  (Fluarix)	  or	  SEB	  (staphylococcal	  enterotoxin	  B)	  as	  positive	  controls	  and	  5	  pools	  of	  aortic	  wall-­‐derived	  proteins	  as	  a	  source	  of	  autoantigen.	  	  	  The	  most	   informative	  procedure	  would	  have	  been	   to	   interrogate	  TA-­‐derived	  T	  cells	   in	  the	   EliSpot	   assay.	   Indeed,	   it	   has	   been	   shown	   that	   T	   cell	   clonotypes	   are	   present	   in	   the	  inflamed	   TA	   that	   react	   towards	   GCA-­‐TA	   extracts	   but	   not	   towards	   control	   extracts	   148.	  These	  assays	  were	  done	  on	  in	  vitro	  expanded	  T	  cells	  that	  migrated	  out	  of	  the	  TA.	  Such	  an	  approach	  is	  not	  applicable	  to	  larger	  screens	  in	  a	  GCA	  cohort	  or	  as	  a	  potential	  test	  in	  the	  clinic.	  Peripheral	  blood	  EliSpots	  on	  the	  other	  hand	  are	  broadly	  used	  in	  the	  clinic	  and	  in	  clinical	  trials	  to	  test	  for	  previous	  antigen	  encounter	  including	  VZV	  163.	  Compared	  to	  age-­‐matched	  inflammatory	  disease	  controls	  or	  healthy	  controls,	  we	  did	  not	  find	  an	  increase	  in	   the	   number	   of	   autoantigen-­‐	   or	   VZV-­‐specific	   T	   cells	   in	   newly	   diagnosed	   GCA.	   GCA	  patients	  were	  rather	  hyporesponsive	  towards	  certain	  antigens.	  This	  could	  potentially	  be	  due	  to	  the	  context	  of	  an	  acute	  systemic	  inflammation.	  We	  also	  cannot	  exclude	  that	  VZV-­‐	  or	  arterial	  wall-­‐specific	  T	  cells	  were	  exhausted	  (e.g.	  due	   to	  repeated	   in	  vivo	   exposure),	  but	   we	   would	   have	   expected	   increased	   responses	   in	   at	   least	   some	   patients	   if	   these	  antigens	  were	  relevant	  to	  GCA	  pathogenesis.	  	  	  Our	  TCR-­‐centered	  approach	  therefore	  was	  chosen	  to	  zoom	  right	  into	  the	  inflamed	  tissue	  compartment	   and	   bears	   the	   potential	   to	   help	   elucidating	   the	   nature	   of	   the	   antigen	  targeted	  by	  specific	  T	  cells	  in	  the	  TA.	  Given	  the	  distinct	  distribution	  of	  clones	  in	  the	  TA	  compared	   to	   bulk	   CD4+	   T	   cells,	  we	   potentially	   have	  missed	   disease-­‐relevant	   clones	   in	  our	  peripheral	  T	  cell	  EliSpot.	  Since	  we	  found	  at	  least	  one	  strongly	  expanded	  T	  cell	  clone	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in	  every	  donor,	  this	  gives	  the	  opportunity	  to	  match	  the	  corresponding	  TCR	  alpha	  chain	  sequence	  based	  on	  its	  frequency	  when	  also	  sequencing	  the	  TCR	  alpha	  chain	  repertoire.	  This	   will	   enable	   us	   to	   reveal	   the	   sequence	   of	   the	   complete	   TCR	  which	   then	   could	   be	  transfected	   into	  TCRαβ-­‐deficient	   Jurkat	  T	  cells	   164.	  These	   transgenic	  T	  cell	   lines	  can	  be	  used	  as	  reporter	  cell	   lines	   to	   test	  peptide	   libraries	   for	  reactivity	  against	  antigens	   in	  an	  HLA-­‐matched	  background.	  	  	  While	  we	  did	  not	  find	  evidence	  for	  any	  expanded	  public	  T	  cell	  clones,	  it	  is	  possible	  that	  shared	  antigen-­‐specific	  T	  cells	  are	  present	  nevertheless.	  A	  slightly	  altered	  CDR3-­‐region	  might	   still	   recognize	   the	   same	  epitope.	  To	   investigate	   enriched	  and	  potentially	   shared	  CDR3-­‐motifs,	  we	  will	   genotype	  MHC	   class	   II	   of	   the	   subjects	   from	   the	  TA	  biopsy	   study	  and	  further	  mine	  our	  TCR	  data	  by	  using	  the	  GLIPH	  algorithm	  165.	  GLIPH	  clusters	  CDR3-­‐regions	   with	   similar	   or	   identical	   enriched	   motifs	   relevant	   to	   binding	   the	   peptide	   or	  specific	  HLA-­‐alleles	  into	  groups.	  The	  TCRs	  within	  these	  groups	  may	  be	  strongly	  enriched	  for	  binding	  the	  same	  antigen,	  thereby	  enhancing	  the	  TCR	  repertoire	  data	  and	  informing	  further	  antigen	  screens.	  	  Based	   on	   the	   histopathology,	   there	   is	   no	   evidence	   for	   substantial	   involvement	   of	   a	  humoral	   immune	   response	   in	   GCA.	   One	   group	   reported	   reduced	   number	   of	   B	   cell	  subsets	   in	   the	   periphery	   and	   increased	   serum	   levels	   of	   BAFF,	   a	   B	   cell	   survival	   factor	  166,167.	   Nevertheless,	   efforts	   have	   been	   undertaken	   to	   investigate	   binding	   of	  autoantibodies	   in	  GCA	  by	  either	   cDNA	   library	   screening	  or	  2D-­‐proteomics,	  which	  may	  have	   a	   use	   as	   a	   simple	   diagnostic	   or	   prognostic	   tool.	   Reactivity	   against	   a	   series	   of	  intracellular	  proteins	  has	  been	  reported,	  many	  of	  them	  matrix	  proteins	  such	  as	  vinculin	  or	   lamin	  A/C	   168,169.	   The	  most	   convincing	   data	   stems	   from	   a	   group	   reporting	   elevated	  concentrations	   of	   antibodies	   targeting	   isoforms	   of	   14-­‐3-­‐3	   protein	   in	   LVV-­‐patients	  undergoing	   surgical	   aortic	   aneurysm	   repair	   170.	   14-­‐3-­‐3	   isoforms	   are	   phospho-­‐serin/threonine-­‐binding	   proteins	   involved	   in	   a	   very	   broad	   range	   of	   cellular	   processes	  171.	   Given	   the	   fact	   that	   most	   of	   the	   previously	   reported	   antibody	   targets	   are	   very	  abundant	   intracellular	   proteins,	   we	   hypothesized	   that	   the	   observed	   reactivity	   was	  rather	  due	  to	  a	  secondary	  immune	  response	  reflecting	  tissue	  damage.	  	  	  After	   testing	   for	   antibody	   binding	   to	   14-­‐3-­‐3	   via	   bead-­‐based	   immunoassay,	   we	   found	  reactivity	  against	  all	  three	  reported	  14-­‐3-­‐3	  isoforms	  (γ,	  ε,	  ζ).	  However,	  the	  binding	  levels	  were	  similarly	  distributed	  between	  the	  LVV-­‐group	  and	  the	  control	  groups.	  Interestingly,	  the	   frequency	   of	   patients	   with	   aortitis	   and	   stroke	   was	   significantly	   higher	   in	   those	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positive	   for	   anti-­‐14-­‐3-­‐3	   ε	   antibodies,	   hinting	   at	   an	   immune	   response	   following	   tissue	  damage.	   Indeed,	   elevated	   levels	   of	   extracellular,	   i.e.	   potentially	   immunogenic	   14-­‐3-­‐3	  isoforms	  have	  been	   reported	   for	   several	   inflammatory	  and	  necrotizing	  diseases	   170,172–174,	   in	  one	  case	  also	  coincident	  with	  autoantibody	  prevalence	   172.	  Patients	  with	  aortitis	  also	   showed	   considerable	   infiltration	   of	   plasma	   cells	   and	   presence	   of	   tertiary	   lymph	  follicles,	  consistent	  with	  a	  locally	  induced	  immune	  response.	  	  The	   highest	   antibody	   levels	   were	   found	   against	   the	   γ-­‐isoform.	  We	   hypothesized	   that	  these	  antibodies	  are	  present	  due	  to	  molecular	  mimicry;	  they	  are	  targeting	  a	  pathogen-­‐derived	   protein	   but	   are	   cross-­‐reactive	   to	   a	   self-­‐protein.	   The	   frequent	   opportunistic	  protozoan	  parasite	  Toxoplasma	  gondii	   seemed	   to	  be	  a	  promising	   candidate,	  being	  also	  able	  to	  secrete	  a	  homologous	  form	  of	  14-­‐3-­‐3	  175.	   Indeed,	   individuals	  seropositive	  for	  T.	  
gondii	   were	   significantly	   more	   frequent	   among	   the	   anti-­‐γ-­‐positive	   (but	   not	   ε-­‐	   or	   ζ-­‐positive).	  Also,	  we	  found	  a	  potential	  epitope	  that	  is	  identical	  between	  the	  protozoan	  14-­‐3-­‐3	  and	  human	  14-­‐3-­‐3-­‐γ,	  but	  not	  ε	  or	  ζ.	  	  Taken	   together,	   we	   found	   evidence	   for	   antigen-­‐specific	   T	   cell	   proliferation	   in	   all	  investigated	   arteries	   based	   on	   dominant	   T	   cell	   clones.	   Defining	   the	   types	   of	   antigen	  targeted	  and	  investigating	  potentially	  shared	  antigens	  is	  the	  goal	  of	  our	  future	  research.	  Being	   interested	   in	   autoreactive	   B	   cells	   as	   biomarkers,	   we	   found	   that	   antibodies	  targeting	   14-­‐3-­‐3	   isoforms	   are	   not	   suitable	   to	   diagnose	   GCA.	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Concluding	  discussion	  
	  The	   focus	   of	   this	   thesis	   are	   cross-­‐reactive	   immune	   responses.	   Cross-­‐reactive	   immune	  cells	   are	  originally	   selected	  against	   one	  epitope,	   but	   are	   also	   able	   to	   recognize	   similar	  epitopes.	   An	   optimal	   influenza	   vaccine	   should	   induce	   selection	   of	   B	   cells	   with	   the	  capacity	  to	  produce	  broadly	  neutralizing	  antibodies	  against	  a	  wide	  range	  of	  strains	  and	  ideally	  even	  against	  other	  serotypes.	  While	  initially	  not	  investigating	  cross-­‐reactivity	  in	  the	  strict	  sense	  (i.e	  a	  single	  epitope),	  we	  found	  that	  vaccine	  responses	  against	  the	  whole	  hemagglutinin	  protein	  are	  to	  a	  certain	  extent	  cross-­‐reactive	  to	  similar	  strains.	  However,	  in	  the	  case	  of	  a	  H3N2	  strain	  that	  emerged	  several	  years	  after	  the	  vaccination	  cohort	  was	  collected,	  we	  described	  a	  single	  point	  mutation	  altering	  an	  epitope	  on	   the	  HA	  head	  by	  removal	   of	   a	   glycan.	   This	  mutation	   resulted	   in	   escape	   from	   a	   large	   proportion	   of	   the	  antibodies	   binding	   to	   the	   HA	  without	   the	  mutation,	   revealing	   the	   vulnerability	   of	   the	  vaccine-­‐induced	  immune	  response.	  Moreover,	  it	  supports	  that	  cross-­‐reactive	  antibodies	  should	   ideally	   bind	   to	   functionally	   indispensable	   structures	   of	   the	   protein,	   thereby	  restricting	  viral	  escape	  to	  a	  minimum.	  	  In	   GCA,	   and	   autoimmunity	   in	   general,	   cross-­‐reactive	   T	   cells	   have	   been	   suggested	   to	  contribute	  to	  the	  immunopathology.	  Specifically,	  infection	  was	  proposed	  as	  a	  trigger	  of	  autoimmune	  responses	  by	  molecular	  mimicry	  of	  host	  proteins	  or	  bystander	  activation	  of	  T	  cells	  resulting	  in	  tissue	  targeting.	  In	  GCA,	  these	  assumptions	  were	  so	  far	  only	  based	  on	   detection	   of	   viral	   DNA	   and	   proteins	   at	   the	   site	   of	   infection	   and	   epidemiological	  inferences.	  We	  aimed	  at	   investigating	  GCA-­‐specific	  T	  cell	  reactivity	  against	  self-­‐protein	  using	   protein	   extracts	   from	   aortic	   wall	   proteins	   that	   could	   have	   been	   further	  characterized	   to	   define	   the	   targeted	  peptide	   sequences.	   In	   peripheral	   blood,	   however,	  we	   found	   no	   evidence	   for	   increased	   T	   cell	   reactivity	   towards	   host	   proteins.	   By	  investigating	   14-­‐3-­‐3	   autoantibodies	   in	   GCA	   patients,	   we	   could	   confirm	   their	   presence	  but	  not	  their	  use	  for	  diagnosing	  GCA	  in	  the	  clinic.	  Interestingly,	  however,	  we	  established	  a	   link	   in	   the	   general	   population	   between	   reactivity	   towards	   14-­‐3-­‐3-­‐γ	   and	   previous	  infection	  with	  Toxoplasma	  gondii.	  This	  protozoan	  secretes	  a	  14-­‐3-­‐3-­‐γ	  homolog,	  hereby	  suggesting	  molecular	  mimicry.	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Summing	  up,	   cross-­‐reactivity	   is	   an	   inherent	   feature	  of	   the	  adaptive	   immune	   response.	  Organisms	  have	  evolved	  measures	   to	  control	  negative	  cross-­‐reactive	  effects	   leading	   to	  autoimmunity.	   But	   humans	   have	   not	   yet	   been	   able	   to	   develop	   a	   cross-­‐protective	  influenza	  vaccine.	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AID	   	   	   	   	   Activation-­‐induced	  cytidine	  deaminase	  
APC	   	   	   	   	   Antigen-­‐presenting	  cell	  
ADCC	   	   	   	   	   Antibody-­‐dependent	  cellular	  cytotoxicity	  
ADCP	   	   	   	   	   Antibody-­‐dependent	  cellular	  phagocytosis	  
BAFF	   	   	   	   	   B	  cell	  activating	  factor	  
BCR	   	   	   	   	   B	  cell	  receptor	  
BER	   	   	   	   	   Base-­‐excision	  repair	   	  
bnAb	   	   	   	   	   broadly	  neutralizing	  antibody	  
CCL	   	   	   	   	   Chemokine	  ligand	  
CDR3	   	   	   	   	   Complementarity-­‐determining	  region	  3	  
DC	   	   	   	   	   Dendritic	  cell	  
DSB	   	   	   	   	   Double-­‐strand	  break	  
DZ	   	   	   	   	   Dark	  zone	  (of	  GC)	  
EBNA1	  	   	   	   	   Epstein-­‐Barr	  nuclear	  antigen	  1	  
EBV	   	   	   	   	   Epstein-­‐Barr	  virus	  
ELISA	   	   	   	   	   Enzyme-­‐linked	  immunosorbent	  assay	  
EliSpot	  	   	   	   	   Enzyme-­‐linked	  immunospot	  
ER	   	   	   	   	   Endoplasmatic	  reticulum	  
Fab	   	   	   	   	   Fragment	  antigen-­‐binding	  (of	  antibody)	  
Fc	   	   	   	   	   Fragment	  crystallizable	  (of	  antibody)	  
FDA	   	   	   	   	   (US)	  Food	  and	  drug	  administration	  
FDC	   	   	   	   	   Follicular	  dendritic	  cell	  
FFPE	   	   	   	   	   Formalin-­‐fixed,	  paraffin-­‐embedded	  
Gal	   	   	   	   	   Galactose	  
GC	   	   	   	   	   Germinal	  center	  
GCA	   	   	   	   	   Giant	  cell	  arteritis	  
GISAID	  	   	   	   	   Global	  initiative	  on	  sharing	  all	  influenza	  data	  
GlcNAc	  	   	   	   	   N-­‐Acetylglucosamin	  
GLIPH	   Grouping	  of	  lymphocyte	  interactions	  by	  paratope	  hotspots	  
GM-­‐CSF	   Granulocyte-­‐macrophage	   colony-­‐stimulating	  factor	  
HA	   	   	   	   	   Hemagglutinin	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HAI	   	   	   	   	   Hemagglutination	  inhibition	  
HBVP	   	   	   	   	   Hepatitis	  B	  virus	  polymerase	  
HLA	   	   	   	   	   Human	  leukocyte	  antigen	  
HPAIV	  	   	   	   	   Highly	  pathogenic	  avian	  influenza	  virus	  
IFN	   	   	   	   	   Interferon	  
IL	   	   	   	   	   Interleukin	  
IMGT	   	   	   	   	   Immunogenetics	  (information	  system)	  
LAL	   	   	   	   	   Limulus	  amoebocyte	  lysate	  
LPAIV	   	   	   	   	   Low	  pathogenic	  avian	  influenza	  virus	  
LPS	   	   	   	   	   Lipopolysaccharide	  
LVV	   	   	   	   	   Large	  vessel	  vasculitis	  
LZ	   	   	   	   	   Light	  zone	  (of	  GC)	  
MBP	   	   	   	   	   Myelin	  basic	  protein	  
MDCK	   	   	   	   	   Madin-­‐Darby	  canine	  kidney	  (cells)	  
MFI	   	   	   	   	   Median	  fluorescence	  intensity	  
MHC	   	   	   	   	   Major	  histocompatibility	  complex	  
MMP	   	   	   	   	   Matrix	  metalloproteinase	  
MMR	   	   	   	   	   Mismatch	  repair	  
moDC	   	   	   	   	   Monocyte-­‐derived	  dendritic	  cell	  
mTEC	   	   	   	   	   Medullary	  thymic	  epithelial	  cell	  
NA	   	   	   	   	   Neuraminidase	  
NHEJ	   	   	   	   	   Non-­‐homologous	  end	  joining	  
NK	   	   	   	   	   Natural	  killer	  (cell)	  
NP	   	   	   	   	   Nucleoprotein	  
OCT	   	   	   	   	   Optimal	  cutting	  temperature	  (resin)	  
PBMC	   	   	   	   	   Peripheral	  blood	  mononuclear	  cells	  
PDB	   	   	   	   	   Protein	  data	  bank	  
PMR	   	   	   	   	   Polymyalgia	  rheumatica	  
RACE	   	   	   	   	   Rapid	  amplification	  of	  cDNA-­‐ends	  
RAG	   	   	   	   	   Recombination-­‐activating	  gene	  
ROS	   	   	   	   	   Reactive	  oxygen	  species	  
RBS	   	   	   	   	   Receptor-­‐binding	  site	  
RdRp	   	   	   	   	   RNA-­‐dependent	  RNA	  polymerase	  
RNP	   	   	   	   	   Ribonucleoprotein	  
RPMI	   	   	   	   	   Roswell	  Park	  Memorial	  Institute	  (medium)	  
SA	   	   	   	   	   Sialic	  acid	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SCID	   	   	   	   	   Severe	  combined	  immunodeficiency	  
SEB	   	   	   	   	   Staphylococcal	  enterotoxin	  B	  
SHM	   	   	   	   	   Somatic	  hypermutation	  
SLE	   	   	   	   	   Systemic	  lupus	  erythematosus	  
TA	   	   	   	   	   Temporal	  artery	  
TCR	   	   	   	   	   T	  cell	  receptor	  
TNF	   	   	   	   	   Tumor	  necrosis	  factor	  
UNG	   	   	   	   	   Uracil	  DNA	  glycosylase	  
VE	   	   	   	   	   Vaccine	  efficacy	  
VSMC	   	   	   	   	   Vascular	  smooth	  muscle	  cell	  
VZV	   	   	   	   	   Varicella	  zoster	  virus	  
WHO	   	   	   	   	   World	  health	  organization	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Measurement	  of	  LPS	  levels	  and	  bacteria-­‐specific	  antibody	  responses	  in	  GCA	  
	  
Introduction	  Given	  the	  importance	  of	  TLR4-­‐engagement	  to	  induce	  transmural	  infiltration	  of	  CD4+	  T	  cells	  in	  an	  experimental	  transplantation	  model,	  we	  hypothesized	  that	  TLR4	  ligands	  are	  available	  in	  increased	  amount	  in	  GCA	  patients	  and	  may	  be	  involved	  in	  the	  arterial	  breakdown	  of	  tolerance.	  LPS,	  bacterial	  endotoxins,	  are	  the	  main	  TLR4	  ligands.	  In	  humans,	  LPS	  can	  enter	  the	  blood	  stream	  if	  the	  integrity	  of	  the	  gastrointestinal	  tract	  is	  disrupted.	  Reduced	  gastrointestinal	  barrier	  function	  has	  been	  reported	  in	  elderly	  people	  1.	  Therefore,	  we	  tested	  whether	  GCA	  patients	  have	  higher	  LPS	  in	  the	  blood	  stream	  that	  may	  activate	  the	  vascular	  DCs	  and	  contribute	  to	  the	  initiation	  process	  of	  the	  disease.	  
	  
Methods	  Plasma	   was	   diluted	   1:10	   and	   protein-­‐LPS	   interaction	   reduced	   by	   adding	   0.2%	  PyrosperseTM.	  After	  heat-­‐inactivation	  (30	  min.	  at	  85°C),	  samples	  were	  diluted	  to	  1:100	  and	   divided	   into	   duplicates	   of	   “real”	   and	   “spiked”	   (with	   50	   pg/ml	   of	   LPS	   from	  E.	   coli,	  L3012,	  Sigma	  Aldrich,	  St.	  Louis,	  MO,	  USA)	  samples.	  LPS	   levels	  were	  determined	  with	  a	  chromogenic	  kinetic	  LAL	  assay	  (LAL	  Kinetic-­‐QCLTM,	  50-­‐650,	  Lonza,	  Basel,	  Switzerland)	  and	   calculated	   using	   WinKQCLTM	   software	   (Lonza).	   Effective	   concentrations	   (c)	   were	  determined	  with	  the	  following	  formula:	  
ceffective	  =	  (cspiked	  –	  creal)	  /	  50	  pg/mL	  *	  creal	  
All	  procedures	  were	  carried	  out	  with	  endotoxin-­‐free	  water	  and	  plastic	  ware.	  	  
To	  generate	  monocyte-­‐derived	  dendritic	   cells	   (moDC),	  monocytes	  were	  enriched	   from	  PBMC	  by	  adherence	  to	  a	   flat-­‐bottom	  plate	   for	  2	  hours.	  These	  were	  then	  cultured	   for	  5	  days	  in	  the	  presence	  of	  1000	  U/ml	  of	  GM-­‐CSF	  and	  IL-­‐4	  in	  RPMI	  medium	  supplemented	  with	   1.5%	   autologous	   heat-­‐inactivated	   human	   plasma	   (37°C,	   5%	   CO2).	   Afterwards,	  moDCs	  were	   treated	  with/without	  200	  pg/mL	  of	  LPS	   for	  24	  hours	  and	  activation	  was	  assessed	   by	   flow	   cytometry.	   Anti-­‐human	   antibodies:	   CD11c	   (APC,	   clone	   BU15,	  21487116,	  ImmunoTools,	  Friesoythe,	  Germany),	  CD14	  (PerCP,	  clone	  TuK4,	  MHCD1431,	  Invitrogen,	   Carlsbad,	   CA,	   USA),	   CD14	   (FITC,	   clone	   MOP9,	   345784),	   CD83	   (PE,	   clone	  HB15e,	   556855),	   CD86	   (PE-­‐Cy5,	   clone	   B70/B7-­‐2,	   555659),	   HLA-­‐DR	   (PE,	   clone	   L243,	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347401);	   all	   BD	   biosciences,	   Franklin	   Lakes,	   NJ,	   USA	   and	   CD209	   (FITC,	   clone	   9E9A8,	  Biolegend,	  San	  Diego,	  CA,	  USA).	  	  
Bacterial	  FACS	  was	  performed	  as	  described	  previously	  2.	  The	  following	  species	  were	  obtained	  from	  the	  clinical	  microbiology	  department	  at	  the	  Basel	  university	  hospital:	  
Escherichia	  coli,	  Bacteroides	  fragilis,	  Enterococcus	  faecalis,	  Staphylococcus	  epidermidis	  and	  Propionibacterium	  acnes.	  Anti-­‐human	  antibodies:	  IgG	  (Alexa	  Fluor	  647,	  polyclonal,	  309-­‐605-­‐008)	  and	  IgA	  (FITC,	  polyclonal,	  309-­‐095-­‐011),	  both	  Jackson	  ImmunoResearch,	  West	  Grove,	  PA,	  USA.	  Bacteria-­‐specific	  IgG-­‐	  and	  IgA-­‐concentrations	  were	  corrected	  for	  total	  plasma	  IgG	  and	  IgA,	  as	  defined	  by	  ELISA	  (Human	  IgG/IgA	  ELISA	  kit,	  801182/801197,	  ZeptoMetrix	  Corporation,	  Buffalo,	  NY,	  USA).	  	  	  
LPS-­‐levels	  are	  elevated	  in	  GCA	  patient	  plasma	  LPS-­‐levels	   were	   significantly	   elevated	   in	   GCA-­‐patients	   at	   time	   point	   of	   diagnosis	  compared	  to	  age-­‐matched	  controls,	   including	  also	  subjects	  with	  GCA-­‐like	  inflammatory	  disease	  (PMR)	  (Figure	  14A).	  Moreover,	  we	  could	  show	  that	  an	  LPS	  concentration	  of	  200	  pg/mL	  (median	  concentration	   in	   the	  GCA	  group)	  was	  sufficient	   to	   induce	  activation	  of	  monocyte-­‐derived	  dendritic	  cells	  (moDC)	  in	  vitro	  (see	  Figure	  14B).	  	  
	  
Figure	  14:	  Plasma	  LPS	  levels	  are	  increased	  in	  GCA	  patients	  and	  suffice	  to	  activate	  moDCs	  in	  
vitro.	   A)	  Plasma	  LPS-­‐concentrations,	  as	  defined	  by	  LAL-­‐assay,	  are	  shown	   for	  GCA-­‐patients	  and	  controls	   (open	   squares:	   PMR-­‐patients)	   at	   time	   point	   of	   diagnosis.	   DL:	   Assay	   detection	   limit.	  Mann-­‐Whitney	   U	   test	   was	   applied	   to	   compare	   group	   distributions,	   *	   p<0.05.	  B)	   moDCs	   were	  treated	  with	  200	  pg/mL	  of	  LPS	  (approx.	  median	  LPS-­‐level	   in	  GCA-­‐group)	  and	  assessed	  by	   flow	  cytometry.	  Median	   fluorescence	   intensity	   (MFI)	   is	   shown	   for	   the	   activation	  markers	  CD86	   and	  HLA-­‐DR.	  moDCs	  are	  gated	  as	  doublet-­‐negative	  CD11c+/CD14-­‐/CD209+.	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The	  presence	  of	  increased	  systemic	  levels	  of	  LPS	  in	  GCA-­‐patients	  indicated	  a	  certain	  degree	  of	  gram-­‐negative	  bacterial	  transfer.	  We	  thus	  decided	  to	  measure	  the	  abundance	  of	  plasma	  IgG-­‐	  and	  IgA-­‐antibodies	  against	  the	  two	  common	  gram-­‐negative,	  commensal	  intestinal	  bacteria	  Escherichia	  coli	  and	  Bacteroides	  fragilis.	  The	  gram-­‐positive	  gut	  bacterium	  Enterococcus	  faecalis	  served	  as	  a	  negative	  control.	  Diluted	  bacteria	  were	  directly	  exposed	  to	  human	  plasma.	  While	  both	  IgG-­‐	  and	  IgA-­‐antibodies	  could	  be	  detected	  against	  all	  bacterial	  species,	  none	  of	  them	  were	  significantly	  more	  frequent	  in	  the	  GCA-­‐patients	  compared	  to	  controls	  (data	  not	  shown).	  
	  
	  
Discussion	  By	   using	   the	   LAL-­‐assay,	  we	   could	   detect	   elevated	   levels	   of	   LPS	   in	   the	   plasma	   of	   GCA-­‐patients.	  LPS	  is	  a	  potent	  activator	  of	  dendritic	  cells	  and	  vascular	  DC	  activation	  seems	  to	  be	  an	  early	  event	  in	  GCA	  pathogenesis.	  The	  measured	  LPS-­‐concentrations	  are	  sufficient	  to	  activate	  mature	  moDCs;	  whether	  this	  holds	  true	  for	  vascular	  DCs	  and	  whether	  LPS	  is	  present	  in	  vascular	  walls	  at	  these	  concentrations	  is	  difficult	  to	  determine.	  	  We	  investigated	  bacterial	  translocation	  from	  the	  intestinal	  tract	  as	  a	  possible	  reason	  for	  the	  elevated	  LPS	  concentrations	  observed.	  While	  we	  did	  not	  find	  differences	  between	  patients	  and	  controls	  in	  antibodies	  targeting	  Escherichia	  coli	  and	  Bacteroides	  fragilis,	  but	  this	  might	  be	  different	  with	  other	  gram-­‐negative	  bacteria.	  It	  is	  not	  feasible	  though	  to	  screen	  for	  antibodies	  against	  the	  whole	  series	  of	  bacterial	  species	  that	  might	  possibly	  colonize	  the	  gut.	  Therefore,	  an	  approach	  would	  be	  to	  investigate	  the	  gut	  microbiota	  in	  patients	  and	  age-­‐matched	  donors	  for	  species	  differences.	  This	  could	  be	  accomplished	  e.g.	  by	  direct	  16S	  rRNA-­‐sequencing	  3.	  The	  GCA-­‐related	  microbiota	  could	  then	  be	  tested	  using	  the	  bacterial	  FACS	  approach.	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Abstract
Background
Acute stress drives a ‘high-alert’ response in the immune system. Psychoactive drugs
induce distinct stress hormone profiles, offering a sought-after opportunity to dissect the in
vivo immunological effects of acute stress in humans.
Methods
3,4-methylenedioxymethamphetamine (MDMA), methylphenidate (MPH), or both, were
administered to healthy volunteers in a randomized, double-blind, placebo-controlled cross-
over-study. Lymphocyte subset frequencies, natural killer (NK) cell immune-phenotypes,
and changes in effector function were assessed, and linked to stress hormone levels and
expression of CD62L, CX3CR1, CD18, and stress hormone receptors on NK cells.
Results
MDMA/MPH >MDMA >MPH robustly induced an epinephrine-dominant stress response.
Immunologically, rapid redistribution of peripheral blood lymphocyte-subsets towards phe-
notypically mature NK cells occurred. NK cytotoxicity was unaltered, but they expressed
slightly reduced levels of the activating receptor NKG2D. Preferential circulation of mature
NK cells was associated with high epinephrine receptor expression among this subset, as
well as expression of integrin ligands previously linked to epinephrine-induced endothelial
detachment.
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Conclusion
The acute epinephrine-induced stress response was characterized by rapid accumulation
of mature and functional NK cells in the peripheral circulation. This is in line with studies
using other acute stressors and supports the role of the acute stress response in rapidly
mobilizing the innate immune system to counteract incoming threats.
Introduction
The response of the body to stress consists in the complex integration of endocrine, neuro-cog-
nitive and immunologic adaptations [1]. Chronic persistent stress has been linked to sup-
pressed immune function and increased susceptibility to infections and cancer [1–4], while
acute stress induces a fight-or-flight reaction, tuned to rapidly respond to injury and subse-
quent entry of infectious agents into the organism. Acute stress-induced changes in the
immune system thus plausibly aim at accelerating wound repair, help prevent infections, and
should occur very rapidly [1].
In contrast to adaptive immunity, the innate immune response is optimized to immediately
respond to pathogens without need for prior cognate exposure. Natural Killer (NK) cells repre-
sent 5–15% of all lymphocytes in the peripheral blood and are important in the defense against
viruses and tumors. Based on their CD56 surface expression-density they can by divided into
cytotoxic CD56dim NK cells (roughly 90%), and the immunomodulatory CD56bright NK cells
(approximately 10% of NK in the peripheral blood). Circulating cytotoxic CD56dim NK cells
detect virally infected or malignantly transformed cells. Their activation results in target cell
lysis and the secretion of cytokines [5]. Previous studies found a strong increase of circulating
NK cells upon stress, suggesting a potential role for NK cells in this context [6].
Stress hormones, including glucocorticoids and catecholamines, are key modulators of
stress-induced immune-dysregulation [7, 8]. However, inter-individual differences in the
endocrine responses often hinder subtle stress-associated immunologic alterations to become
apparent. Thus, a well-controlled experimental model triggering a homogeneous endocrine
stress response should allow to better study how stress impacts the immune system.
3,4-Methylenedioxymethamphetamine (MDMA, “ecstasy”) and methylphenidate (MPH,
“Ritalin1”) are widely used psychoactive substances that induce an endocrine and cardiovascu-
lar stress response that has been extensively studied [9–12]. Previous murine and human stud-
ies suggested that MDMA impacts both the innate and the adaptive immune responses [13,
14]. Data regarding the effect of MPH on the immune system are sparse. Both drugs result in
an increase in norepinephrine levels, i.e. have sympathomimetic effects. While MDMA
enhances serotonergic neurotransmission [15] and increases cortisol levels [11], MPH elevates
dopamine concentrations but has no serotonergic effects [16], and does not increase cortisol
levels [11]. Thus, both MDMA and MPH share sympathomimetic and psychostimulant effects,
yet with distinct hormone profiles.
Here we used drug-induced stress to test its effects on the human immune system. Specifically,
we studied stress hormone-mediated recruitment of NK cell subsets in the context of a random-
ized, double-blind, placebo-controlled clinical trial of subjects receiving MDMA and/or MPH.
Materials and Methods
Clinical study
Healthy subjects (n = 12, mean age 24.9 years, 8 female, 4 male) from a pharmacological
study (NCT01465685) on the effects of single-dose MDMA (125 mg), MPH (60 mg) or a
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combination of the two drugs were tested for the effects of the drugs on the immune system.
Characteristics of the study and the participants have previously been published [12]. All
subjects provided written informed consent. The study was approved by the ethics committee
of the canton of Basel, Switzerland (EKBB 228/11) and conducted in accordance with the
Declaration of Helsinki. All subjects received each drug condition once in a double-blind, pla-
cebo-controlled, crossover design with four experimental test sessions (placebo–placebo,
MPH–placebo, placebo–MDMA, and MPH–MDMA). Drugs were taken orally. Washout peri-
ods between two conditions were at least 10 days. All blood draws were performed via an
indwelling intravenous catheter placed in an antecubital vein and the baseline blood draw was
at 8 am for all study subjects. Peripheral blood mononuclear cells (PBMC) were isolated using
LymphoprepTM (Axis-Shield, Oslo, Norway) density centrifugation and cryopreserved until
use, in order to be able to measure all study timepoints (i.e. conditions) for each subject on the
same day. The cardiovascular stress response (systolic blood pressure and heart rate) was
repeatedly recorded and plasma levels of norepinephrine, epinephrine, dopamine and cortisol
were determined before and 2h after drug administration [12].
Flow cytometry based immunophenotyping
PBMC were immunophenotyped using the following antibodies: CD3-PerCP (UCHT1),
CD4-APC (OKT4), CD18-PE (TS1/18), CD19-PE (HIB19), NKG2D-APC (1D11),
CX3CR1-FITC (2A9-1, all Biolegend), CD3-Pacific Blue (UCHT1), CD8-FITC (HIT8a),
CD16-PE-Cy5 (3G8), CD56-PE, -Alexa Fluor 647 or -PE-Cy7 (B159), CD69-FITC (FN50) (all
BD Biosciences), CD62L-FITC (LT-TD180) (ImmunoTools), GCR-Alexa Fluor 488 (D8H2)
(Cell Signaling Technology) and ADRB2 pure (S364, RayBiotech). The antibody against
ADRB2 was coupled to R-phycoerythrin (RPE) in house using the ABSelect BSA Removal Kit
to clean and concentrate the pure ADRB2 antibody followed by fluorochrome coupling with
the Lightning-Link1 R-Phycoerythrin Conjugation Kit according to manufacturer’s instruc-
tions (Innova Biosciences).
All stainings were performed as surface-stainings for 30 min. at 4°C, with exception of the
intracellular GCR staining that was performed in whole blood according to a standard ICS pro-
tocol (Cell Signaling Technology). All sample acquisitions were performed on an AccuriTM C6
(immune cell subsets and NK function) or a LSRFortessaTM (NK receptor phenotyping) flow
cytometer (BD Biosciences).
NK cell in vitro stimulation assays
NK cell function was assessed by IFNγ production and degranulation (CD107a) as an indirect
marker of cytotoxicity [17]. NK cells were stimulated with K562 cells by co-culture of 106
PBMC at a 10:1 effector-to-target ratio as previously described [18]. Following 30 min. of pre-
incubation, cells were incubated during 4 hours in the presence of Brefeldin A (Biolegend) at
0.5 μg/mL, Monensin (Golgi-StopTM, BD Biosciences) at 0.3 μg/mL and anti-CD107a-APC
(H4A3) (BD Bioscience). Cells were then surface-stained using anti-CD3 PerCP and anti-
CD56 PE followed by intracellular staining for IFNγ using Cytofix/CytopermTM (BD Biosci-
ences) and anti-IFNγ-FITC (4S.B3) (Biolegend). For experiments testing the impact of stress
hormones on NKG2D expression in vitro, cells were incubated for 3 h in serum-free RPMI
1640 (Life Technologies) in the presence of cortisol (Sigma) at 280 ng/mL, epinephrine (Sinte-
tica) at 50 pg/mL, or a combination of both and NKG2D mean fluorescence intensity (MFI)
was assessed.
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Hormone receptor quantification on NK cell subsets using real-time RT
PCR
The β2-adrenergic receptor (ADRB2) and the glucocorticoid receptor (GCR) expression on NK
cell subsets were quantified by real-time PCR. CD56bright and CD56dim NK cells were sorted on a
FACSAriaTM III (BD Bioscience) and RNA was extracted using the QIAamp1 RNA Blood Mini
Kit (Qiagen). Genomic DNA was removed and first-strand cDNA was generated by means of
GoScriptTM Reverse Transcription System (Promega). RT-PCR was performed with GoTaq1
qPCRMaster Mix in duplicates in a 7500 Fast Real-Time PCR System (Applied Biosystems)
using the following primers (Microsynth, Switzerland): ADRB2: 5’-ACAGGGGAGCAGAGTG
GATA-3’ and 3’- ACAGTACCTTGATGGCCCAC-5’ and GCR: 5’-TGGGGACTCTGAACTTC
CCTG-3’ and 3’- CTGTTGTTGCTGTTGAGGAGC-5’ (Complete primer list available in S1
Protocol). The amplification process consisted of polymerase activation at 95°C for 10 min.,
45 cycles with 15 s of denaturation at 95°C and 1 min. of annealing and elongation at 60°C and a
final elongation step for 1 min. at 60°C. For all samples signals were detected between cycles
24 and 35. Two reference genes (GADPH and PKG1) were used for relative quantification. A
more detailed description of the qPCR protocol is available in S1 Protocol.
Data analysis and statistics
All flow cytometry data was analyzed blinded for the drug condition using FlowJo Software
(Version X 10.0.7). Gating strategies for the analyses are shown in the supporting information
(S2 Fig and S3 Fig). Statistical analyses and data visualization was performed using Prism soft-
ware (Prism 6.0, Graphpad). Group comparisons were performed using t-tests or Kruskal Wal-
lis tests followed by Dunn’s comparisons. Correlation analyses were performed using
Spearman Rank tests.
Results and Discussion
Drug-induced cardiovascular stress responses associate with an
increased proportion of peripheral Natural killer cells
The cardiovascular response and stress hormone levels in the peripheral blood can indicate
stress. MDMA, MPH, and the combination of the two drugs induced an increase in systolic
blood pressure (SBP) and heart rate peaking three hours after drug administration (Fig 1A and
1B). Details to the cardiovascular response in the study subjects have been reported previously
[12]. The MDMA/MPH combination induced the strongest increase in SBP, and MPH alone
induced a SBP increase of lower magnitude than the conditions that included MDMA (Fig
1A). Contrarily, the heart rate was highest in treatment conditions including MPH (Fig 1B).
Since these differences might be linked to different stress hormone profiles induced by the dif-
ferent treatments, levels of cortisol and catecholamines were analyzed and compared with lev-
els measured in placebo treated study subjects. Hormone levels two hours after drug
administration (i.e. at their peak) were compared to the baseline blood draws, which were all
performed at 8 am. All active drug conditions resulted in a comparable, albeit non-significant
increase of norepinephrine at 2 hours (data not shown). The most striking difference between
the drug conditions was an increase in cortisol concentration upon exposure to MDMA
(p< 0.001) or MDMA/MPH (p< 0.0001) compared to placebo or MPH alone (Fig 1C). Corti-
sol levels fell in the placebo and MPH condition, consistent with known circadian changes in
cortisol, given the timing of the blood draws, all starting at 8 am [19]. The increase in epineph-
rine concentrations was higher in individuals exposed to MDMA/MPH (p< 0.0001) than in
those exposed to MDMA alone (p< 0.01) and lowest in participants after MPH intake alone,
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suggesting an additive effect of MDMA and MPH on the epinephrine stress response (Fig 1D).
The cardiovascular stress response (i.e. HR increase and SBP increase) correlated with both,
the epinephrine (HR: p = 0.0035, r = 0.42; SBP: p = 0.0001, r = 0.53), and cortisol increase (HR:
p = 0.0001, r = 0.53; SBP p<0.0001, r = 0.71). Together, the findings suggest that the study con-
ditions resulted in distinct cardiovascular and endocrine stress response profiles.
Acute stress has been linked to a recruitment of NK cells to the peripheral blood in various
models [6]. To test whether the same applies to pharmacological stress induced by MDMA,
MPH or their combination, we monitored the change in lymphocyte subset-distribution at
baseline and three hours after drug administration. This time-point was chosen based on the
stress hormone level peak that occurs around 2–3 hours after drug-intake [11]. We then calcu-
lated the percentage change in T cells (CD4+ and CD8+), B cells and NK cells compared to the
baseline distribution (gating strategy is depicted in S2 Fig). The most striking observation was
a dramatic increase of NK cells within the lymphocyte compartment that was most pro-
nounced upon exposure to combination treatment of MDMA and MPH (p< 0.001 Fig 1E).
The other immune cell subsets were variably decreased (Fig 1F–1H). Pacifici et al. also
reported a comparable and rapid increase of total NK cells in MDMA treated subjects, which
was however not further investigated [14, 20–22]. To enable an immediate response to any
threat it is plausible that early stress-induced adaptations act through cell redistribution, and
preferentially impact innate immunity that can unfold much more rapidly [6, 23].
Because this rapidly occurring redistribution of lymphocyte subsets suggested stress hor-
mone-mediated effects, we next correlated stress hormone levels (2 hours post administration)
Fig 1. Drug-induced stress induces a pronounced cardiovascular responses and NK cell recruitment. (A) Systolic blood pressure (SBP) in mmHg and
(B) heart rate (HR) in beats per minute (bpm) are shown three hours (i.e. one hour after the stress hormone peak) post-adminstration of the study drug
(n = 12). The grey shaded area indicates the normal values. Serum cortisol (C) and epinephrine (D) levels were measured before and two hours post drug
administration and the difference from baseline was calculated. Box plots indicate median and IQR, whiskers indicate range. (E-H) Lymphocyte subset
distribution 3 hours after drug administration was examined (n = 12). Percent change from baseline level to three hours post administration (Δ%) was
calculated for each lymphocyte subset. Mean Δ% and S.E.M is shown for the four main lymphocyte subsets: (E) NK cells (CD3- CD56+), (F) B cells (CD3-
CD19+), (G) CD8 cytotoxic T cells (CD3+ CD8+) and (H) CD4 T helper cells (CD3+ CD4+). Kruskal-Wallis test with Dunn’s correction to test for multiple
comparisons was used (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).
doi:10.1371/journal.pone.0145635.g001
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with the individual NK cell increase, irrespective of the treatment. NK cell increase correlated
with the change in epinephrine levels (p = 0.0049, r = 0.44; S1A Fig), but not with the change
of cortisol or norepinephrine (S1B and S1C Fig). Dopamine was only very weakly (median
0.03 nmol/L, IQR -0.03–0.09) and inconstantly increased following any drug administration and
the change in dopamine levels showed no correlation with the change in NK cell frequencies
(data not shown). Similarly, we found no correlation between drug induced neuropsychological
effects -namely changes in activity or emotional excitability- and NK cell redistribution. Taken
together, this hinted at a more pronounced role of epinephrine in NK cell redistribution.
Stress enriches for circulating cytotoxic NK cells with unaltered effector
functions and activation state
Given their strong relative increase upon drug-induced stress, we performed a more detailed
analysis of the specific NK cell subsets and their functionality. Although both cytotoxic
(CD56dim) and immunomodulatory (CD56bright) NK cell subsets increased, the most pro-
nounced effect was detected for CD56dim NK cells upon the combined drug stimulation (Fig
2A). This indicated that CD56dim NK cells were recruited preferentially upon stress. The stron-
ger correlation between the change in CD56dim NK cells and the alteration in epinephrine lev-
els (p = 0.004, r = 0.45, Fig 2B), as compared to the correlation with change in cortisol levels
(Fig 2C, p = 0.041, r = 0.31), further supported this notion. In contrast, we did not detect any
correlation of CD56bright NK cells and hormone levels (data not shown). Interestingly, the shift
in the NK cell subsets did not translate into enhanced NK effector functions against target cells
(Fig 2D). Previous studies variably associated acute stress with enhanced [6], or decreased NK
cell activity [24, 25], which could relate to different assay conditions (e.g. not including human
plasma in the culture media, cryopreservation [26]), some of which were, however, inevitable
in order to test all samples from a donor simultaneously with the same target cell conditions.
Reduced function has moreover been attributed to glucocorticoid-induced epigenetic changes,
which we might have missed by testing NK function within three hours post-stressor [27].
Drug-induced stress consistently associated with a moderate, but significant lower per-cell
expression (i.e. mean fluorescence intensity; MFI) of NKG2D, an NK cell activating receptor
recognizing stress-induced proteins (Fig 2E). This decrease was limited to CD56dim NK cells,
and NKG2D on bulk T cells was slightly increased (data not shown). NKG2D expression on
CD56dim NK cells was inversely correlated with the change in epinephrine levels (Fig 2F,
p< 0.0001, r = -0.59), compared to an again more moderate effect of cortisol (Fig 2G,
p = 0.036, r = -0.32). This NKG2Dlow phenotype might reflect a safety measure preventing an
overshooting NK stimulation that would result in excessive immunopathology [28–31]. Due to
sample availability, we could however not address this hypothesis experimentally. Treatment
of NK cells with synthetic epinephrine and cortisol in vitro dampened NK function, as expected
from the literature [32]. Yet, this NK cell inhibition was independent of NKG2D expression, as
NKG2D was only reduced inconstantly (i.e. six of eleven healthy donors) and showed no corre-
lation with NK function. Moreover, a reduction in NK function was also observed against
721.221 target cells not expressing NKG2D ligands (data not shown). Together, this indicates
that the NKG2Dlow phenotype results from mobilization of these NK cells rather than from a
receptor down-modulation by direct hormone effects.
Inherent expression differences of key surface receptors may explain
preferential recruitment of CD56dim NK cells
Our immunophenotypic data suggested that drug-induced stress associated with the preferen-
tial recruitment of cytotoxic NK cells without substantially affecting their function. Thus, we
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next aimed at defining molecular differences between CD56dim and CD56bright NK cell subsets
that may explain the preferential recruitment of the CD56dim subset. First, we assessed the
expression-profile of receptors previously linked to epinephrine-mediated lymphocyte redistri-
bution, namely high expression of the fractalkine receptor CX3CR1 and low expression of
CD62L [33], in five healthy untreated individuals. The flow cytometry gating strategies are
shown in the supporting information (S3 Fig). Indeed, we found that the CD56dim subset
expressed very high levels of CX3CR1 (Fig 3A), but low levels of CD62L (Fig 3B). This expres-
sion profile was inverse in the CD56bright subset (CX3CR1, p< 0.0001; CD62L, p = 0.001). In
contrast, CD18, an integrin known to bind to ICAMs and thereby enhancing NK cell migration
[34] was slightly more expressed on the CD56dim NK subset (p = 0.008, Fig 3C). Next, we
assessed mRNA and protein levels of the β2-adrenergic receptor (ADRB2) and glucocorticoid
receptor (GCR), i.e. the receptor for epinephrine and cortisol respectively, in the two NK cell
Fig 2. Unaltered NK function but reduced NKG2D expression upon drug-induced stress. (A) Percent change in the two NK cell subsets was calculated
and expressed as mean + S.E.M. (B,C) The percent change of CD3- CD56dim NK cells was correlated to the change in serum epinephrine (B) and cortisol (C)
levels 2 hours p.a. in all drug categories together (n = 44). (D) NK function against K562 target cells was assessed. Changes in IFNγ+ or CD107a+
(degranulation) CD56dim NK cells are shown for each drug category as absolute change in percentage (n = 11, mean + S.E.M). (E) Example histograms of
NKG2DMFI before (grey) and after (black) MPH / MDMA treatment are shown for a donor with a strong (left) and weak (right) response (upper panels). The
numbers indicate the MFI. Absolute change in the MFI of NKG2D expression (n = 12, mean + S.E.M) is displayed for each drug condition (lower left panel).
NKG2DMFI at baseline and 3 hours p.a. is shown separately for all subjects for the condition with a significant difference to placebo (MPH / MDMA) (lower
right panel). The absolute change in MFI of NKG2D was correlated to serum epinephrine (F) and cortisol (G) levels irrespective of drug treatment (n = 44).
Spearman correlation and nonlinear fit were applied for correlation analyses and Kruskal-Wallis test was applied for all group comparisons. *P < 0.05,
**P < 0.01, ***P < 0.001.
doi:10.1371/journal.pone.0145635.g002
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Fig 3. Preferential recruitment of CD56dim NK cells depends on distinct hormone andmigration
receptor expression profiles. Expression of three receptors important in cell adhesion and migration were
assessed by flow cytometry. (A-C) Example stainings gated on CD3- CD56+ lymphocytes are shown for
CX3CR1 (A), CD62L (B) and CD18 (C). The frequency (A, B) or MFI (C) of receptor expression on CD56bright
and CD56dim is indicated (upper panels). Data on freshly derived PBMCs from five healthy, unstressed
donors are summarized (A-C lower panels). (D, E) Expression of the epinephrine receptor (ADRB2) (D) and
the glucocorticoid receptor (GCR) (E) were assessed on CD3- CD56+ lymphocytes by flow cytometry. Isotype
control stainings for ADRB2 and GCR are shown, followed by an example staining (left panels). The MFI of
the two subsets is indicated for CD56bright (upper right corner) and CD56dim NK cell subsets (lower right
corner). Flow cytometric data of the aforementioned five donors is summarized for CD56bright and CD56dim
NK cells (middle panels). Differential ADRB2 and GCR expression on the two NK cell subsets were also
confirmed on mRNA level by measuring relative hormone receptor expression on sorted CD56dim (n = 3) and
CD56bright NK cells (n = 2) by qPCR (right panels). (F) Differential expression of ADRB2 on CD56bright and
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subsets. Both qPCR- and flow cytometry-based quantification indicated higher expression of
the ADRB2 among CD56dim, compared to the CD56bright, NK cells (p = 0.019 for MFI, Fig
3D). In contrast, the GCR was lower expressed in CD56dim NK cells (p = 0.005 for MFI, Fig
3E). Taken together, and in line with the correlation analyses of the in vivo data, this was sug-
gestive that the CD56dim subset was able to respond more vigorously to epinephrine.
Interestingly, we observed that ADRB2 abundance varied considerably between individuals
(Fig 3D). Therefore, we next tested whether the individual ADRB2 receptor expression on NK
cells might have determined the increase of NK cells in vivo in the clinical study. We first con-
firmed the inter-individual and NK subset-specific variability of ARDB2 expression in seven
subjects included in the clinical stress study (Fig 3F). Importantly, the individual ADRB2
expression was stable over time, as the same donors showed comparable levels on separate
study days (data not shown). Taking advantage of the distinct hormone changes induced by
the different drug conditions (Fig 1C and 1D), epinephrine effects were analyzed by correlat-
ing the change in NK cells and altered ADRB2 expression in the presence (MDMA or MDMA/
MPH group) or absence (MPH) of a concomitant cortisol increase. We found a very strong
correlation between an increase of NK cells and ADRB2 expression in the MPH group
(p = 0.02, r = 0.86), i.e. in absence of a cortisol response. Similar trends, albeit much weaker,
were seen in the other groups (Fig 3F), suggesting that cortisol might contribute to NK cell dis-
tribution in these conditions.
Together, our findings pointed at an important role of epinephrine in the early changes in
the NK cell compartment. Interestingly, in the absence of a cortisol response and at low epi-
nephrine levels (i.e. the MPH treatment condition), NK cell redistribution correlated almost
perfectly with the expression level of the beta-adrenergic receptor. This is in line with a model
of selective catecholamine-dependent regulation of NK cell adhesion to the endothelia [24], as
supported by studies using beta-adrenergic blockade suggesting catecholamines as master reg-
ulators of early stress effects on the immune system [35].
Conclusion
Stress was observed to induce an enrichment of CD56dim NK cells in the peripheral blood,
which associated with a strong epinephrine response. These NK cells expressed a receptor pro-
file that would enable them to rapidly re-distribute to a site of injury or infection, where this
cytotoxic subset could contribute to pathogen defense and wound healing. Differences in hor-
mone receptor expression might explain differences in the magnitude of individual stress
responses. The insights gained from this controlled clinical trial setting, using standardized
stressors that consistently induced distinct stress hormone profiles, support that, in humans,
NK cells can be recruited through epinephrine dependent mechanisms, which may be benefi-
cial e.g. in leukemia or cancer therapy [36]. Our study thus adds a rationale to interventions
that increase endogenous epinephrine levels (i.e. physical activity, MDMA etc. . .) currently
explored e.g. as adjunctive cancer treatments.
Supporting Information
S1 Fig. Correlation of NK cell increase with serum hormone levels. Absolute change in NK
percentage 3 hours after drug administration was correlated to change in concentrations of
CD56dim NK cells was confirmed in study participants 1 hour after placebo treatment (left panel, n = 7).
ADRB2 expression was correlated to the increase in NK cell percentage upon drug administration. Paired t
tests were applied for all group comparisons and Spearman correlation and nonlinear fit for correlation
analyses. *P < 0.05, **P < 0.01, ****P < 0.0001.
doi:10.1371/journal.pone.0145635.g003
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epinephrine (A), cortisol (B) and norepinephrine (C) 2 hours post treatment. Spearman corre-
lation and nonlinear fit were applied.
(TIFF)
S2 Fig. Gating strategy to define lymphocyte and NK cell subsets and to assess NKG2D
expression and IFNγ and CD107a production in NK cell subsets. The top row shows the gat-
ing in order to distinguish B cells, CD4+ and CD8+ T cells. A second panel was used to detect
NK cells, further subdividing them into CD56 dim and CD56 bright NK cells and analyzing
IFNγ and CD107a production (2, middle row, data is shown for CD56 dim). A third panel was
designed to detect NKG2D expression (3, CD314, bottom middle) and a last one to stain for
the glucocorticoid receptor (4, bottom right) on NK subsets. In grey, full stainings are shown
whereas in white, an FMO staining is depicted for NKG2D and an isotype control for GCR. All
data was acquired on an Accuri C6 (Becton Dickinson).
(TIFF)
S3 Fig. Gating strategy for the analysis of adhesion and hormone receptor expression on
NK cell subsets. NK cells were defined by CD16 and CD56 expression on single, live CD3-
cells (upper row). The first panel stained for ADRB2 and CD62L on NK cell subsets whereas
the second panel stained for CX3CR1 and CD18. Example stainings on CD56dim NK cells are
shown in dark grey while isotype control (ADRB2) or fluorescence minus one controls (FMO,
for CD62L, CX3CR1 and CD18) are shown in light grey. All data was acquired on an LSRFor-
tessa flow cytometer (Becton Dickinson).
(TIFF)
S1 Protocol. Detailed RT-PCR protocol for the hormone receptor analysis incl. a complete
list of the primers used.
(DOCX)
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S1	  Fig.	  Correlation	  of	  NK	  cell	  increase	  with	  serum	  hormone	  levels.	  Absolute	  change	  in	  NK	  percentage	  3	  hours	  after	  drug	  administration	  was	  correlated	  to	  change	  in	  concentrations	  of	  epinephrine	  (A),	  cortisol	  (B)	  and	  norepinephrine	  (C)	  2	  hours	  post	  treatment.	  Spearman	  correlation	  and	  nonlinear	  fit	  were	  applied.	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S2	  Fig.	  Gating	  strategy	  to	  define	  lymphocyte	  and	  NK	  cell	  subsets	  and	  to	  assess	  NKG2D	  
expression	  and	  IFNγ	  	  and	  CD107a	  production	  in	  NK	  cell	  subsets.	  The	  top	  row	  shows	  the	  gating	  in	  order	  to	  distinguish	  B	  cells,	  CD4+	  and	  CD8+	  T	  cells.	  A	  second	  panel	  was	  used	  to	  detect	  NK	  cells,	  further	  subdividing	  them	  into	  CD56	  dim	  and	  CD56	  bright	  NK	  cells	  and	  analyzing	  IFNγ	  and	  CD107a	  production	  (	  2,	  middle	  row,	  data	  is	  shown	  for	  CD56	  dim).	  A	  third	  panel	  was	  designed	  to	  detect	  NKG2D	  expression	  (	  3,	  CD314,	  bottom	  middle)	  and	  a	  last	  one	  to	  stain	  for	  the	  glucocorticoid	  receptor	  (	  4,	  bottom	  right)	  on	  NK	  subsets.	  In	  grey,	  full	  stainings	  are	  shown	  whereas	  in	  white,	  an	  FMO	  staining	  is	  depicted	  for	  NKG2D	  and	  an	  isotype	  control	  for	  GCR.	  All	  data	  was	  acquired	  on	  an	  Accuri	  C6	  (Becton	  Dickinson).	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S3	  Fig.	  Gating	  strategy	  for	  the	  analysis	  of	  adhesion	  and	  hormone	  receptor	  expression	  on	  
NK	  cell	  subsets.	  NK	  cells	  were	  defined	  by	  CD16	  and	  CD56	  expression	  on	  single,	  live	  CD3-­‐	  cells	  (upper	  row).	  The	  first	  panel	  stained	  for	  ADRB2	  and	  CD62L	  on	  NK	  cell	  subsets	  whereas	  the	  second	  panel	  stained	  for	  CX3CR1	  and	  CD18.	  Example	  stainings	  on	  CD56dim	  NK	  cells	  are	  shown	  in	  dark	  grey	  while	  isotype	  control	  (ADRB2)	  or	  fluorescence	  minus	  one	  controls	  (FMO,	  for	  CD62L,	  CX3CR1	  and	  CD18)	  are	  shown	  in	  light	  grey.	  All	  data	  was	  acquired	  on	  an	  LSRFortessa	  flow	  cytometer	  (Becton	  Dickinson).	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SUPPLEMENTARY	  METHODS	  
Primers	  for	  real-­‐time	  RT	  PCR	  
All	  primers	  were	  designed	  with	  Primer3	  software	  in	  a	  way	  to	  create	  amplicons	  spanning	  exon-­‐exon	  junctions	  wherever	  possible	  (except	  for	  ADRB2	  and	  ACTB).	  We	  also	  aimed	  for	  maximal	  isoform	  coverage	  with	  help	  of	  the	  Ensembl	  database.	  Primers	  were	  ordered	  at	  Microsynth	  Switzerland.	  
Symbol	   Forward	  primer	   Reverse	  Primer	   Product	  length	  ADRB2	   ACAGGGGAGCAGAGTGGATA	   ACAGTACCTTGATGGCCCAC	   104	  bp	  GCR	   TGGGGACTCTGAACTTCCCTG	   CTGTTGTTGCTGTTGAGGAGC	   111	  bp	  ACTB	   CGAGCACAGAGCCTCGCCTT	   CATCATCCATGGTGAGCTGGCG	   70	  bp	  GADPH	   TCTTCTTTTGCGTCGCCAGCC	   CCCAATACGACCAAATCCGTTGA	   87	  bp	  PKG1	   GTTGACCGAATCACCGACCT	   GTCGACTCTCATAACGACCCG	   115	  bp	  HPRT	   ATGGACAGGACTGAACGTCT	   TCCAGCAGGTCAGCAAAGAA	   113	  bp	  
	  
Hormone	  receptor	  expression	  using	  real-­‐time	  RT	  PCR	  NK	  cells	  were	  enriched	  from	  PBMC	  using	  the	  magnetic	  beads	  based	  NK	  enrichment	  kit	  (Miltenyi	  Biotec)	  according	  to	  the	  manufacturer’s	  instructions.	  	  CD56bright	  and	  CD56dim	  NK	  cells	  were	  then	  sorted	  on	  a	  FACSAria	  III	  (BD	  Bioscience)	  and	  RNA	  was	  extracted	  using	  the	  QIAamp	  RNA	  Blood	  Mini	  Kit	  (Qiagen).	  	  Up	  to	  1	  μg	  of	  extracted	  RNA	  was	  treated	  with	  1	  unit	  of	  DNAse	  I	  (Promega)	  to	  remove	  genomic	  DNA.	  	  Immediately	  afterwards,	  first-­‐strand	  cDNA	  was	  generated	  by	  means	  of	  GoScriptTM	  Reverse	  Transcription	  System	  according	  to	  manufacturer’s	  protocol	  (Promega)	  using	  random	  hexamer	  primers	  and	  a	  MgCl2	  concentration	  of	  3	  mM.	  	  RT-­‐PCR	  reactions	  (20	  μl)	  contained	  variable	  amounts	  of	  template	  cDNA	  (5	  μl),	  2x	  GoTaq	  Probe	  qPCR	  Master	  Mix	  (10	  μl),	  nuclease-­‐free	  water	  (3	  μl)	  and	  500	  nM	  forward	  and	  reverse	  primers	  each	  (2	  μl).	  	  Reactions	  were	  run	  in	  duplicates	  in	  a	  7500	  Fast	  Real-­‐Time	  PCR	  System	  (Applied	  Biosystems).	  	  The	  amplification	  process	  consisted	  of	  polymerase	  activation	  at	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95°C	  for	  10	  minutes,	  45	  cycles	  with	  15	  s	  of	  denaturation	  at	  95°C	  and	  1	  minute	  of	  annealing	  and	  elongation	  at	  60°C	  and	  a	  final	  elongation	  step	  for	  1	  minute	  at	  60°C.	  	  Specificity	  of	  all	  primer	  pairs	  was	  confirmed	  with	  melt	  curves,	  efficiencies	  (E)	  were	  calculated	  with	  a	  standard	  curve	  of	  four	  serial	  dilution	  points	  according	  to	  the	  following	  formula:	  	  
𝐸 =   10(! !!"#$!)	  	  For	  normalization,	  suitable	  reference	  genes	  had	  to	  be	  found.	  	  This	  was	  done	  by	  application	  of	  the	  GeNorm	  algorithm	  [40]	  for	  assessing	  the	  most	  stable	  expression	  in	  four	  potential	  reference	  genes	  in	  five	  samples.	  	  The	  two	  best	  reference	  genes	  (GADPH	  and	  PKG1)	  were	  used	  for	  relative	  quantification	  by	  application	  of	  the	  following	  formula:	  	  
𝑁𝑅𝑄 =    𝐸!!",!"#,!"#𝐸∆!",!"#$%,!"#$%   ∗ 𝐸∆!",!"#!,!"#!	  	  where	  NRQ	  is	  normalized	  relative	  quantity,	  Cq	  is	  cycle	  of	  quantification	  and	  goi	  is	  gene	  of	  interest.	  	  
